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Abstract    
As the antibody sector has matured, it has seen significant increases in cell culture 
titres. However, it is hard to predict the consequences of titre increase on impurity 
levels and downstream processing (DSP) performance. Hence it is critical to have 
systematic methods to explore such interactions. This project explored the potential 
of high throughput cell culture linked to multivariate analysis, uncertainty analysis 
and bioprocess economics to characterise cell culture processes, not only in terms of 
growth and productivity but also host cell protein (HCP) levels, robustness and costs. 
A Quality by Design (QbD) approach to cell culture process development is 
presented. Using this QbD framework it was shown that there is scope for cell 
culture processes in which the ratio of mAb to HCP can be increased and the 
association of mAb titre to HCP reduced. It is therefore feasible to identify 
conditions whereby it is possible to increase antibody titre with little impact on HCP 
levels and hence subsequent DSP operations. (36.5 oC, 313 mOsm kg-1 media 
osmolality, 1 × 106 cells mL-1 seeding density, pH 6.8 and low cell generation 
number in this case). The impact of cell culture factors on protease activity 
(problematic HCP species) was assessed. Culture temperature was found to have a 
significant impact on protease activity, with a decrease in temperature resulting in 
lower protease activity. The relationship between HCP levels and protease activity 
was also examined and it was shown that an increase in total HCP levels at harvest 
did not result in a concomitant increase in protease activity. Multivariate data 
analysis based on regression was used to derive statistical cause-and-effect 
correlations able to link mAb titre and HCP levels to key cell culture factors. The 
resulting cell culture predictive correlations were then integrated into a whole 
bioprocess economics and optimisation framework. This allowed the identification of 
the most cost effective cell culture strategies as well as the impact of uncertainty in 
cell culture parameters on outputs (product output (kg) and HCP final (ng/mg)) and the 
likelihood of these falling out of specification. The work in this thesis highlights the 
benefits of a systematic approach to providing enhanced process understanding of the 
impact of cell culture strategies on downstream processes. This can be used to 
facilitate effective process integration and enable continuous improvements. 
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Chapter 1  
1 Literature review  
As the antibody sector has matured, it has seen significant increases in upstream 
(USP) productivities that have opened up the possibility for radical changes to the 
design and operation of cell culture suites. However, due to the inherently complex 
set of interactions that can affect cell culture performance, it is hard to predict the 
consequences on the impurity profiles and hence robustness of downstream (DSP) 
operations as titre increases. Quality by Design (QbD) initiatives are driving the need 
for greater understanding of the impact of USP changes on DSP, such as the impact 
of cell culture strategies on the downstream processing equipment duties so as to 
enable effective process integration and hence continuous improvements.  
This project will explore state-of-the-art high throughput cell culture and 
multivariate data analysis techniques to characterise cell culture operations, not only 
in terms of growth and productivity but also impurity levels. The resulting cell 
culture statistical cause-and-effect correlations will be integrated into process 
economics models so as to identify the most cost-effective integrated USP and DSP 
manufacturing strategies for the future.  
This introductory chapter provides an overview of biopharmaceutical drug 
development, impurities and the challenges they pose within the manufacturing 
process as well as outlining statistical and bioprocess economics modelling 
techniques. Section 1.1 provides an overview of biopharmaceutical drug 
development and its associated costs and risks. Section 1.2 reviews the current and 
future trends of monoclonal antibody manufacturing. Section 1.3 gives an outline of 
existing small-scale cell culture systems. Sections 1.4 and 1.5 focus on impurities 
present in biopharmaceutical manufacturing and the challenges they pose, with an 
emphasis on host cell proteins. Sections 1.6 and 1.7 highlight statistical and 
economics modelling techniques employed in evaluating biopharmaceutical 
manufacturing processes. Finally, the aim and organisation of the thesis are presented 
in Section 1.8.  
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1.1 Biopharmaceutical drug development   
Biopharmaceuticals are being developed to target different types of illnesses such as 
diabetes, multiple sclerosis, cancer, hepatitis and viral infections. They can be split 
into several categories: enzymes, hormones, antisense drugs, vaccines, monoclonal 
antibodies, cytokines, clotting factors, peptide therapeutics and cell therapies 
(Sekhon, 2010). In this thesis the focus will be towards monoclonal antibodies 
(mAbs) as they have become essential to current medicine and represent one of the 
main biopharmaceutical products in development at the moment (Rodrigues et al., 
2010; Ecker et al., 2015).  
1.1.1 Marketed biopharmaceuticals  
Biologics are increasingly important and now represent some 50 % of the portfolio of 
major pharmaceutical companies. Every year there are more than 600 biologics 
under development, the majority of which are monoclonal antibodies (Van Amum, 
2015). The first recombinant protein approved on the market was genetically 
engineered insulin in 1982. Following insulin’s great success on the market, the US 
Food and Drug Administration (FDA) has approved more than 300 non-recombinant 
therapeutics, including vaccines and blood products as well as over 100 recombinant 
protein biopharmaceuticals (www.fda.gov; Rader, 2013). 
Mammalian cell expression has become the predominant production system 
for recombinant proteins due to its ability to carry out human-like post-translational 
modifications and to synthesize proteins very similar to those occurring naturally in 
terms of biochemical properties and molecular structure (Zhu, 2011, Khan, 2013). 
Almost all of the biopharmaceuticals approved are made in either mammalian cells, 
bacterium (E.coli) or yeast (Pichia pastoris, Saccharomyces cerevisiae) (Berlec and 
Strukelj, 2013). Around 70 % of approved recombinant proteins are expressed in 
CHO cells (Gutierrez et al., 2012). This shows that mammalian expression systems 
are the main choice for biopharmaceutical manufacturing.  
With regards to the economic impact of marketed top selling 
biopharmaceutical products (Table 1-1), almost 75 % of the total revenue comes 
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from products manufactured using mammalian cell expression systems and the 
remaining 25 % from products manufactured using bacterial (e.g. E.coli). The 
worldwide market of therapeutic proteins was valued at $93 billion in 2010 and is 
predicted to increase to $141.5 billion by 2017. This constitutes an increase rate of 
6.2 % within the 7 years period (GBI Research, 2011).  
1.1.2  Marketed monoclonal antibodies   
Monoclonal antibodies (mAbs) represent a considerable proportion of the 
biopharmaceutical industry’s current biotherapeutics portfolio (Zhang et al., 2014).  
As a result of their extensive application range, mAbs are globally used in a wide 
range of applications such as therapeutics or diagnostics. In therapeutics they are 
used to treat a wide range of disease conditions, with autoimmune disorders and 
different types of cancer being the most frequent targets (Table 1-2) (Shukla and 
Thommes, 2010; Elvin et al., 2013).  
The majority of mAbs on the market and in clinical development are derived 
from a few mammalian cell lines: Sp2/0, NS0, CHO (Chinese Hamster Ovary). CHO 
cells are the most commonly used expression system for the industrial production of 
recombinant proteins, including monoclonal antibodies. Some of the key advantages 
of CHO include the fact that methods for gene amplification, cell transfection and 
clone selection are well characterized and the protein of interest is secreted in the 
culture media which simplifies the purification process (Gutierrez et al., 2012; 
Bailey-Kellogg et al., 2014).  
The mAbs market experienced newfound interest at the turn of the century 
and has been steadily increasing over the past decade. Antibodies are the fastest 
growing segment of biopharmaceuticals; in 2006, the global mAbs market was 
estimated to be $20.6 billion with only 25 approved mAbs on the market (Coco-
Martin and Hamsen, 2008), in 2008 to be $39 billion while in 2013 this grew to $75 
billion, and 47 mAb products approved in the US and Europe, almost double 
compared to 2006. The mAbs market has seen a 90 % increase in growth sales 
between 2008 and 2013, compared to 26 % for sale of other recombinant protein 
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therapeutics. Out of the 47 mAb products approved in 2013, 18 of them had sales 
over $1 billion, 7 had sales over $6 billion and Humira (AbbVie Inc.) reported record 
sales of ~ $12.5 billion in 2014. Their success will continue to dominate the 
biopharmaceutical pipeline and market, with analysts forecasting a compound annual 
growth rate of 3-5 new products approved/year, leading to 70 mAb products on the 
market by 2020 and combined world sales of nearly $125 billion (Ecker et al., 2015). 
The main drivers behind the continuing increase of mAb products on the market are 
the ageing worldwide population as well as an increase in standard of living in 
emerging markets. 
1.1.3 Development costs and risks  
The development of therapeutic antibodies is a long, expensive and risky process that 
has to comply with rigorous regulatory requirements. Tough decisions must be made 
in order to find a balance between speed to market, low cost, high quality and 
flexibility (Farid, 2009). Biopharmaceutical companies therefore need to achieve 
development efficiency and an advantage over competitors by starting to use new 
bioprocess technologies (Bareither and Pollard, 2011). Drug supply development 
cost needs to be lowered and the time from discovery to market must also be 
reduced. To develop and bring a new drug to the market takes up to 10-15 years 
(Roy, 2011; Schnatz, 2013). The estimate for drug development costs was $802m in 
2003 (DiMasi et.al, 2003), over $1 billion in 2010 (Adams and Brantner, 2010) and 
$2.6 billion in 2015 (Avorn, 2015). Due to FDA’s strict regulatory requirements 
clinical trials have low success rates (~16 % from Phase I to market). On average, 
seven years are needed to go through the clinical trials and obtain the regulatory 
approvals, to market a new drug (Kaitin, 2010).   
Clinical trials are made up of three phases. In Phase I, the required drug is 
tested for safety on a small number of healthy volunteers (20-80), in Phase II, the 
drug is tested in terms of safety and efficacy on a small number of patients (100-300) 
and Phase III involves much larger scale clinical studies that monitors the long term 
use of the drug with up to 3000 patients participating. They account for most of the 
drug development cost, with reports showing up to 70 % of all research and 
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development (R&D) costs being spent on Phase I to Phase IV clinical trials (Bernt 
and Cockburn, 2012). A high number of candidates must be screened in order to pick 
out a small number of prospective drugs. From these, only a few are found to be 
effective at treating diseases. For a company to remain successful, it needs to have a 
selection of drugs in the pipeline. Using an economic model of drug discovery and 
development, Paul et al. (2010) predicted that large Pharma companies should aim 
for 2-5 launches per year, requiring 18-45 molecules to enter Phase I clinical trials. 
These numbers are rarely achieved, even by very large companies. A more realistic 
estimation would be 1-2 launches per year, requiring around 9-18 molecules to enter 
Phase I clinical trials (Farid, 2001). The success rate of bringing a new drug to the 
market has lowered since the FDA has become stricter regarding the approval 
processes. In 2007, FDA approved only 19 new drugs, representing the lowest 
number since 1983 (Courtenay, 2008).  
1.1.4 Manufacturing development and costs 
Monoclonal antibodies have relatively low potency and require high doses over an 
extended period of time, which involves large amounts of purified product per 
patient (Aldington and Bonnerjea, 2007; Tao et al., 2014). Antibody manufacturing 
facilities now reach sizes of around 45,000 m2 and have multiple bioreactors with 
total capacities up to 200,000 L (Farid, 2009).   
One of the major challenges of biopharmaceuticals, especially monoclonal 
antibodies is reducing the selling price in order to make them more affordable to 
patients. Monoclonal antibodies based therapeutics for autoimmune diseases cost 
around $15,000 - $20,000 per year to treat a single patient. Products designed for rare 
diseases will cost a lot more. The reason why these therapies are so expensive is 
partly due to the need for frequent administration of high doses.  It is also due to the 
high drug development costs given the high attrition rates that mean companies need 
to recoup the investment made in the development of not only the successful drug 
but also the failed drugs. A major component of the drug development process is the 
establishment of robust manufacturing processes and analytical methods for each 
drug candidate in the portfolio. Monoclonal antibodies are manufactured in 
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mammalian cells, involving a time-consuming two weeks of cell culture to obtain the 
product. Monoclonal antibody based drugs also require frequent injections at high 
doses to be effective. Taking Humira, a mAb based drug to treat rheumatoid arthritis, 
as an example, the recommended dose is 40 milligrams every two weeks, with a total 
of over 1 g per year, per patient (Fanneau de la Horie, 2010). 
Fixed capital investment (FCI) represents the amount of money required to 
build the biopharmaceutical facility ready to use. It generally involves the 
construction expenses for the buildings, the cost of purchased equipment, piping and 
instrumentation and utilities. Investment costs for monoclonal antibodies 
manufacturing facilities range between $40 M to $650 M with $7,130 - $17,000 per 
m2 and $1,765-$4,220 per L for volumes between 20,000-200,000 L (Farid, 2007). 
Table 1-3 shows the capital investment costs reported for facilities built by large 
biopharmaceutical companies such as Genentech and Lonza. Table 1-3 also shows 
that these facilities reach sizes of 500,000 ft2 (46,450 m2) with bioreactor volumes of 
up to 200,000L attained with multiple bioreactors (Farid, 2007). 
The biopharmaceutical industry is facing some difficult challenges such as 
pressure from healthcare providers to decrease drug prices, reduced average patent 
life, increased competition in generic markets and a reduction in revenues due to 
patent expiration (Collier, 2009). Biopharmaceutical manufacturing involves 
advanced technology and very rigorous regulatory compliance such as good 
manufacturing practices (GMP). Pharmaceutical companies are under high pressure 
to minimise fixed costs so they resort to reducing their internal capacities in 
manufacturing and R&D and increase their outsourcing (Zhang et al., 2011). The 
current total global pharmaceutical outsourcing market is around $130 billion. From 
2009-2014 it grew at a compound annual growth rate (CAGR) of 9.4 % and is further 
expected to grow at a CAGR of 8.7 % from 2015-2020. It is predicted to reach up to 
$215 billion by 2020 (PR Newswire Research, 2015).  
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Table 1-1: Top 10 best-selling biotech drugs in 2014* 
Product 
Revenue 
US $  
Billion (B) 
Date 
approved 
Manufacturer Expression system Indication 
Humira 12.54 2002 AbbVie Mammalian (CHO) Rheumatoid arthritis, 
Remicade 9.25 1998 Johnson & Johnson, Merck Co. Mammalian (NSO) Crohn disease 
Rituxan 8.68 1997 Roche, Biogen Idec Mammalian (CHO) Non-Hodgkin lymphoma 
Enbrel 8.54 1998 Amgen, Pfizer Mammalian (CHO) Rheumatoid arthritis 
Lantus 7.28 2000 Sanofi E.coli Diabetes 
Avastin 6.96 2004 Roche Mammalian (CHO) Colorectal cancer 
Herceptin 6.79 1998 Roche Mammalian (CHO) Breast cancer 
Neulasta 5.86 1998 Amgen, Kyowa Hakko Kirin E.coli Myelosuppressive Chemotherapy 
Prevnar 4.46 2002 Pfizer Bacterial Prevension of invasive pneumococcal disease 
Avonex 3.01 1996 Biogen Idec Mammalian (CHO) Multiple sclerosis 
 
* Adapted from http://cellculturedish.com/2015/03/10-biologics-on-best-selling-drugs-list-for-2014/ 
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Table 1-2: FDA approved antibody-based therapeutics*  
Brand Name: INN Target: Antibody type Indication Company Approval Date 
(Pending): Idarucizumab Dabigatran: Humanized Fab Anticoagulation Boehringer Ingelheim Pending 
(Pending): Mepolizumab IL-5: Humanized IgG1 Asthma GlaxoSmithKline Pending 
(Pending): Necitumumab EGFR: Human IgG1 Cancer Eli Lilly & Co. Pending 
Repatha: Evolocumab PCSK9: Human IgG2 High cholesterol Amgen Pending 
Praluent: Alirocumab PCSK9: Human IgG1 High cholesterol Sanofi and Regeneron Pharmaceuticals 2015 (US) 
Unituxin: Dinutuximab GD2: Chimeric IgG1 Cancer United Therapeutics 2015 (US) 
Cosentyx: Secukinumab IL-17a: Human IgG1 Autoimmune Novartis 2015 (US,EU) 
Opdivo: Nivolumab PD1: Human IgG4 Cancer Bristol-Myers Squibb 2014 (US) 
Blincyto: Blinatumomab CD19, CD3: Murine bispecific tandem scFv Cancer Amgen 2014 (US) 
Keytruda: Pembrolizumab PD1: Humanized IgG4 Cancer Merck & Co. 2014 (US) 
Cyramza: Ramucirumab VEGFR2: Human IgG1 Cancer Eli Lilly & Co. 2014 (US,EU) 
Entyvio: Vedolizumab 47 integrin: Humanized IgG1 Autoimmune Takeda Pharmaceuticals U.S.A. 2014 (US,EU) 
Sylvant: Siltuximab IL-6: Chimeric IgG1 Castleman disease Janssen Biotech 2014 (US,EU) 
Gazyva: Obinutuzumab CD20:Humanized IgG1, glycoengineered Cancer Genentech 
2013 (US)  
2014 (EU) 
Kadcyla: Ado-trastuzumab 
emtansine 
HER2: Humanized IgG1, immunoconjugate Cancer Genentech 2013 (US,EU) 
Abthrax: Raxibacumab B. anthrasis PA: Human IgG1 Anti-infective Human Genome Sciences 2012 (US) 
Perjeta: Pertuzumab HER2: Humanized IgG1 Cancer Genentech 
2012 (US) 
 2013 (EU) 
Adcetris: Brentuximab vedotin CD30: Chimeric IgG1, immunoconjugate Cancer Seattle Genetics 
2011 (US) 
2012 (EU) 
Benlysta: Belimumab BLyS: Human IgG1 Autoimmune Human Genome Sciences 2011 (US,EU) 
Yervoy: Ipilimumab CTLA-4: Human IgG1 Cancer Bristol-Myers Squibb 2011 (US,EU) 
 Adapted from *Chames et al. (2009), Ecker et al. (2015), FDA 
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Table 1-3: Capital investment costs for antibody-based facilities using mammalian cells* 
 (Adapted from *Pollock (2013))
 Production bioreactor capacity 
Manufacturing facility 
Date facility 
completed 
Capital Investment 
($ US M) 
Area 
(sq. feet) 
Number 
Size 
(L) 
Total 
(L) 
Boehringer ingelheim expansion 
—Biberach, Germany 
2003 315 – 6 15,000 90,000 
Lonza Biologics expansion—Portsmouth, NH, 
USA 
2004 207 270,000 3 20,000 60,000 
Amgen—BioNext, West Greenwich, RI, USA 2005 500 500,000 9 20,000 180,000 
Genentech expansion—Oceanside, CA, USA 2005 380 470,000 6 15,000 90,000 
Imclone expansion—Branchburg BB50, NJ, 
USA 
2005 260 250,000 9 11,000 99,000 
Biogen Idec—Hillerød, Denmark 2007 350 366,000 6 15,000 90,000 
Lonza biologics—Tuas, Singapore 2009 250 – 4 20,000 80,000 
Genentech expansion—Vacaville, CA, USA 2009 600 380,000 8 25,000 200,000 
Bristol-Myers Squibb – Devens, MA, USA 2011 750 – 6 20,000 120,000 
Pfizer Biotech Campus, Grange Castle, Ireland 2011 1800 – 6 12,500 75,000 
MedImmune, Frederick, MD, USA 2011 600 337,000 4 12,500 50,000 
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1.2 Antibody manufacture 
The immune’s system B-lymphocytes produce monoclonal antibodies in response to 
foreign proteins named antigens. The primary function of antibodies is recognizing 
and attacking foreign bodies like bacteria and viruses, which invade the organism. 
The history of therapeutic antibodies began in 1986 when the FDA approved the first 
of a generation of murine derived antibodies, OKT3TM. The use of murine derived 
antibodies has its limitations, such as the production of anti-murine antibodies 
(HAMA) by the human immune system. Further development gave rise to ReoProTM, 
the first chimeric antibody (only the light chains of the antibody were of murine 
origin) in 1993 by Johnson & Johnson. In this case the human immune response was 
not as strong as with OKT3TM. This immunogenicity had to be reduced, therefore 
scientists tried to find a way to eliminate the murine component. As a consequence, 
in 1998, Genentech introduced on the market the first humanized antibody, 
HerceptinTM, developed to fight against breast cancer. Then in 2002, FDA approved 
the first human antibody produced by phage display technology, HumiraTM (AbbVie 
Inc). Most of the approved mAbs in current use are either chimeric or humanized 
(Sommerfeld and Strube, 2005; Chames et al., 2009).  
1.2.1 Antibody platform process 
Platform processes are defined as a series of manufacturing operations that can be 
relevant to more than one product, with the aim of reducing manufacturing 
investments and eliminating process re-design for each new product. Antibody 
manufacture adopts a platform approach with standard unit operations used for the 
downstream process including clarification using centrifugation as well as depth and 
membrane filtration, antibody capture through Protein A affinity chromatography, 
polishing, virus removal and formulation (Curling, 2004). Platform processes give a 
general approach to antibody production, which significantly lowers the development 
time (Farid, 2009). An antibody platform often used for monoclonal antibodies is 
presented below.  
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Figure 1-1 : Typical upstream process for monoclonal antibodies  
(Adapted from Shukla and Thommes (2010)) 
 
Figure 1-2: Typical downstream process for monoclonal antibodies  
(Adapted from Shukla and Thommes (2010)) 
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In the upstream process cells are grown stepwise. Firstly, the cells are frozen 
in a master cell bank and various working cell banks. Then, the cells are cultured in 
shake flasks and grown in gradually larger volumes for a few weeks. This will then 
constitute the inoculum for large-scale fermentation (10,000-20,000 L). Once the 
cells are added to the large-scale bioreactors, they are cultured for approximately 2 
weeks, predominately as fed-batch processes. For large-scale production of mAbs a 
typical bioreactor train is shown in Fig. 1-1 (Sommerfeld and Strube, 2005). 
The harvest material is first clarified by either centrifugation or filtration, 
widely used current techniques for harvest operations. Centrifugation may not give 
an acceptable degree of solid removal in order to be able to load the centrate directly 
onto the first chromatography capture step. A filtration step using depth filters may 
also additionally be required. Depth filters are capable of removing host cell protein 
(HCP), any potential cell debris and other impurities. It has also been shown to 
reduce the level of turbidity seen in Protein A eluate of a monoclonal antibody 
process (Yigzaw et al., 2006). Protein A Chromatography involving a low pH elution 
step captures and purifies monoclonal antibodies. This step also acts as a viral 
inactivation step. Two polishing steps such as cation- (CEX) and anion- (AEX) 
exchange chromatography are usually employed in order to meet the purity 
requirement imposed by the regulatory authorities. A virus filtration step is necessary 
to provide additional assurance that the virus is removed and the product is safe, 
followed by a final ultrafiltration/diafiltraton step which helps formulate and 
concentrate the product (Fig. 1-2). Overall purification yields range from 70-80%. 
Different companies use similar platform processes as it can be seen in Table 1-4. 
(Shukla et al., 2007; Kelley, 2009; Shukla and Thommes, 2010; Zhang et al., 2014).  
Looking at several existing manufacturing processes employed by companies 
for the production of marketed monoclonal antibodies (Table 1-4) it can be observed 
that clarification (achieved by centrifugation or microfiltration) is the common first 
step in these processes. In the majority of cases, Protein A affinity chromatography is 
used as a capturing step which also incorporates a viral inactivation step due to its 
low pH elution. Several ion exchange steps follow protein A. These polishing 
chromatographic steps are used for the removal of DNA fragments, HCPs, potential 
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leaches from Protein A and other impurities. If the required purity is not attained, 
extra chromatographic steps such as hydrophobic interaction or size exclusion may 
be considered (Sommerfeld and Strube, 2005). 
Table 1-4: Analysis of different production processes for marketed antibody-based 
therapeutics* 
 Herceptin Rituxan MabCampath Synagis Remicade Simulect 
Cell removal 1 1 1 1 1 1 
Affinity 
chromatography 
2 2 2  2 2 
Virus 
inactivation 
3 3 3 4 3 3 
Cation 
exchange 
4 5 4 2 4 5 
Anion 
exchange 
5 4  3, 6 6, 7 4 
Hydrophobic 
interaction 
6      
Size exclusion 
chromatography 
  5 8   
Virus clearance  6 6 5, 7 5 6 
Sterile filtration 7 7 7 9 8 7 
            *Adapted from Sommerfeld and Strube (2005) 
1.2.2 Quality by Design  
The concept of Quality by Design (QbD) for biopharmaceutical drug development 
was initiated by the Food and Drug Administration (FDA) and involves a better 
understanding of the product and its manufacturing process, aiming to build product 
quality into the process by design, as opposed to testing for it at the end. QbD 
comprises of three main components: process knowledge involving a good 
understanding of the impact process inputs have on process performance, the 
identification of potential critical quality attributes (CQA) and understanding the 
relationship between the manufacturing process and these CQA as well as the link 
between CQA and product’s clinical properties. A CQA can be defined as a quality 
attribute of the product that has the ability to influence safety and efficacy (Abu-Absi 
et al., 2010; Eon-Duval et al., 2012a). The Quality by Design approach for 
characterising mammalian cell culture processes has been widely used (Abu-Absi et 
al., 2010; Horvath et al., 2010; Rouiller et al., 2012).  
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1.2.3 Increases in mAb titres  
The bioreactor concentration of recombinant products, cultured in mammalian cells 
has seen an increase of over 20-fold within the last two decades. The main reasons 
for these advances have been improvements in the capability to isolate high producer 
cell lines through gene amplification and cell isolation as well as the development of 
improved fed-batch protocols (Butler and Meneses-Acosta, 2012). Further factors 
contributing to the increase in production yield are optimisation of culture media, 
addition of small molecule enhancers and improvement to process control such as 
dissolved oxygen, pH, temperature and media osmolality (Bai et al., 2011). These 
advances are able to increase cell productivity, extend culture duration and maintain 
a high viability for longer (Lu et al., 2013). Bai et al. (2011) showed that a 
combination of iron and citrate added to chemically defined media increased mAb 
production in CHO cells by 30-40 %, without impacting on product quality. 
Modelling approaches, such as multivariate data analysis helped improve the sector’s 
knowledge with regards to culture conditions in order to optimize cell growth and 
improve product titre (Elvin et al., 2013). Nowadays, mAb concentration of 3-5 g L-1 
are commonly achieved and titres up to 10-13 g L-1 in fed-batch processes are 
reported (Kelley, 2009; Li et al., 2010). Antibody titres as high as 17 and 25 g L-1 
have also been attained. Titres of 17 g L-1 have been reported in concentrated fed-
batch cultures while titres of 25 g L-1 were reported in perfusion cultures. Both 
systems are based on the alternative tangential flow (ATF) system (Shevitz et al., 
2011). Antibody titres of 25 g L-1 were achieved in PER.C6 human cells using a 
continuous cell culture process operated in “concentrated fed-batch” mode (eXtreme- 
Density, XD). This was performed using a modified ATF perfusion system to retain 
the cells and the product in the bioreactor (Schiermer et al., 2010; Chon and Zarbis-
Papastoitsis, 2011). Improvements in mAb titres are essential in order to assist high 
drug dosage, increased demands and be able to control production costs (Robert et 
al., 2009).  
 Improvements in cell culture processes have resulted in higher mAb titres by 
increasing culture duration, cell densities and specific cell productivity (Brodsky et 
al., 2012). This involves bioreactors operating at high cell densities (>1 × 107 cells 
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mL-1), leading to higher levels of host cell proteins, nucleic acids, media and feed 
components (Westoby et al., 2011). XD cultures exhibit very high cell densities (> 
150 × 106 viable cells mL-1) compared to conventional levels of 10-20 × 106 cells 
mL-1, in fed-batch cultures. These high levels of cell densities put increased pressure 
on harvesting techniques (both centrifugation and filtration) due to their high solids 
content (≤ 40%). Changes in upstream processes require optimisation of downstream 
process methods (Tscheliessnig et al., 2013).  
 Processes featuring higher titres can pose facility fit challenges in 
biopharmaceutical purifications suites (Brodsky et al., 2012; Yang et al., 2014). The 
large volumes of buffers, chromatography resins and large filter areas needed to cope 
with higher titres, are generally incompatible with current manufacturing facilities 
(Aldington and Bonnerjea, 2007; Kelley, 2009; Stonier et al., 2012). Mismatch in 
equipment sizes can cause bottlenecks and together with process fluctuations upon 
scale-up leads to discarding expensive product. Yang et al. (2014) explains that large 
scale manufacturing facilities which have fixed equipment, find it harder to adopt 
debottlenecking strategies that involve equipment changes in response to fit issues 
derived from higher titres. They found that titre, CEX and AEX eluate volumes were 
the most significant factors impacting unexpected mass loss and they propose three 
debottlenecking solutions. Using larger volume pool tanks for AEX, CEX and viral 
inactivation steps, reducing the eluate volumes of the CEX and AEX steps as well as 
using higher capacity resins for these steps could minimise product loss.  
These high mAb concentration feed volumes are putting increased pressures 
on legacy facilities with downstream equipment that was designed for a much lower 
amount of mAb (Stonier et al., 2012; Yang et al., 2014; Tao et al., 2014). These 
pressures arise from the increased level of solids affecting harvesting operations and 
the higher amount of impurities (higher level of total HCPs and problematic HCPs) 
affecting purification steps. The harvest and purification equipment reach their limits 
in terms of capacity, which results in higher material consumption, processing times 
and cost. At low mAb titres, the cost of upstream manufacturing is higher than 
downstream but higher titres shift the cost from USP to DSP (Chon and Zarbis-
Papastoitsis, 2011; Levy et al., 2014). The downstream costs for CHO processes 
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represent between 50-80 % of the total cost of manufacturing a recombinant protein 
(Lowe, 2001; Guiochon and Beaver, 2011). In order to minimise these cost and to 
ensure the DSP is able to cope with the upstream feed, improvements need to be 
made to current technologies as well as looking into cheaper, more efficient 
technologies. Alternative steps should be able to either purify the proteins 
individually or minimise the burden on the current purification steps through partial 
purification (Butler and Meneses-Acosta, 2012; Saraswat et al., 2013). 
1.2.4 Future trends of antibody platform 
The upstream process platform for monoclonal antibodies production has 
considerably progressed in terms of the cell line development and bioreactor process 
that resulted in high product titres. Even though the current process platform is safely 
and widely used in industry, a number of drivers will lead to further development in 
the next decade. Due to the recent development in achieving high titres, the necessity 
to build biopharmaceutical facilities with high volume bioreactors (eg. 20,000L) will 
decrease. Producing lower volumes will lead to higher use of disposables in 
manufacturing and will emphasize the need for facility flexibility (Shukla and 
Thommes, 2010).  
New cell culture technologies are being evaluated to make the processes even 
more robust and to reduce the operation costs. Some of these new technologies 
include the development of new on-line process monitoring and control systems as 
well as the development of high-throughput cell culture systems. Cell culture 
monitoring using accurate in situ sensors for measuring relevant parameters could 
improve the development and optimisation of cell culture processes. Stainless steel 
tanks are the current choice for laboratory and pilot scale process development as 
well as for the large-scale manufacture of antibodies. The capital investment and 
maintenance cost for fixed plant equipment is very high and the validation 
requirements in terms of cleaning and sterility are high as well. These issues can be 
overcome by the use of disposable bioreactors, which have become extensively used 
in mammalian cell bioprocesses. They have the advantages to increase plant capacity 
and flexibility by reducing the turnaround time, easier and more rapid to implement 
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design changes and smaller footprint (Li et al., 2010; Butler and Meneses-Acosta, 
2012). 
Product recovery for centrifugation can be low due to an increased need of 
desludging (particularly in large-scale continuous centrifugation). Clarification post 
centrifugation can also be affected due to shear forces cell disruption. Depth filters 
alone are unable to handle high-solids feedstreams and are usually used in 
combination with centrifugation. Tangential flow filtration (TFF) is able to handle 
high solids but the yield might be poor. Schirmer et al. (2010) presented an 
alternative method to centrifugation, which in combination with filtration would 
benefit the clarification of high-density cell harvests. The enhanced cell settling 
method (ECS) involves the addition of weak IEX matrices to the cell culture harvest, 
which enhances cell settling. They demonstrated that this method greatly reduces 
HCP and DNA levels in partially clarified harvests. Westoby et al. (2011) showed 
how a reduction in cell culture fluid pH to 4.7-5 induced flocculation and 
precipitation of impurities which increased the average particle-size. This method 
enhanced impurity removal and improved tangential flow microfiltration throughput 
and filter capacity.   
Most of the manufacturing processes use Protein A chromatography as the 
capturing step, but there are some potential disadvantages associated with Protein A 
chromatography such as high resin cost, potential ligand leaches and sensitivity to 
product residence time (Chon and Zarbis-Papastoitsis, 2011; Saraswat et al., 2013). 
Alternatives to Protein A for capture of mAbs include batch chromatography (cation-
exchange chromatography (CEX) (used in the process of manufacturing HUMIRA 
and Synagis), mixed-mode chromatography and continuous chromatography. Cation-
exchange processes used to have low capacity (20-30g/L) and in the past they were 
not able to deal with high cell culture titres. Most recently processes have been 
developed with higher CEX capacities, of 100 g/L, for monoclonal antibodies, 
demonstrated using real feeds as well as model systems. These newly improved 
chromatographic media have the ability to achieve high capacity at only 1/5 of 
Protein A cost, making them a more appealing alternative to affinity chromatography 
(Gagnon, 2010; Chon and Zarbis-Papastoitsis, 2011). Tao et al. (2014) showed the 
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feasibility of using CEX for direct capture of mAbs from high titre cell culture 
harvest. Another alternative for the capturing step is mixed-mode chromatography 
(anion exchange and hydrophobic interaction) which can be optimised by design of 
experiments and can present comparable yields to those seen in Protein A, but at a 
much lower cost (Toueille et al., 2011). Pezzini et al. (2011) used mixed-mode 
chromatography for capture of mAbs from CHO cell culture supernatants. They also 
evaluated four types of mixed-mode resins, in their ability to minimise HCP levels. 
Semi-continuous chromatography (e.g. periodic counter current (PCC)) has been 
successfully applied to the capture of mAbs from cell culture supernatant. Mahajan et 
al. (2012) showed the application of three small-scale columns operated using the 
PCC principles for the purification of low and high mAb titres. It also highlighted a 
40 % reducing in the cost of resin, buffer and processing time when the multi-column 
chromatography was compared to affinity chromatography. Pollock et al. (2013) 
evaluated the application of semi-continuous 3-column and 4-column PCC 
chromatography system for the capture of mAbs and showed that the use of semi-
continuous chromatography can reduce manufacturing costs of early clinical phase 
material.  
Non-chromatographic purification methods such as membrane 
chromatography or selective precipitation are likely to arise (Shukla et al., 2007). 
Membrane chromatography uses filtration membranes with ligands immobilised to 
the inner pore surface resulting in a selective adsorption of molecules, separating 
them based on their chemical behaviour (Frohlich et al., 2012). Membrane 
chromatography has been used in both flow through and bind-and-eluate mode in 
industrial applications (Hirai et al., 2009; Liu et al., 2010). Precipitation can be used 
as an impurity removal step prior to harvest (using caprylic acid) (Brodsky et al., 
2012) or capture by CEX (using PEG) (Lain et al., 2010). Brodsky et al. (2012) 
showed the use of caprylic acid precipitation being implemented in a bioreactor prior 
to harvest as well as being used as an alternative to polishing chromatography, 
following Protein A affinity chromatography.  
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1.3 Small scale cell culture 
The relationship between culture conditions and process outcomes is very 
complex. A multi-factorial experimentation strategy can be used to analyse 
relationships and provide the highest amount of data in the shortest amount of time 
(Montgomery, 2009). It is difficult to apply this strategy to bench-top or large-scale 
bioreactors due to high resource requirements as well as high capital equipment and 
infrastructure costs (Lewis et al., 2010). The need to perform large numbers of 
experiments under controlled, bioreactor conditions has resulted in the development 
and implementation of high-throughput, small-scale systems for process 
development (Legmann et al., 2009; Lewis et al., 2010; Jones et al., 2015).  
Among the small-scale devices investigated are shake-flasks, microtitre plates 
and stirred bioreactors (Kumar et al., 2004; Betts and Baganz, 2006; Duetz, 2007). 
Fed-batch cultivations are not easily conducted on a routine basis and under 
controlled conditions making shake flasks less favourable for bioprocess 
optimisation. To overcome these limitations new small-scale and high throughput 
(HT) systems are now being commercialized. These are better able to mimic the 
performance of stirred tank bioreactors and provide sufficient data. HT technologies 
facilitate faster timelines, shorter development times while fewer resources are 
required.  (Amanullah et al., 2010). Various designs of HT micro-scale bioreactors 
have been reported in literature, starting from simpler standard plate with integrated 
sensors measuring pH and oxygen levels (microtitre plate based bioreactors, e.g. 
Simcell), to more advanced cell culture systems with better control capabilities 
(stirred mini bioreactors, e.g. Micro 24® MicroReactor (Pall Life Sciences, Port 
Washington, NY) and the ambr® (Sartorius Stedim, Royston, UK). To be able to 
support the HT micro-scale bioreactors, HT analytical techniques such as the 
Gyrolab workstation (Gyros, Uppsala, Sweden) (quantification of HCP 
concentration) have also been implemented in industry.  
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1.3.1 Traditional small-scale culture systems 
1.3.2 Shaken vessels  
1.3.2.1 Shake flasks 
Shake flasks are widely used and have the advantage of low price and being easy to 
handle. Shake flasks are manufactured in different sizes with capacity ranging from 
25 mL to 5L, made of plastic or borosilicate glass and equipped with or without 
baffles. They are usually operated on orbital shaking devices at specific shaking 
frequencies while only the temperature is controlled. The mixing and mass transfer 
within the flasks is achieved due to orbital shaking (Büchs et al., 2000). Flasks not 
containing baffles should be operated in a way in which bubbles are not formed and 
this will provide good gas-liquid mass transfer conditions (Büchs, 2001). pH is kept 
within a reasonable range with the help of buffers and with the use of recent optical 
sensor system. Dissolved O2 can also be accurately measured (Tolosa et al., 2002; 
Witmann et al., 2003). pH can be measured by using invasive pH probes. The 
dependency of shake flasks on orbital shaking for agitation and on surface aeration 
makes reduced oxygen transfer a major limitation in comparison with stirred tank 
reactors (Bareither and Pollard, 2011). Baffled shake flasks with high agitation and 
smaller working volume can be used to maximize oxygen transfer (Lotter and Büchs, 
2004). The use of shake flasks for process development is limited not only because 
of oxygen transfer issues but also because of little similarity to stirred tank 
bioreactors, difficulty to control DO, pH and maintain feed capability (Bareither and 
Pollard, 2011). 
1.3.2.2 Spin tubes  
To increase the throughput and reduce the size of shake flasks, De Jesus et al. (2004) 
developed a scale-down system named “Tube Spin”. Centrifuge tubes of 50 mL are 
used for culturing, set on a rotational shaker in the incubator. In situ control and 
measurement of DO and pH cannot be performed, but the system can still be used for 
large screening experiments, primarily for cell line selection and media optimisation. 
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Vented caps can be used for this system in order to allow gas exchange via the 
headspace. Tube Spin can be connected to an automated liquid handling system to 
increase its capabilities.  
1.3.2.3 Microtitre plates 
Due to their increased throughput, microtitre plates (MTP) are increasingly replacing 
shake flasks (Silk et al., 2010). The pharmaceutical industry invested significantly in 
the development of high throughput screening (HTS), in order to accelerate drug 
discovery. Microtitre plates can be manufactured in a wide range of sizes (6-1,536 
wells) however only 24, 48 and 96 well formats are commonly used in the 
development of bioprocesses. In strain selection process for primary screening the 96 
well plates is normally used (Bareither and Pollard, 2011). Common volumes used in 
microtitre plate vary from 0.025 mL to 5 mL therefore the use of these provide at 
least 50-fold decrease in medium needed compared to shake flasks as well as a cost 
reduction (Silk et al., 2010). This process can be automated with the help of robotics 
with modern pipetting and dispensing systems. In this way, numerous samples can be 
managed in a short period of time. Being able to perform parallel cultivation in 
microwell plates with a reduction in scale and lower labour costs demonstrates that 
new biopharmaceuticals produced will be able to get to the market more quickly 
(Silk et al., 2010). 
Many studies regarding mixing and oxygen mass transfer rate (OTR) in 
MTPs have been published (Lye et al., 2003; Harms et al., 2006), which shows that 
OTR is sufficient to support the needs of suspension cell culture (Chen et al., 2009). 
Microtitre plates face challenges related to liquid evaporation rates while keeping 
acceptable aeration and gas exchange rates (Chen et al., 2009) and contamination 
risks produced by aerosol formation at high shaking rates (Kumar et al., 2004). To 
tackle the online monitoring problem of microtitre plates, non-invasive fluorescent 
technology is used by the incorporation of fluorescence patch sensors into the base of 
each well for monitoring and measurement of OD, pH and DO (Chen et al., 2009; 
Bareither and Pollard, 2011). Silk et al (2010) presented a technique for the 
successful fed-batch culture of mammalian cells (GS-CHO cell line) in shaken 24-
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standard round well plates with growth rates, antibody productivities and viabilities 
that are the same as those in standard shaken flasks. This work demonstrated the 
possibility of carrying out fed-batch mammalian cell cultures in shaken micro well 
formats. 
1.3.2.4 Micro 24 bioreactor 
The Micro 24 is a miniaturized bioreactor system used as a scale-down model for 
cell culture process development. It uses a specialized 24 deep-well plate as shown in 
Fig 1-3. Each individual well can be controlled like an independent bioreactor. In this 
way, throughput can be increased whilst maintaining data quality and quantity. Each 
well contains non-invasive sensors for temperature, pH and DO, as well as a 0.2 μm 
sparge membrane for gas blending using air and a thermal heat conductor. To seal 
each well, vent caps are used. 
 
 
 
 
 
 
Figure 1-3: Micro 24 bioreactor 
Chen et al. (2009) first showed the assessment of the Micro 24 for process 
development of mammalian cell culture. They compared the performance of the 
miniaturized bioreactor (5 mL w/v) with that of a 3L (2 L w/v) bench-scale 
bioreactor using fed-batch culture of CHO cells. DO, pH and temperature were 
controlled within each well and agitation was controlled at plate level. In term of 
gases, N2, clean air and CO2 were monitored and controlled. These experiments were 
carried out to examine the reproducibility between all 24 wells and scalability 
between M24 and the 2 L bioreactor. Similar results have been shown for the two 
systems in terms of percent cell viability, culture doubling time as well as the 
integrated viable cell counts. Ammonia, lactate, glucose and glutamate profiles were 
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also similar when comparing the M24 and 2L bioreactor cultures. This work shows 
that M24 is a good scale-down model for cell culture applications but no engineering 
basis for the M24 – 2L bioreactor comparison was presented. 
1.3.3 Stirred systems  
Stirred systems are generally better than most of the static or shaken systems 
regarding online monitoring and control. Stirred systems give a high degree of 
freedom to increase mass transfer and mixing by increasing gassing rate and stirred 
speed as well as offering a consistent environment (Kumar et al., 2004).  
1.3.3.1 Spinner-flasks 
Spinner-flasks were the first stirred bioreactors designed for animal cell growth 
(Wang et al., 2002). A standard spinner-flask has a stirred shaft and side arms with 
screw caps. The medium and inoculum can be added through these arms as well as 
different types of probes such as pH and temperature, for gassing the flask with O2 
and CO2 (Kumar et al., 2004, Yeatts and Fisher, 2011). The maximum culture volume 
which can be used is dependent on the cell types, how often the culture media is 
changed and how the culture conditions vary throughout the culture cycle. Online 
measurement of cells oxygen uptake rate (OUR) and pH control can be achieved. 
CHO suspension cell cultures can be easily cultivated in spinner-flasks (Kumar et al., 
2004).  
1.3.3.2 Stirred minibioreactors 
Stirred minibioreactors are a miniature version of conventional stirred bioreactors. 
These bioreactors are fabricated from borosilicate glass, polycarbonate or stainless 
steel having the top head-plate made of PEEK (polyetheretherketone) or 
polycarbonate. These are equipped with various ports for probes such as temperature, 
pH and dissolved O2.  Common volumes used vary from 50 mL to 300 mL.  Stirred 
minibioreactors have comparable performance to traditional bioreactors and even if 
these are small, critical operating parameters such as temperature, pH and dissolved 
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O2 can still be monitored and controlled at the required levels. These are ideal for 
research studies or later stage cell culture process development, as small amounts of 
medium are required in order to run long-term fed-batch operations. Some of the 
disadvantages associated with these are their limitations in high-throughput screening 
and their high cost in comparison with other small scale devices as well as a high 
degree of manual operations such as cleaning and sterilization (Kumar et al., 2004).  
1.3.3.3 ambr system (advanced micro scale bioreactor) 
(a)                                           (b) 
  
Figure 1-4: Illustration of (a) ambr microscale bioreactor vessel (b) automated ambr 
workstation   
The ambr is an advanced micro scale bioreactor, which attempts to mimic the 
performance of large scale bioreactors at a 10-15 mL microscale, using disposable 
reactor cartridges. The selection of improved cell lines can be achieved faster due to 
the system’s ability to enable fast evaluation of various bioreactor cultures while 
providing significant savings in terms of materials and labour. The ambr system has 
3 key components: the ambr bioreactor vessel (Fig. 1-4 (a)), which provides the scale 
down mimic, the automated ambr workstation (24 or 48) (Fig. 1-4 (b)), which allows 
parallel bioreactor cultures and saves user time and the ambr software that helps 
process the data. The ambr bioreactor vessel is composed of non-invasive sensors for 
measuring and controlling DO and pH, placed at the bottom of the bioreactor. In 
contrast to the micro 24 system (Section 1.3.2.4) it has a marine impeller just like the 
one used for large bioreactors, a sparge tube for the gas supply with an in-line filter 
and a vessel cap designed for reliable robotic removal and replacement. Automation 
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is achieved for culture set-up, inoculation, liquid additions (media, cells, antifoam, 
feeds), sampling, therefore the risk of cross contamination is minimized. 
Lewis et al. (2010) evaluated the capability of the ambr 24 system to replicate 
the characteristics of classical bioreactors at micro-scale by comparing it to a 7L 
bench-top bioreactor. It has been shown that viability profiles and antibody titres 
obtained in the ambr 24 system under fed-batch conditions are in good correlation 
with those seen in the 7L bioreactor. Batch cultures were carried out simultaneously, 
in all 24 vessels under identical conditions in order to demonstrate reproducible 
growth profiles across all 24 bioreactors. It was demonstrated that the ambr system 
shows good vessel-to-vessel consistency in terms of viable cell number as well as 
consistent antibody titres between individual bioreactors and between the two culture 
stations within the system. Similar work performed by Hsu et al. (2012) and Moses 
et al. (2012) showed good comparability between ambr 24 and 2L, 3L bench-top 
bioreactors, respectively, in terms of online controls, culture performance, 
metabolites and product quality. Nienow et al. (2013) showed good comparability 
between the ambr system and 5L bioreactors as well as investigating the physical 
characteristics of this microscale bioreactor system. Rameez et al. (2014) also 
showed highly reproducible results between the ambr 24 and 3L, 15L and 200 L 
stirred tank bioreactors in terms of cell growth, process capabilities and product titre.    
1.3.3.4 Microfluidic “SimCell” bioreactor 
Seahorse Bioscience Inc. (Billerica, MA) has developed the SimCell system, which 
is a high-throughput micro-bioreactor scale-down model based on microfluidic 
technologies (Kim et al., 2011; Kim et al., 2012). This system is a fully integrated 
robotics platform that was created to reproduce the required conditions within 
suspension culture bioreactors. The platform contains micro-bioreactor arrays, each 
composed of 6 micro-bioreactors. These bioreactors are secured in a cassette-type 
system containing transparent, biocompatible, membranes that allow gas transfer, 
used to reach up to 20 million cells mL-1 (Heath and Kiss, 2007; Legmann et al., 
2009). Each micro-bioreactor has a volume smaller than 800 μL. Oxygen and carbon 
dioxide transfer is possible in each micro-bioreactor due to the gas permeable 
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membrane. Losses due to evaporation are minimized due to their controlled design. 
Agitation of multiple cassettes can be achieved by rotational agitation (20 rpm) 
inside each incubator. Computational fluid dynamics (CFD) confirmed that this 
mimics the expected shear rate of conventional stirred tank bioreactors (Bareither 
and Pollard, 2011). The SimCellTM System is comprised of five incubators, each of 
them able to hold maximum 42 micro bioreactors (MBs) with 1,260 experiments in 
total. At the incubator level, parameters such as gas composition for DO and pCO2, 
temperature and relative humidity can be controlled. Fluorescence detection can be 
used for measuring pH and dissolved oxygen in the micro-bioreactors (Amanullah et 
al., 2010). The “SimCell” system is able to achieve high throughputs (more than 
1000 concurrent experiments) and data generation rates due to a fully automated 
robotics system capable of sampling, controlling temperature, pH and monitoring 
dO2, cell mass by optical density within each of the six microbioreactors on each 
plate (Heath and Kiss, 2007).  
Amanullah et al. (2010) presents the application of SimCellTM micro-
bioreactor for the fed-batch culture of GS-CHO transfectant expressing a model lgG4 
monoclonal antibody. For examining process scalability and reproducibility in a 250 
mL shake flask, 3 and 100 L bioreactors, 114 parallel MBs were used. The 
performance of the MBAs, including viable cell density, MBA protein titer and 
metabolite profiles were compared to those obtained in the shake flask, 3 and 100 L 
bioreactor cultures. Titre profiles, glucose concentration profiles and lactate 
concentration were comparable to the scale-up versions and within ±20 % of 
historical data. The results show that the SimCell platform operated in fed-batch 
mode with pH, glucose and DO control is able to successfully reproduce both shake 
flask and bioreactor cultures and sustain viable cell concentrations up to 12 × 106 
cells mL-1.  
1.4 Impurities in biopharmaceutical manufacturing 
The impurities present during the manufacturing process of therapeutic proteins such 
as mAbs can be divided into two main categories: product and process related 
impurities. Product-related impurities could comprise of unwanted molecular 
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variants of the product such as oxidized forms, precursors, aggregates or degraded 
products. Process-related impurities arise from the manufacturing process itself 
(either upstream or downstream). Process-related impurities include host cell 
proteins (HCPs), DNA, chemical additives  (inducers, antibiotics, protease inhibitors) 
as well as impurities from the downstream process (e.g. leachables such as Protein A, 
plastics, heavy metals) (Shukla et al., 2008; Tscheliessnig et al., 2013).  
1.4.1 Host cell proteins (HCPs) 
HCPs are a unique and complex group of impurities that can be present in the 
supernatant due to secretion of the host cell or released through cell breakage and 
reduced viability of the cells. They account for a large subgroup of process-related 
impurities (associated with the type of process used and not the product itself). It has 
been reported that their presence in the final recombinant mAb product can raise 
safety concerns, as particular HCP species could cause adverse clinical effects in 
humans, even when low levels are present. For this reason it is required to closely 
monitor them and demonstrate that the downstream manufacturing process is able to 
reduce HCPs to acceptable low levels as detected by a sensitive analytical method 
(FDA, 1997). Typical target values of impurities in the final recombinant mAb 
products are <100 ppm of host cell proteins, <5% high molecular weight 
immunogenic aggregates and 10 ng/dose of DNA (Wang et al., 2009; Chon and 
Zarbis-Papastoitsis, 2011; Levy et al., 2014; Reisinger et al., 2014).   
 HCPs are complex in their structure and composition, displaying a wide 
range of properties. A group of HCPs resulting from one process can be very diverse 
compared to another process, presenting different structure, isoelectric points, 
molecular mass and hydrophobicity. They can pose significant challenges to the 
downstream process, due to the varying amount, composition and characteristics 
during a particular cell culture process (Gronemeyer et al., 2014). The protein of 
interest, the host organism, subcellular localization of expression, cell culture and 
harvest conditions have been shown to influence the abundance and composition of 
HCPs present in the harvest material (Shukla et al., 2008; Wang et al., 2009; Jin et 
al., 2010; Gutierez et al., 2012; Tarrant et al., 2012). Jin et al. (2010) explored the 
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effect of several upstream process parameters on HCP profile and found culture 
viability had the most significant impact on the HCP profile. A similar result was 
also published by Tait et al. (2012) which found that most of the HCPs were present 
in the supernatant, originating through lysis or cell breakage associated with a 
decrease in viability. Hogwood et al. (2013) showed that the choice of depth filters 
during primary recovery modified the HCP profile and HCP concentration in 
harvested cell culture fluid. Schirmer et al. (2010) reported a reduction in harvest 
HCP levels of 60 % when the enhanced cell settling method (ECS) was used while 
Shukla et al. (2008) reported 2.3 logs of HCP clearance (LRV) over Protein A step. 
This figure dropped to 1.4 when the “worst-case” strategy was applied. The “worst-
case” strategy involved operating steps at a combination of operating parameters that 
give the poorest clearance of HCPs over that step.  
 A sub-group of these HCPs are known as problematic and prove difficult to 
remove during purification due to their association with the mAb or with the 
chromatographic matrix (Dorai et al., 2011; Aboulaich et al., 2014; Levy et al., 2014; 
Valente et al., 2015). Varying combinations of USP factors that have the potential to 
alter the impurity profile which is then carried on to the downstream process can 
make clearance of these difficult to remove impurities more complicated. Wu (2013) 
showed that the USP composition of HCPs can impact impurity clearance during 
purification. Individual problematic HCPs should be identified early in process 
development (USP) and their clearance monitored during downstream. During 
process development it is essential to understand the impact of the USP and DSP 
process on the HCP profile. This could help reduce the cost of goods by minimizing 
the burden of HCPs on the DSP or through the implementation of alternative, more 
cost effective methods. Ensuring a minimal HCP content in the supernatant could 
reduce the risk of any residual immunogenic HCPs to be found in the final drug 
product (Hogwood et al., 2014).  
1.4.2 Analytical tools for detection, monitoring and quantitation of HCPs 
Highly sensitive and appropriate analytical methods are required for measuring 
HCPs at various stages within the manufacturing process, in order to support process 
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development, validation and to ensure regulatory approval. The ideal method (or 
combination of methods) should be able to produce quantitative results, to identify 
all HCP species present in a sample, to provide high-throughput measurements and 
have a short processing time (Tscheliessnig et al., 2013). The current methods 
currently used to monitor, measure and identify HCPs are split into two categories: 
immuno-specific and non-specific. Immuno-specific methods identify HCPs by using 
polyclonal anti-HCP antibodies produced by immunization of a production animal 
(rabbits or goats) using supernatant or partially purified material from a relevant null 
cell line culture. A null cell line refers to a production cell line that does not have the 
product coding gene (Jin et al., 2010; Tscheliessnig et al., 2013). Nearly all 
biopharmaceutical companies use antibody reagents that were generated especially 
for their cell lines. Immuno-specific methods include ELISA, western blot and slot 
blot while non-specific methods include gel electrophoresis and mass spectrometry. 
Commonly used methods are described below.   
1.4.2.1 ELISA 
Enzyme-linked immunosorbent assay (ELISA) is an immuno-specific method and is 
the current gold-standard approach used to detect and measure total HCP 
concentrations during bioprocessing manufacturing and in the final drug substance. 
These assays are highly selective; provide high sensitivity and high-throughput mode 
operation. While ELISA can provide a good evaluation of the total level of HCPs in 
a given sample, it does not give any information on the specific HCP species that are 
found within the whole population. This prevents determining the risk associated 
with certain problematic HCPs (Jin et al., 2010; Bracewell and Smales, 2013; 
Hogwood et al., 2014; Thompson et al., 2014; Zhu-Simoni et al., 2014; Bracewell et 
al., 2015). ELISA cannot be used to identify qualitative changes in HCP population 
(Reisinger et al., 2014). Another drawback with this assay is the fact that in any anti-
HCP antibody pool, there are no antibodies that are able to identify every HCP 
species that might be present. There is the likelihood that very weak immunogenic or 
non-immunogenic species will not be identified (Bracewell et al., 2015). The 
sensitivity of this method relies on the antibody reagent used and generic HCP assay 
 54 
 
kits might not be able to identify a wide range of HCPs, resulting from different cell 
line. Cell-line specific assays would provide improved sensitivity.  ELISA has been 
an invaluable tool for measuring and monitoring HCP concentrations during process 
development as well as in the final drug product and it will continue to be widely 
used by the biopharmaceutical industry to monitor and control HCPs. Another 
method for quantifying HCP levels is fourier transform mid infrared spectroscopy 
(FT-MIR). This method has the advantage of being able to measure the HCP 
concentration directly in the bioreactor or in a bypass. Capito et al. (2012) used FT-
MIR to quantify HCPs in a CHO cell culture fluid producing mAbs, after treatment 
with different polyelectrolytes for semi-selective clarification. The results were 
comparable to those obtained by ELISA.  
1.4.2.2 Gel electrophoresis 
Since ELISA is not capable of determining the diversity of HCPs within a sample, or 
how the HCP composition changes throughout a manufacturing process, extra 
methods to complement ELISA need to be used to be able to provide a more in-depth 
analysis of the HCP population (Bracewell et al, 2015). Due to the drawbacks of 
antibody-based immunoassays and the problem of identifying problematic HCP 
species which have the ability to associate with the product, it is crucial to use 
orthogonal methods that do not depend on immunoreactivity of HCP for HCP 
detection (Zhu-Simoni et al., 2014). ELISA can be used together with non-specific 
methods such as 1D- and 2D- polyacrylamide gel electrophoresis (1D/2D-PAGE). 
Gel electrophoresis is generally used to provide qualitative analysis of proteins 
within a sample. 2D electrophoresis is more regularly used during process 
development and characterization, in order to monitor changes in the HCP profile. 
They have the ability to analyze different HCPs on a single gel. 2D-PAGE gels 
separate HCPs first on the basis of the isoelectric point followed by separation due to 
size. The sensitivity of detection can be enhanced by the use of different staining 
methods which allows visualization of less abundant spots (Tscheliessnig et al., 
2013; Hogwood et al., 2014).  
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Gel-based methods are unable to identify low abundance HCPs, are labour 
intensive, time consuming and low throughput, also many HCPs could be masked by 
the product. 2D-PAGE gels can be used in combination with mass spectrometry 
(MS) to identify the specific HCPs correlating to particular spots on the gel. They 
have been widely used to examine the HCP composition at different stages of the 
manufacturing process, either by themselves (Jin et al., 2010) or in combination with 
mass spectrometry (Tait et al., 2012; Tarrant et al., 2012; Hogwood et al., 2013; 
Aboulaich et al., 2014; Levy et al., 2014; Valente et al., 2015). Jin et al. (2010) used 
2D-PAGE to estimate differences in HCP composition under different upstream and 
harvest conditions while Hogwood et al. (2013) used 2D-PAGE to investigate HCPs 
that are present post Protein A from both a mAb producing and null cell lines.      
1.4.2.3 Mass spectrometry (MS)  
Tscheliessnig et al. (2013) and Hogwood et al. (2014) presented several orthogonal 
methods that can be used to complement ELISA as well as 2D-PAGE gels. The 
method that has been widely used in recent years and appears to be the main 
complementary tool to ELISA is mass spectrometry. Mass spectrometry has the 
capability to detect and monitor multiple HCPs, including low abundance proteins, in 
the same sample, in a short time and in a HT way. Matrix-assisted laser 
desorption/ionization time-of-flight mass spectrometry (MALDI-TOF MS) and 
surface-enhanced laser desorption/ionization time-of-flight mass spectrometry 
(SELDI-TOF MS) are common mass spectrometry methods that either alone or in 
combination with 2D-PAGE gels have been used to monitor HCPs during process 
development. In comparison to 2D-PAGE gels that are not high throughput, require 
large sample volumes and are labour intensive, SELDI-TOF is much faster and 
requires smaller sample volumes. Both methods give information across distinct 
mass ranges, SELDI-TOF being able to provide information in the low molecular 
weight range whilst 2D-PAGE giving information across a higher molecular weight 
range.  
 Tait et al. (2012) used SELDI-TOF MS as a comparison method to 2D-PAGE 
gels, to investigate supernatant HCP profiles at different times throughout the 
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culture. Valente et al. (2015) used 2D-PAGE gels in combination with MALDI-
TOF/TOF MS to identify HCPs in harvest material that showed varied expression 
across different cell ages. Tarrant et al. (2012) used SELDI-TOF MS to determine 
the impurity profile within Protein A eluate pools for four different resins. Using this 
method they identified a number of residual HCPs present after Protein A. Pezzini et 
al. (2011) used mass spectrometry to determine the HCP profiles in the elution 
fractions of four different mixed-mode chromatography resins.  
 Liquid chromatography techniques can be coupled with mass spectrometry 
(LC-MS/MS) for the identification and quantification of HCPs from CHO cells 
(Doneanu et al., 2012). Thompson et al. (2014) presented an HCP enrichment 
method combined with LC-MS/MS which improved the identification and 
determination of relative abundance of HCPs present in a mAb drug product. After 
the enrichment step it was possible to identify 19 HCPs, compared to only one before 
the method was applied. There are also computer-based methods used for HCP 
identification and risk assessment (bioinformatics portals) (Wang et al., 2009) as well 
as for analyzing the immunogenicity risk from HCPs in CHO-based protein 
production (Bailey-Kellogg et al., 2014).    
1.5 Problematic HCPs 
1.5.1 Introduction  
The development of high producing recombinant protein expression systems is 
causing increased focus to be placed on the product’s composition and the 
downstream processing steps required to remove process-related impurities such as 
HCPs, lipids, DNA, etc. Even though this is the case, limited knowledge still exists 
about the range of HCPs that are problematic either by associating with the product 
throughout the manufacturing process and potentially eliciting an immune response 
in patients and/or causing product modification. There is also limited understanding 
regarding the relationship between the protein of interest, bioprocess conditions (both 
in USP and DSP) and problematic HCPs (Bracewell and Smales, 2013).  
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After the purification process, low levels of residual HCPs can still be found 
in the final product (Thompson et al., 2014). The main concern regarding the 
presence of residual HCP impurities in recombinant protein therapeutics is their 
potential impact on patient safety, by inducing an unwanted immune response with 
serious side effects. For this reason, HCP levels need to be reduced to a limit that is 
considered safe by the regulatory authorities. At present, immunoassays such ELISA, 
are almost always used to measure and monitor the total amount of residual HCP, but 
the composition is generally unknown. The levels of specific, critical HCPs are not 
independently measured (Zhang et al., 2014). Protein A affinity chromatography is 
the workforce of the mAb purification process due to its high specificity and 
capability to remove a large fraction of the total HCP and most other impurities in 
the supernatant (Butler et al., 2012; Zhang et al., 2014; Gronemeyer et al., 2014). 
Even after Protein A, problematic HCPs can still be found in the product fraction as 
well as persisting throughout the whole downstream process until final product 
(Aboulaich et al., 2014). Recent work has confirmed the need for a better 
understanding of the presence and potential risk of certain problematic HCPs. 
  HCPs can be found in the product fraction of bind-and-elute chromatographic 
steps. This can be due to two main methods. The first method is product-association 
(Shukla and Hinckley, 2008; Tarrant et al., 2012; Levy et al., 2014; Aboulaich et al., 
2014) through strong interactions that specific HCPs have with the mAb, resulting in 
their binding to the product. These species can then be transported through the DSP 
process, in combination with the mAb. The second mechanism involves certain 
HCPs binding to either the resin backbone or the ligand of the chromatographic step, 
resulting in their elution into the product fraction (Tarrant et al., 2012; Levy et al., 
2014; Valente et al., 2015). Out of the two mechanisms, the HCP-mAb interaction 
seems to be the more common cause by which problematic HCPs are found in the 
final product. Previous research performed by Tait et al. (2012), Nogal et al. (2012), 
Sisodiya et al. (2012) and Hogwood et al. (2013) has demonstrated that interactions 
during Protein A affinity chromatography are generally the main cause of HCPs co-
purifying with the product during the purification process. They have also noted that 
mAbs might interact only with specific subpopulations of the total HCPs (Aboulaich 
et al., 2014; Levy et al., 2014). Levy et al. (2014) showed that intracellular proteins 
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(found in cytoplasm, lysosome) represent a large fraction of all proteins interacting 
with mAbs. This emphasizes how minimizing HCP levels upstream might ease the 
pressure on downstream process in terms of HCP removal. A subgroup of 118 HCPs 
have been mentioned in literature as particularly hard to remove during downstream 
purification due to one of the two described mechanisms (Valente et al., 2015). 
Several publications have presented the importance and implementation of 
wash steps in order to disrupt HCP-mAb interactions during the purification of mAbs 
using Protein A affinity chromatography (Shukla et al., 2008; Shukla and Hinckley, 
2008; Aboulaich et al., 2014). Shukla and Hinckley (2008) compared the efficiency 
of various intermediate wash buffers in terms of their capability to disrupt HCP-mAb 
interactions during Protein A and identified a potential wash that can be used as a 
platform wash condition for Protein A (25 mM Tris, 10% isopropanol, 1 M urea and 
pH 9.0).  Aboulaich et al. (2014) investigated the effects of different wash modifiers 
on dissociating HCP-mAb interactions. They found that a combination of two wash 
modifiers (e.g. urea and sodium caprylate; caprylate and arginine) can have the 
potential to enhance HCP clearance through combined effects, reducing different 
types of interactions such as hydrogen bond, electrostatic and hydrophobic 
interactions. Levy et al. (2014) shows that by applying a high-salt wash, product-
associated impurities in a protein A affinity chromatography could be removed 
before product elution.   
Process-related impurities must be closely monitored and removed during the 
downstream process, to ensure that their concentration in the final product does not 
exceed the general guidelines of less than 100 ppm (ng/mg) for HCPs and 10 ng/dose 
for DNA (Chon et al., 2011). Important questions arise about what forms/ species of 
HCPs make up this 100 ng/mg limit and if any of the individual proteins found in 
this general mass defined as residual HCPs are likely to transform the product 
through association with it or enzymatic activity. There is reason to believe that this 
final HCP target might not be acceptable and instead of defining a general limit for 
all HCPs, there should be a more detailed criteria, based on a better understanding of 
the HCP population present (Bracewell et al., 2015). 
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1.5.2 Common problematic HCPs  
1.5.2.1 Protease 
Unwanted proteolytic activity is well known in mAb manufacturing due to an 
unknown mixture of proteolytic enzymes likely to be present among the broad range 
of HCPs present in the harvested cell culture fluid (Sandberg et al., 2006). The issue 
of proteolytic degradation of recombinant proteins is more common in serum-free 
cultures, due to the absence of serum proteins which would adsorb the proteases 
released in the culture medium (Elliott et al., 2003).  
There are numerous examples in literature that identify proteases as being 
problematic HCPs, by either association with the product or due to their impact on 
the therapeutic protein’s structural stability. Sandberg et al. (2006) describes how 
metalloproteases can destabilize Factor VIII production in CHO cells, Robert et al. 
(2009) and Dorai et al. (2011) showed how aspartic proteases and serine-threonine 
proteases are responsible for the fragmentation of fusion recombinant proteins and 
Gao et al. (2011) reports a high-purity human IgG1 mAb exhibiting fragmentation, 
that can be associated to residual proteolytic enzyme activity. In more recent studies, 
Dorai and Ganguly (2014) show how the presence of intracellular and secreted 
proteases can result in the enzymatic degradation of recombinant proteins, during 
fermentation and Aboulaich et al. (2014) identified serine protease as a problematic 
HCP, as it bound to all four mAb investigated and had the potential risk to cause 
enzymatic degradation of the mAbs. Serine protease was also identified as a 
purification challenge by a few other publications, which have seen it persist after 
Protein A chromatography (Doneanu et al., 2012; Hogwood et al., 2013) and mixed-
mode chromatography (Pezzini et al., 2011). Wang et al. (2014) outlines the 
significant impact residual host cell proteases can have on the long-term storage 
stability of the product. The US FDA raised safety concerns regarding these 
impurities, by delaying two Phase III clinical trials, as a result of antibodies against 
residual HCPs being present (Gutierrez et al., 2012).  
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In order to minimise the impact of degrading enzymes, such as proteases, the 
addition of inhibitors could in some cases be advantageous (Robert et al., 2009). 
Dorai et al. (2011) showed how protease cocktail inhibitors as well as inhibitors for a 
specific protease class (serine-threonine) inhibited the clipping process of a fusion 
protein. Clipping is a common cause of protein degradation, mostly attributed to the 
activity of proteases released by cells. The use of inhibitors specific for a particular 
type of proteases can also help identify the exact variety that is responsible for 
product degradation. Dorai et al. (2011) also investigated the effect of specific 
inhibitors for cysteine protease, metalo-protease and aspartic acid protease, each of 
them with no effect on the clipping process.  
1.5.2.2 Thioredoxin  
The thioredoxin system or parts of the thioredoxin system (TXN1) have been 
identified as being the causative factor for the reduction of inter-chain disulphide 
bonds of monoclonal antibodies produced by CHO cell culture upon scale-up (Kao et 
al., 2010; Trexler-Schmidt et al., 2010; Koterba et al., 2012). The thioredoxin system 
is present in the cytoplasm and together with glutathione/glutaredoxin system 
maintains the cellular redox balance and keeps intracellular protein disulfides 
reduced. The thioredoxin system is also known as a cell antioxidant (Koharyova and 
Kolarova, 2008; Kao et al., 2010).  
Trexler-Schmidt et al. (2010) firstly identified this problem during harvest 
operations and determined that the cause was the release of cellular enzymes due to 
mechanical cell shear. They tested several approaches to try and prevent disulfide 
reduction and found various levels of chemical inhibitors (EDTA, CuSO4, L-cystine), 
air sparging and low harvest cell culture fluid (HCCF) pH efficiently inhibited the 
mAb disulfide reduction. Kao et al. (2010) has built on the work of Trexler-Schmidt 
et al. (2010) and further identified through an in vitro experiment, that an active 
thioredoxin system or other reducing enzymes with thioredoxin-like activity were 
responsible for the mAb reduction problem in the HCCF. As the main causes for 
mAb reduction were identified to be the Trx system, hexokinase and G6PD, any 
inhibitor targeting any of these enzymatic pathways has the potential to prevent 
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disulfide bond reduction in mAb manufacturing. Koterba et al. (2012) also identified 
reduction of the mAb’s disulfide bonds during large-scale manufacturing of an IgG1 
mAb in CHO cells. They established that mammalian thioredoxin 1 (TXN1) is the 
enzyme responsible for the reduction and showed that by using transduction of a 
lentivirus expressing TXN1 shRNA, the expression of TXN1 in CHO cells can be 
reduced and the disulfide bond reduction prevented.  
1.6 Statistical modelling  
1.6.1 Introduction 
High value pharmaceutical products such as vaccines, hormones and monoclonal 
antibodies are mainly produced using mammalian cell cultures. Culture conditions 
are highly specialized and by making minor variations to these conditions cells are 
likely to either become nonviable or have reduced productivity. Mammalian cells 
have a very complex internal structure where interlinked biochemical processes take 
place, therefore making an accurate prediction of cell culture behaviour represents a 
significant challenge (Kontoravdi et al.,2005; Sidoli et al., 2005). 
Some of the most important aims of biopharmaceutical industry are the 
optimisation of cell culture processes in order to maximize antibody production as 
well as to reduce the time to market. An important task in defining an optimisation 
strategy is to identify and predict cell culture behaviour (De Alwis et al., 2007). In 
order to improve antibody production yields, cell culture experimentation is used. This 
involves trial and error optimisation of cell culture parameters, resulting in a large 
number of experiments, which can be time-consuming and expensive (Ho et al., 2006). 
Using mathematical models, initial experimental information can be organized in a 
coherent manner which helps identify and quantify key relationships between 
variables, process parameters and product output rates (Bailey,1998). Parameters that 
have significant effect on antibody production could  be identified by analysing these 
mathematical models. These can then be singled out for more detailed studies and used 
to help design experiments. This approach will result in a significant reduction in the 
required number of experiments with time and cost-saving implications (Ho et al., 
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2006). Using mathematical relationships to characterise different parts of mammalian 
cell culture behaviour and their integration into a predictive model, would contribute 
to the control of product quality and maximization of antibody production (Sidoli et 
al., 2004). The aim of mathematical modelling for mammalian cell cultures includes 
substitution of expensive and time consuming laboratory experiments with in silico 
ones, developing model-based algorithms for controlling product quality (Kontoravdi 
et al., 2005, 2007), process characterisation and identification of design space (Amit, 
2010; Abu-Absi et al., 2010; Rouiller et al., 2012) and the probability of process 
outputs falling out of specification (Stockdale and Cheng, 2009; Eon-Duval et al., 
2012b).  
1.6.2 Multivariate Data Analysis  
Biotech unit operations are often described by a large number of inputs (operational 
parameters) and outputs (performance parameters) along with complex interactions 
between them (Rathore et al., 2014). Given the large amount and complexity of 
variables in biological systems, it is almost impossible to extract and analyse the 
information using simple charting, univariate or bivariate methods of analysis. These 
types of analyses are usually ineffective and likely to result in misleading 
conclusions (Kourti, 2004; Kirdar et al., 2008). Significant information can be found 
in the correlations among process parameters and this information is overlooked 
when parameters are analysed independently (Rathore et al., 2014). This large 
amount of complex data needs methods of analysis that are able to handle multiple 
variables simultaneously but also reveal the relationship between them. 
Multivariate data analysis (MVDA) can overcome challenges associated with 
univariate or bivariate analysis such as missing data, variation introduced by 
deviating factors (noise and experimental error) and multicollinearity (Martin et al., 
2002; Kirdar et al., 2008). Multivariate data analysis is the analysis of multiple 
statistical variables at the same time and it helps understand, visualize and make 
predictions from the data. MVDA has significant advantages over traditional 
statistical tools. The powerful data mining abilities allows the analysis of complex 
data sets to identify essential patterns, while advanced regression methods can be 
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employed to accurately predict the system’s performance. It can predict the effect a 
change in one variable will have on other variables (www.camo.com). Multivariate 
data analysis in combination with design of experiments can greatly benefit biotech 
companies by improving process quality and understanding, reducing development 
timeframes and manufacturing costs and minimising time to market. Multiple linear 
regression (MLR), principal component analysis (PCA) and partial least squares 
(PLS) are some of the commonly used projection and regression methods in 
multivariate data analysis (Rathore, 2007).  
PCA is a mathematical analysis that provides a tool for dimensionality 
reduction leading to better visualisation and quantification of relations between the 
many variables. It uses an orthogonal transformation to convert a set of observations 
of potentially correlated variables into new, uncorrelated variables called principal 
components. The first principal component explains the highest variability in the 
data, with each folowing component, which are orthogonal to the previous principal 
components, accounting for most of the remaining variance (Kirdar et al., 2008; 
Rathore et al., 2014). 
PLS is a regression analysis technique for modelling relations between sets of 
observed variables. PLS constructs new predictor variables, named latent variables, 
which are optimal linear combinations of the original explanatory variables. As 
opposed to PCA which is generally used for the determination of trends, clusters and 
outliers and process analysis, PLS is used to relate process parameters to process and 
product quality attributes (Schwartz et al., 2009; Rathore et al., 2011; Abdi & 
Williams, 2013; Rathore et al., 2014). PCA and PLS are both methods that help 
compress data by keeping important information and disregarding the noise.  
Multiple linear regression (MLR) is a mathematical technique used to model 
the relationship between multiple independent predictor variables and a single 
dependent outcome variable (Marill, 2004). Multiple regression has the ability to 
predict an unknown response variable corresponding to a set of predictor variables as 
well as understanding the functional relationships between the dependent and 
independent variables. When multiple regression is used for prediction, the result is 
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an equation containing partial regression coefficients (McDonald, 2013). MLR 
provides a linear equation with respect to the predictor variables, but is unable to 
integrate any non-linear relationships that may occur between the predictors and the 
response variable. The linearity is only restricted to the model’s coefficients 
therefore the predictor variables can be non-linear. This allows the addition of non-
linearly transformed predictor variables (e.g. quadratic terms) in the linear regression 
modelling. Integrating such variables in the analysis allows for the non-linear 
behaviour in the data and the interaction between different variables to be taking into 
account while still having an easy explicable linear model (Hassan et al., 2013).  
1.6.3 Cell culture models  
Cell culture mathematical models are usually classified as mechanistic (kinetic) and 
empirical (statistical) models. Empirical models are only expected to accurately 
describe a set of observation, without taking into account the underlying mechanism. 
On the other hand, a mechanistic model describes the process, either directly 
observable or unobservable, under which the data was generated. In predictive 
microbiology models involve more empirical components (Baranyi and Pin, 2001). 
Mathematical models can play an essential role in the optimisation and control of 
bioreactors and fermentation processes. 
1.6.3.1 Kinetic models  
Tsuchiya et al. (1966) presented a microbial model classification spectrum that can 
also be applied to mammalian cell models. In this long established classification 
system, a mathematical kinetic model can be organized into each of the following 
categories (Sidoli et al., 2004): unstructured versus structured, unsegregated versus 
segregated, deterministic versus stochastic. Description of each model type in 
regards to cell culture modelling is presented in Table 1-5. 
Unstructured kinetic models  
Unstructured models are empirical and generally use extracellular data that is 
typically monitored during a culture, while considering intracellular processes as a 
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“black box”. Even though this method does not allow in depth study of cellular 
processes, these kinds of models have been described as being important in 
supporting optimisation and monitoring strategies (Provost and Bastin, 2004). In 
addition these models are useful for new cell systems when data is limited (Ho et al., 
2006). Quite a few examples of unstructured models used to describe mammalian 
cell growth (hybridoma cells) have been presented in the literature (Glacken et al., 
1989; Frame and Hu, 1991; Xie and Wang, 1994; Zeng, 1996; Jang and Barford, 
2000).  
Table 1-5: Classification system of mathematical kinetic cell culture models* 
* Adapted from Sidoli et al. (2004); Kontoravdi et al. (2007a, 2007b) 
Structured kinetic models  
Structured kinetic models, as opposed to unstructured kinetic models, which do not 
take into account the inner structure of the cell, incorporate biological knowledge by 
grouping the biomaterial into distinct compartments (Sidoli, Matalaris and Asprey, 
2004). Many structured models have been reported in literature (Tsuchiya et al., 
1966; Harder and Roels, 1982; Lee, 2001). As the number of parameters greatly 
increases with such detailed models, it becomes hard to provide parameter estimation 
(Flickinger, 2013). A structured, segregated and stochastic model offers the most 
realistic representation of cell behaviour during cell culture (Sidoli et al., 2004).  
Classification Description 
Unstructured Does not take into account the inner structure of the cells 
Structured 
Incorporates biological knowledge by separating the cells 
into compartments that are chemically and/or physically 
distinct 
Unsegregated 
Cell culture is homogeneous and composed of identical 
average cells 
Segregated 
Cell culture is heterogeneous and composed of cells in 
different stages of development 
Deterministic Cellular processes are not subject to variability 
Stochastic Cellular processes are random 
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1.6.3.2 Hybrid models  
Several hybrid models used in chemical and biochemical engineering have been 
presented in literature throughout the years (Schubert et al., 1994; Roubos et al., 
2000; Roubos, 2002; Ho et al., 2006; Kontoravdi et al., 2007). Hybrid models are 
powerful tools for process monitoring, control and optimisation (Galvanauskas et al., 
2004).  
1.6.3.3 Statistical models  
Kinetic versus statistical models  
Unstructured kinetic models are mechanistic models, which use mathematical and 
kinetic equations to describe growth rate, substrate consumption and product 
synthesis. A structured model can be developed from an unstructured kinetic model 
while splitting the whole process into small parts for a more detailed assessment. In 
terms of cell culture processes, the metabolism and growth of cells are multistage 
and complex biochemical processes, thus it is nearly impossible to produce a 
complete description of the growth and production mechanism. These structured 
models require the measurement of large numbers of parameters (Baughman and 
Liu, 1995), therefore are rarely used for the design, control and optimisation of 
bioprocesses. Statistical (empirical) models are alternatives to conventional model 
approaches, which are guided by kinetics, material and energy conservation rules 
(Lee and Gilmore, 2006). One of the disadvantages of statistical models when 
compared with structured kinetic models is the need for large number of experiments 
to investigate relationships between factors and responses. A solution to this is the 
use of design of experiments (DoE) approach, which minimises the number of 
experiments that need to be performed.  
Design of experiments  
Statistical methods require a large number of experiments. In most cases, cost, time 
and required resources limit the process of generating large amounts of data, 
therefore the data obtained needs to be rich in information. Using a statistically 
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designed experiment provides a good solution for acquiring information-rich data 
from the process of interest (Haaland, 1989, Montgomery, 2004). The design of 
experiments (DoE) is a computer-enhanced, systematic approach to experimentation 
that considers all factors simultaneously. The objective of a statistically designed 
experiment is to obtain effective results in the shortest possible time and with 
minimum resources (Cornell, 2002, Myers and Montgomery, 2002). Statistical 
models can be useful when there is no accurate mathematical model equation as well 
as when there are complex biochemical reactions and interaction between variables. 
Statistically designed experiments offer the ability to analyse many variables at the 
same time, with a low number of observations (Lee and Gilmore, 2006). 
1.6.4 Predictive modelling  
The introduction of the QbD concept has changed the way of looking at process 
understanding and control in the pharmaceutical and biopharmaceutical industry. 
Risk assessments, design of experiments, predictive models, process analytical 
technology and data analysis are essential tools within QbD. Process modelling is an 
essential part of the QbD framework (Kourti, 2015). Models are useful in facilitating 
process understanding and control, determination of design space and process 
development, making them part of the product lifecycle (Kourti, 2010). Statistical 
models combined with scale-down HT experimental systems can help improve the 
ability of gaining a much better design space confidence.  
Abu-Absi et al. (2010) developed regression models for specific growth rate 
and final viability at the seed bioreactor stage as well as normalized titre, high 
molecular weight (HMW) aggregate species, N-Linked oligosaccharide profile and 
analytical CEX change variant profiles at the production bioreactor stage. The design 
space for a monoclonal antibody cell culture process was mapped. The operational 
parameters at each stage (vial thaw, shake flask inoculum expansion, seed bioreactor 
and production bioreactor) were prioritized by a risk analysis approach such as 
failure modes and effects analysis (FMEA) and classified as non-key, key and 
critical. The model terms with significant effects on titre were seed bioreactor 
temperature, seed bioreactor final viable cell density (VCD), production bioreactor 
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temperature shift timing, production bioreactor pH, production bioreactor initial 
VCD and production bioreactor dissolved oxygen. The resulting regression model 
for titre had a reasonable prediction capability (predicted R2 of 0.61). Using 
predictive models, process conditions were optimised in order to achieve high 
product titre while controlling glycosylation.  
Rouiller et al. (2012) generated models for product titre, bioactivity and the 
levels of various product variants (glycoforms, oxidized forms), product-related 
impurities (HMW species, clipped forms) and process-related impurities (HCP, 
DNA). The production bioreactor step of an Fc-Fusion protein manufacturing cell 
process was characterized following quality by design (QbD) principles. A risk 
assessment exercise was employed to identify potential critical and key process 
parameters with a possible impact on product quality and process performance. 
Analysis of variance (ANOVA) was used to generate models for titre and each of the 
critical quality attribute identified using Design Expert software. The parameters 
influencing product titre were pH, dissolved oxygen (DO), culture duration and 
seeding density, while those influencing HCP were pH and to a lesser extent 
dissolved oxygen and culture duration. The resulting models were used to define the 
cell culture design space. The design space established for cell culture process 
resulted in the establishment of operational ranges for pH, DO and cell culture 
duration in order to provide consistent delivery of a cell culture harvest that meets 
the DSP requirements for impurities and the drug substance.   
1.7 Bioprocess economics modelling  
1.7.1 Introduction  
The success of new biopharmaceutical candidates relies more and more on economic 
issues. Pressures for cost and time reduction of drug development lead to links being 
made between a company’s manufacturing strategy and business strategy (Farid et 
al., 2005b). In order to minimize cost of development, reduce time-to-market and 
quantify risks for maintaining economic returns, fast and effective tools are 
necessary. Computer-aided design tools are able to help achieve these objectives and 
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guarantee rapid delivery of drugs to patients. The use of software tools to help make 
business decisions is critical. The application of process-cost modelling enables rapid 
comparison of different manufacturing and development options (Lim et al., 2010). 
Simulations can be used for cost analysis, resource utilization and mass balance 
assessment and are an important part in the analysis and selection of process options 
and characterization of unit operations, contributing to better decision-making in 
terms of business and process needs (Lim et al., 2005).  
1.7.2 Factors impacting COG/g 
In order to lower COG/g, efforts are made to try and decrease batch costs or to 
increase the overall process productivity by an increase in step yields. Increases in 
titres are expected to have a significant impact on lowering COG/g, assuming that 
DSP costs do not countermand the improvements in USP. As titres increase, the main 
costs of the manufacturing process are shifted to the DSP process as high proteins 
loads are needed to be purified by the chromatography steps (Butler and Meneses-
Acosta, 2012). This would result in adopting higher number of cycles or purchasing 
larger columns in order to cope, leading to an increase in costs per batch. The overall 
COG/g could still be reduced if the increase in the overall productivity compensates 
the higher DSP costs. As mAb titres will increase further in future years, the 
purification process will become a significant contributor to the overall COG/g and 
will drive the need for optimisation and cost savings (Farid, 2009).  
 The number of downstream steps as well as the yield of each step has an 
impact on the overall DSP yield. Increases in step yields combined with a reduction 
in DSP steps have led to a 40-75 % increase in overall yield, contributing to lower 
cost of goods (Werner et al., 2004; Li et al., 2005). Sommerfeld and Strube (2005) 
highlighted the importance of individual step yield increase on the overall COG/g. 
They showed that increasing the average step yield in a seven-step process from 85 
to 95 % led to an increase in the overall yield from 30 to 70 %, corresponding to a 40 
% lower downstream COG/g. In mAb manufacturing, the overall yield could be 
improved through the elimination of buffer exchange steps, by developing 
chromatography steps able to process material eluted from the previous step, with no 
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further treatment. Higher protein loads resulted from high titre cultures has an impact 
on the capacity of chromatography columns, especially when the limit for column 
diameters is 2 m. More cycles required to cope with the increased load will result in 
longer processing times, reducing the facility throughput and influencing COG/g. 
Improvements in resin binding capacity would reduce resin volumes and amount of 
buffer used. This would reduce consumables costs, a main part of the COG/g at 
higher demands and titres (Sommerfeld and Strube, 2005; Farid, 2009).  
1.7.3 Classification of process economic models 
Standard process economic models deal with problems such as predicting COGs, 
capital investment and cash flow analysis as well as risk assessment and project 
management. In order to determine COGs for a process, process models need to be 
combined with cost models (Farid et al., 2000). Certain parameters from process 
models such as resource usage and overall output are essential to COG models (Farid 
et al., 2005a, Mustafa et al., 2006). When selecting an appropriate software platform 
for these models, factors such as the desired outputs, the tool’s requirements 
specification and the level of detail need to be considered. Based on which decisions 
are made, the model can be static or dynamic and deterministic or stochastic (Table 
1-5). 
Table 1-6: Classification system of process economic models  
 
Classification Description 
Static   Unable to account for time dependent variations 
Dynamic  
Allow the evaluation of simultaneous processes over time  
Enable a more realistic estimation of cost 
Deterministic  Process outputs do not account for risk  
Stochastic  
Incorporate uncertainty within outputs  
Give a more realistic overview of the process 
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1.7.3.1 Static versus dynamic models  
Static models are the most commonly used models, spreadsheet-based, simple and 
easy to build. Static process models can be combined with cash flow models, to work 
out how profitable investments are as well as to COGs models in order to obtain the 
cost breakdown and evaluate how sensitive COG is to different process parameters. 
These can be best applied to estimate costs in early stages of projects. Puich and Paz 
(2004) showed that static models are not suited for situations where delays occur due 
to resource constraints.  
 Dynamic models are more complicated to build and use compared to static 
models, but these provide a more realistic tool for outputs estimation such as cost and 
throughput. They are time-dependent therefore they can evaluate how operations will 
change over time. Dynamic models are able to analyse simultaneous events, logistics 
and delays taking place during manufacturing process due to resource limitations 
(Puich and Paz, 2004, Rathore et al., 2004, Farid, 2007a). Dynamic process models 
are best implemented using discrete -event software packages while COG and cash 
flow are better observed in spreadsheet-based software (Mustafa et al., 2004, Lim et 
al., 2005, Lim et al., 2006).  
1.7.3.2 Deterministic versus stochastic models  
Deterministic models are conventional process models, which assume the process is 
certain if the inputs are fixed. The process outputs do not account for risk that might 
occur. This is not realistic as a manufacturing process is always facing technical and 
market-related uncertainties such as batch failures, cell culture titres, purification 
yields and processing time (Biwer et al., 2005, Lim et al., 2006).  
Stochastic (or probabilistic) models are models in which some of the model’s 
components are taken from a probability distribution. The outputs of these models 
are able to capture uncertainties giving a more realistic overview of the process 
studied (Wang, 2010). An overview of the deterministic and stochastic bioprocess 
economics models presented in the next section are shown in Fig. 1-5.
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Figure 1-5: Overview of deterministic and stochastic bioprocess economic models presented in this section 
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1.7.4 Deterministic process economics 
1.7.4.1 Biosolve  
Biosolve is a Microsoft Excel-based process-cost modelling tool that can be used for 
the optimisation and development of cost-effective bioprocesses. It can be applied in 
early stages of process development in order to recognize the impact of scale, as well 
as financial impact and to help make better business decisions. Biosolve can also be 
used to examine the most recent technologies and analyse their impact on specific 
processes (www.biopharmservices.com). The software is easy to use particularly by 
users that are already familiar with Microsoft Excel and it has a flexible 
configuration. Within the cost model a sequence of unit operations is defined. 
Process parameters such as flux rates and binding capacity can be specified as well 
as personnel requirements and operating time. The effects of varying different 
parameters on the operating costs can be analysed through two analysis tools: 
Sensitivity and Scenario. A cost database is included within the model to maintain 
costs regarding labour, consumables, etc. The main outputs of the software include 
capital investment, materials cost, all of which play a part in the COG calculation 
(Lim et al., 2010).  
Sinclair (2010) used the Biosolve software to assess the impact of different 
geographic locations on the COGs of a standard monoclonal antibody process. A 
case study is used to estimate cost contributions of different single-use systems on 
the manufacturing costs, making the comparison with stainless steel systems by 
taking into account various geographical regions. It was observed that the capital 
required to build a stainless steel facility was lowest in China, followed by 
Singapore, Japan and the UK. This is due to the lower labour fees paid in China. A 
29 % reduction is observed when comparing the UK with China. When changing 
from stainless steel to disposables, similar savings are occurring in each region. It is 
observed that the amount of savings is lowered as manufacturing costs are reduced.  
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1.7.4.2 SuperPro Designer  
SuperPro Designer is a commercial batch simulation package used to model 
bioprocesses. It involves all the process and subprocess steps as well as the cost 
associated with them. The generated COG models allow accurate estimation of the 
final cost of the product produced at manufacturing scale – from vial thawing to final 
product (Costioli et al., 2010). Some of its advantages include the ability to estimate 
profitability and cost, to quickly scale-up or scale-down equipment sizes for various 
annual outputs and the ability to generate graphical representation of flowsheets. 
This tool is able to simultaneously perform equipment sizing and costing, economic 
evaluation and material and energy balances (Shanklin et al., 2001). Some of the 
limitations associated with static models such as SuperPro Designer include the 
inability to account for constraints such as resource and utility as well as handling 
large datasets (Stonier et al., 2012). Another downside is the fact that probability 
distributions cannot be used to incorporate and illustrate uncertainties associated with 
parameters (Mustafa et al., 2006). 
 SuperPro Designer has been used to estimate the production cost, capital 
investment and key profitability indicators of monoclonal antibodies production 
processes using mammalian cell culture. Oh et al. (2004) used this tool to investigate 
the impact caused by increasing the staggered number of fermenters to double the 
annual production rate. A comparison between the base case and the optimized case 
showed that by increasing capacity, the total capital investment increases by 12% and 
the annual production cost increases by 88% while the ROI increases by 78% and the 
unit production cost decreases by 7%. Harrison et al. (2003) demonstrated how 
sensitive the production cost is to the annual production rate and showed the 
exponential decrease of the production cost as the production rate is 10 times higher. 
It has also been shown that the annual production rate influences the upstream to 
downstream costs ratio, therefore when the production rate increases, the costs move 
towards the downstream processing.  
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1.7.5 Stochastic process economics 
It is difficult to manage the manufacturing of biopharmaceuticals in order to 
maximize throughput and minimize the COGs due to technical, clinical and 
commercial uncertainties. There is an increased interest in the ability to model 
uncertainty in manufacturing operations. The most common uncertainties influencing 
the manufacture of biopharmaceuticals are technical and market-related. Some of the 
technical uncertainties include downstream processing yield, duration of 
manufacturing tasks, product titre during cell culture and the possibility of 
contamination. Market uncertainties comprise of dosage levels, costs of resources 
and market demand (Lim et al., 2005; Stonier et al., 2012). There are different ways 
of considering uncertainty such as sensitivity analysis and risk analysis including risk 
adjusted values and Monte Carlo simulations. These methods are described below.  
1.7.5.1 Sensitivity analysis  
Carrying out a sensitivity analysis of the principal variables is the easiest method of 
determining and quantifying uncertainties related with a particular project. 
Sensitivity analysis gives a systematic way to examine the effect of changing 
parameters by determining the impact of ± x % changes in each variable on the 
output measures therefore establishing the stability of the base case (Lim et al., 2005; 
Thabane et al., 2013).  
1.7.5.2 Risk analysis  
Risk analysis is an important part of Process Analytical Technology (PAT) used in 
the biopharmaceutical industry. PAT is an essential tool for the implementation of 
QbD, which can be used to monitor and control the manufacturing process (Riley 
and Li, 2011). Methods of incorporating risk necessary for more complicated 
problems require the assessment of probability functions for key uncertain factors. 
This can be done through ‘risk adjustment’ and ‘Monte Carlo simulation’ (Farid et 
al., 2005; Farid, 2007a). In risk adjustment, each input is weighted by how likely it is 
to occur. The output measures are then risk-adjusted values that illustrate expected 
average values, which consider all possible outcomes.  
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Monte Carlo Simulation  
Monte Carlo simulation is a type of stochastic modelling that can be used to 
determine the impact of project uncertainties on the outputs. It uses the input 
probability distributions to find out the probability distributions of the outputs. 
Monte Carlo technique imitates the randomness inherent in manufacturing by 
generating random outcomes for probabilistic factors when applied to a static or 
dynamic model. Repeating this simulation process a large number of times leads to a 
range of possible output values that help determine the system’s performance. Monte 
Carlo simulation has been used in various bioprocessing economic studies in order to 
examine the impact of manufacturing uncertainties such as batch failure, product titre 
and yield on cost (Pollock et al., 2013; Simaria et al., 2012; Allmendinger et al., 
2014b). Gold Sim (GoldSim Technology Group LLC, Washington, USA) and 
@RISK (Palisade Corporation, Newfield, NY, USA) are some of the commercial 
packages used for Monte Carlo simulations.  
1.7.6 Dynamic and stochastic studies 
Upstream process decisions are generally based on either perfusion or fed-batch 
cultures. Lim et al. (2006) used a risk-based discrete-event tool to assess the 
economic feasibility of fed-batch and perfusion cultures via a case study based on 
commercial production of antibodies at the 50 kg scale. The lower productivity and 
higher start-up costs of fed-batch processes were compared to the higher productivity 
and higher operational risks of perfusion processes. The deterministic analysis 
showed that the annual COG/g were very similar for both options under the stated 
assumptions, with 3% reduction in the perfusion option compared to the fed-batch. 
The deterministic analysis (no risk) recommended the perfusion option as the more 
economically feasible option due to the higher projected net present value (NPV) and 
lower initial investment. The stochastic analysis (incorporating risk by accounting for 
fluctuations in product titre, DSP yield and the feasibility of contamination and 
equipment failure) showed that the perfusion option had a lower reward/risk ratio 
and failed to meet the expected output. This would make the perfusion option 
infeasible when accounting for uncertainties and risks. The studies presented 
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highlighted the importance of incorporating risk and uncertainty when making 
manufacturing and economical decisions and the limitations of relying on 
deterministic analysis alone.  
1.7.6.1 Financial and operational multi-criteria decision-making (MCDM) 
Multiattribute decision making (MADM) models involve making decisions in the 
presence of various, usually conflicting criteria (Rao, 2007). The models have the 
ability to include qualitative as well as nonfinancial aspects of performance in the 
evaluation of different decisions (Farid et al., 2005b). The use of multiple criteria can 
be supported through multi-criteria decision-making (MCDM), one of the most 
common sections of decision-making (Triantaphyllou, 2000). A variety of methods 
are available in MCDM that have been used to process non-financial and financial 
data. For example, Platts et al. (2002) used the additive weighting technique to 
analyse the decision to invest in internal manufacturing capabilities or to outsource, 
Farid et al. (2005b) used the same method to investigate the decision to either build a 
pilot plant with only stainless steel equipment, a pilot plant based on fully disposable, 
components or a hybrid pilot plant with stainless steel fermenters but with fully 
disposable components in the downstream production areas. Furthermore, Steuer and 
Na (2003) published a review of 265 publications that concentrate on using MCDM 
to assist decision-making in financial situations. 
George et al. (2007) presents the development of a decision-support 
framework for decision-making scenarios that uses multi-criteria decision-making 
(MCDM). Its functionality is demonstrated through a case study based on a 
biopharmaceutical company confronted with several options for purchasing 
commercial manufacturing capacity. A stochastic analysis of options was carried out. 
The framework was implemented in Microsoft Excel and is composed of four 
features: a biomanufacturing process model, a profit and loss model, a MCDM 
technique (additive weighting technique) and a number of criteria used to 
differentiate between the different options. The model’s input variables are the 
expected fermentation titre, the anticipated success rate of each batch, the annual 
demand and the overall product yield, whereas the model’s outputs are COG/g and 
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the fixed capital investment (FCI) for constructing the plant. The deterministic 
analysis showed that the Build, Partner and Partner/Build options scored higher than 
the average additive weighting technique score. The Build option was the preferred 
option after this analysis as it had the highest score, followed by the Partner option 
and the Partner/Build option. This option results in the highest NPV value and the 
highest total value of assets. The sensitivity analysis showed that the most significant 
factor influencing the deterministic results was the company’s market capture. Monte 
Carlo simulation has demonstrated that the most profitable option and the one that 
has a greater potential to generate profit was the CMO/Build option. A stochastic 
analysis proved that the ranking positions remain the same as for the deterministic 
analysis with Build, Partner and Partner/Build being the top three. The application 
of the model to a case study highlighted the limitations of using a single criterion 
when making strategic manufacturing decisions as other important criteria might 
have been omitted. For the best option to be identified, the use of multiple criteria 
analysis under uncertainty is critical.  
1.7.6.2 Discrete-event simulation  
Stonier et al. (2013) presents the implementation of a decision-support tool designed 
to resemble process variations using advanced multivariate statistical techniques, to 
help discover the reasons of short-term facility fit problems. The large datasets 
generated from biopharmaceutical industrial batch processes are evaluated using 
principal component analysis together with clustering algorithms. This study expands 
on an already developed database-driven simulation platform that includes process 
economics, equipment sizing and mass balancing of purification sequences in 
antibody manufacturing processes (Stonier et al., 2012). This study presents the 
expansion of the tool to be able to mimic the stochastic aspects of industrial batch 
processes achieved by creating the ability to perform Monte Carlo simulations and 
identifying what is the best way to incorporate the stochastic results into advanced 
multivariate statistical analysis techniques. A typical monoclonal antibody 
manufacturing process was simulated in a 10.000 L facility. Generation of the base 
case data considering a titre of 2 ± 0.2 g/L shows that the predicted throughput is 
below the required one. This suggests a potential facility fit problem. The simulation 
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tool registered an error event when the tanks volume is exceeded. This arose in the 
AEX chromatography and virus inactivation pool volumes. As the largest volume 
that these tanks can hold is 2500 L, the extra volume was sent to waste resulting in 
product losses. These losses have a big influence on the overall throughput when a 
high number of batches are performed. This facility fit problem could be resolved by 
modifying the facility to redirect the product into auxiliary tanks. After the process 
modification, the variation in mass loss is removed.  
1.7.6.3 Evolutionary (genetic) algorithms (EA)  
Single-objective optimisation  
Optimisation techniques are used when the number of scenarios to be explored is too 
large for the scenarios to be individually evaluated. Simaria et al. (2012) introduces a 
meta-heuristic optimisation approach using genetic algorithms to focus on the 
difficulty of designing facilities with several possible permutations. This single-
objective optimisation technique is able to address various decisions at the same time 
in order to decide how best to design these facilities and minimise COG/g. This 
paper focuses on the design of flexible and cost-effective facilities while considering 
various purification sequences per product. The design of these facilities is regarded 
as an optimisation problem in which choices made at levels such as product, facility 
and unit operation represent the decision variables. The problem consists in 
determining the equipment sizing for each operation, the optimal upstream to 
downstream trains ratio as well as the sequence of purification steps that needs to be 
used for each product, while minimising COG and maintaining purity and demand 
for various products having different yields, demands and impurity levels. The 
algorithm is connected to a detailed process economics model to examine the 
numerous operational and financial outputs of each option.  The applicability of this 
algorithm is demonstrated through an industrially relevant case study. The case study 
examines the design of optimal purification sequences and chromatography column 
sizing strategies for a manufacturing facility producing three mAbs in different 
stages of development, with different demands and titres. The tool allowed the 
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selection of the most cost-effective purification sequences and sizing for each 
product in the facility.  
 Allmendinger et al. (2014a) builds on the work of Simaria et al. (2012) and 
examines the application of evolutionary algorithms for the identification of 
chromatography column sizing strategies for the sequence of purification steps used 
in the purification of mAbs. The closed-loop optimisation problem was defined as 
single-objective (minimise COG/g), subject to various constraints and uncertain 
parameters. Monte Carlo (MC) simulations based on probability distributions were 
adopted in order to account for the impact of uncertainty (fluctuations in titre) on 
COG/g. To demonstrate the framework’s ability to identify cost-effective 
chromatography equipment sizing strategies, an industrially-relevant case study 
looking at a single-product mAb facility was used. Chromatography column sizing 
strategies that resulted in savings up to 20 % in COG/g compared to the common 
approach used by industry (base case) where identified by the algorithm. Using 
stochastic EAs allowed the determination of more robust solutions, able to handle 
titre fluctuations.  
Multiobjective optimisation 
Allmendinger et al. (2014b) presented a framework which linked an evolutionary 
multiobjective optimisation algorithm (EMOA) to a process economics model. The 
aim was to identify sequences of chromatography purification steps and column 
sizing strategies that are subject to multiple objectives including COG/g, robustness 
in COG/g and the ability to remove impurities. An industrially relevant case study 
with different demands, USP: DSP train ratios and HCP levels was used to show the 
framework’s ability to identify purification processes that satisfy the objectives and 
are robust to uncertainty. The uncertainty was modelled using probability 
distributions during Monte Carlo trials in factors such as product titre, eluate 
volumes, dynamic binding capacities, step yields, HCP log reduction and initial 
HCP. The aim was to understand the influence of uncertainty on the DSP design with 
regards to chromatography sequence and column sizing. Variations in step yields and 
product titre have the most significant impact on COG/g while variations in initial 
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HCP levels and HCP logs impacted on HCP level post purification. The framework 
was able to identify purification processes that offered savings up to 10% compared 
to the industrial platform.   
 Making good decisions early in the development cycle of biopharmaceuticals 
is critical to the success of this sector. The use of computer-assisted models which 
are able to integrate bioprocess economics with stochastic behaviour, multiple 
conflicting objectives, manufacturing logistics and numerous constraints have been 
presented. Decision-support tools provide a very important resource to use in 
assessing alternative strategies to handle future challenges (Farid, 2013). 
1.8 Aims and Organisation of thesis 
The previous sections of this chapter outlined the current-state and future directions 
of biopharmaceutical drug development focusing on monoclonal antibodies. 
Overviews of the impurities encountered in biopharmaceutical manufacturing (with 
an emphasis on host cell proteins) including the challenges they pose were presented. 
In addition, statistical and economics modelling techniques currently used in 
evaluating biopharmaceutical manufacturing process were also highlighted. In the 
literature review it was shown that the antibody sector has made significant progress 
in increasing cell culture titres. However there is a limited understanding of the 
consequences of mAb titre increases on impurity levels and the subsequent 
downstream processing performance. Therefore, it is essential to have systematic 
methods to explore such interactions. Also, the impact of cell culture conditions on 
the levels of certain problematic HCPs (e.g. protease) as well as the relationship 
between HCP levels and protease activity has not been previously investigated.  
The aim of this thesis was to develop a systematic framework based on QbD 
principles, combining state-of-the-art, DoE driven, high throughput cell culture 
experiments (ambr system) with statistical cause-and-effect predictive correlations 
and process economic models. This will facilitate the identification of cell culture 
strategies that balance the needs of upstream and downstream manufacturability, 
robustness to process fluctuations and cost-effectiveness, early in the development 
cycle. An additional aim was to provide a better understanding of the relationship 
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between the protein of interest (mAb), cell culture conditions and the levels of HCPs 
and certain problematic HCPs (proteases) present in the harvest material. In order to 
achieve these aims, certain objectives were formulated and these form the basis of 
the subsequent chapters.  
 Chapter 2 provides an overview of the materials, equipment and analytical 
techniques used to perform small-scale cell culture experiments and protease studies. 
Statistical methods used to derive and evaluate predictive correlations developed 
based on high throughput ambr are presented. Software used to facilitate the 
statistical and economics analysis of cell culture strategies was also shown.  
 Chapter 3 presents a QbD approach to cell culture process development (high 
throughput ambr experimentation and Gyrolab analytics linked with DoE) to 
characterise cell culture performance associated with different generation numbers 
and explore the consequences of titre increase on HCP levels at harvest.  
 Chapter 4 investigates the impact of cell culture parameters (temperature, 
media osmolality and seeding density) on protease activity at harvest as well as 
examines the relationship between HCP levels, mAb concentration and protease 
activity resulting from unclarified harvest samples. A commercially available 
protease assay was optimised in order to make it suitable for the analysis of 
unclarified cell culture harvest. 
 Chapter 5 presents the use of multivariate analysis techniques (multiple linear 
regression) to characterise the high throughput cell culture data generate in Chapter 3 
using the ambr system and derive predictive cause-and-effect correlations. The 
statistical equations are able to predict cell culture outputs (mAb titre and HCP 
levels) based on cell culture inputs (temperature, seeding density, media osmolality, 
pH and timing of feed initiation).  
 Chapter 6 explores the integration of the predictive modelling equations 
derived in Chapter 5 with a prototype bioprocess economics and optimisation tool in 
order to identify the most cost-effective cell culture strategies as well as the impact 
of uncertainty in cell culture parameters on outputs (product output (kg) and HCP final 
(ng/mg)) and the likelihood of these falling out of specification. 
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Chapter 7 presents a summary of the main conclusions and discusses possible 
directions for future work.  
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Chapter 2  
2 Materials and methods  
2.1 Equipment used  
2.1.1 ambr system  
The ambr 24 and ambr 48 systems were used, consisting of 24/48 single-use 
bioreactors split into two/four cultures stations (CS1, CS2, CS3, and CS4) each 
containing 12 micro bioreactors. The ambr 24 was used for generating AMBR 1, 
AMBR 2 and AMBR 3 experimental data while ambr 48 was used to generate 
AMBR 4 experimental data. Each culture station has independent stirring and 
temperature control. Each micro bioreactor is equipped with a miniature marine 
impeller, a sparger for gas supply, as well as integrated optical sensors for pH and 
dissolved oxygen (DO) providing individual closed loop control of these parameters. 
In order to maintain aseptic operations during the culture, the system is placed inside 
a bio-safety cabinet (Lewis et al., 2010; Hsu et al., 2012; Moses et al., 2012).  
2.2 Cell culture  
2.2.1 Cell line  
The cell line used was a proprietary MedImmune CHO high producing cell line, 
expressing an IgG1 antibody. The cell line was cultured in protein-free CHO media 
supplemented with a two-part proprietary nutrient feed. Cells from different cell 
stocks (presenting different generation numbers) have been used for each of the 
AMBR experiments: 33, 44, 54 and 59 for AMBR 1, 2, 3 and 4 respectively. The 
cells with a generation number of 33 within AMBR 1 are closer to a mid-generation 
number as used by MedImmune for this particular cell line, whereas cells with a 
generation number of 54 within AMBR 3 are closer to a late generation number. For 
the purpose of this thesis, experiments with a generation number of 33, 44 and 54 
will be referred to as low, mid and high generation. 
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2.2.2 Fed-batch protocols  
Three levels of osmolality were used throughout the experiments: base level, 
intermediate and high osmolality media. The base osmolality refers to the osmolality 
of the proprietary MedImmune media, used for routine cell culture. The intermediate 
and high osmolality conditions were prepared by the addition of different amounts of 
NaCl stock solution to the base medium, while the concentration of all other 
components was kept constant. One day prior to inoculation 8 mL of media of 
different osmolalities was added to each ambr vessel, according to the DoE design.  
Prior to ambr inoculation, different shake flasks were set up with double the seeding 
density intended within the ambr DoE design, in the corresponding media osmolality. 
An 8 mL volume was then added from each shake flask to the corresponding ambr 
vessel to make up a final volume post inoculation of 16 mL with the correct seeding 
and media osmolality.   
Feeding of the cultures started on day two with five subsequent additions that 
involved the addition of a two-part feed (average 400 µL Part A feed and 24 µL Part 
B feed). For all ambr cultures, glucose concentration was monitored throughout and 
fed up to 8 g L-1 when the concentration fell below 5 g L-1. A sample of 100 µL was 
taken every day from each ambr microbioreactor for the measurement of glucose and 
lactate concentration. Starting from the media addition day, 20 μL of antifoam was 
added every other day to each AMBR culture. Cell counts measurements were 
performed every day using ViCell. A sample of 600 µL was taken on day 0 followed 
by a ¼ dilution with PBS for the subsequent days until harvest (150 µL). Titre and 
HCP samples (500 and 400 µL, respectively) were taken in the last five days of 
culture (day 11-15). Offline pH measurements (400 µL) were performed every other 
day starting with day 1. For all cultures, pH was controlled within ± 0.1 of the set 
value for each culture using CO2 in the inlet gas and the DO was maintained at 50 % 
of air saturation. According to the vendor guidance, a working volume of between 
10-15 mL in ambr 24 is sufficient in order to maintain optimum gas exchange and 
mixing time. Taking into account all the sample and addition volumes, the working 
volume within all of the ambr experiments did not drop below 10 mL until day 14. 
From day 13-15, the volume dropped from 10 mL to 8.1 mL. As the working volume 
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was maintained over 10 mL until day 14, it is not believed that the sampling and 
additions had any impact on the growth of the cultures (peak viable density usually 
achieved in day 8-10). Differential dilution across different conditions could only 
come from the small differences in glucose addition based on the algorithm 
presented above and base additions during the culture. There were very small 
differences in final volumes between different conditions which suggests that the 
differences were negligible. 
2.3 DoE experiments 
2.3.1 AMBR 1 
A DoE design with two parameters (seeding density and media osmolality) varying 
on three levels (32 full factorial) was set up for each of the two culture stations within 
AMBR 1, using low generation cells (33). The micro bioreactors were seeded at a 
density of 0.49, 0.8 and 1.14 × 106 cells mL-1, respectively and osmolalities of 314, 
353 and 394 mOsm kg-1 were used. A standard culture temperature of 36.5 oC was 
maintained for all cultures within CS1, while in CS2, a temperature shift to 33 oC 
was carried out after day 4 of culture. Certain cultures within AMBR 1 and AMBR 3 
were identified as outliers using PCA analysis. These cultures also showed an 
abnormal lactate profile compared to the rest of the cultures (data not shown) and 
were removed from subsequent analysis. The experimental design for AMBR 1 as 
well as the exact number of outliers removed from each culture station within each 
ambr experiment is summarised in Chapter 3, Table 3-1.  
2.3.2 AMBR 2 
For each culture station within AMBR 2, a 32 full factorial DoE design was carried 
out, using mid generation cells (44). For CS1, the seeding density and pH were 
varied on three levels (0.42, 0.69 and 1.06 × 106 cells mL-1; 6.6, 6.8 and 7) while the 
addition of feeds started on day 2 of culture for all 12 micro bioreactors. For CS2, all 
micro bioreactors were seeded at a density of 0.9 × 106 cells mL-1, while pH and 
timing of feed initiation were varied on three levels (6.6, 6.8 and 7; feed start day 1, 2 
and 3). A temperature of 36.5 oC and an osmolality of 313 mOsm kg-1 was 
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maintained for all 24 experiments. The experimental design for AMBR 2 is 
summarised in Chapter 3, Table 3-1. 
2.3.3 AMBR 3 
A DoE design with two parameters (seeding density and media osmolality) varied on 
three levels (32 full factorial) was set up for each of the two culture stations within 
AMBR 3 using high generation cells (54). The micro bioreactors were seeded at a 
density of 0.58, 1.19 and 1.8 × 106 cells mL-1, respectively and osmolality levels of 
310, 356 and 389 mOsm kg-1 were used. A standard culture temperature of 36.5 oC 
was maintained for all cultures within CS1, while in CS2, a temperature shift to 33 
oC was carried out after day 4 of culture. The experimental design for AMBR 3 is 
summarised in Chapter 3, Table 3-1. 
2.3.4 AMBR 4 
An ambr 48 was used to set up a face centred full factorial DoE design with centre 
and axial points at two temperatures. The samples from these experiments were used 
to carry out assay development work as well as generating results for protease 
analysis. Within the DoE design, three numerical factors were varied on five levels, 
seeding density (0.53, 1.1, 1.6, 2.1 and 3.57 × 106 cells mL-1), media osmolality (311, 
323, 335, 350, 365 mOsm kg-1) and pH (6.6, 6.8, 7, 7.2, 7.4). A standard culture 
temperature of 36.5o C was maintained for all cultures within CS1 and CS2, while for 
CS3 and CS4, a temperature shift to 33 oC was carried out after day 4 of culture.  
2.4 Analytical techniques 
2.4.1 CCH, qMab and specific HCP productivity (qHCP) 
Cell population growth was assessed in terms of the cumulative cell hours (106 cells 
ml-1 h). CCH was calculated by summing the areas under the viable cell growth 
curve. Each area (corresponding to the area between successive cell counts) was 
calculated as follows: 
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where VCD0 ,VCD1 represent the viable cell density (cells mL
-1) in day 0 and day 1 
whereas h0, h1 represent the elapsed time (in hours) between two cell concentration 
readings. CCH was then calculated by summing the areas underneath the entire 
growth curve from inoculation to harvest: 
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The qHCP at harvest was calculated as follows:  
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2.4.2 Cell generation number  
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(5) 
where VCD(passage) represents the viable cell density (cells mL
-1) of the day of passage 
(each 3 days) and VCD(seeding) represent the seeding density = 0.3 × 10
6 cells mL-1. 
The final generation number was calculated by adding the increase in generation 
number with each passage to the generation number of the previous passage.  
 n noGen ...  2 noGen   1 noGen  n -1 noGen    (6) 
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2.4.3 Viable cell concentration and Viability  
Viable cell concentration and percent viability were determined by the trypan blue 
exclusion method using Vi-CellTM XR Cell viability analyzer (Beckman Coulter, 
High Wycombe, UK). 
2.4.4 Protein A HPLC Analysis 
Monoclonal antibody concentrations were determined by protein A High Pressure 
Liquid Chromatography (HPLC) using an Agilent 1200 Series HPLC system 
(Agilent Technologies, South Queensferry, UK). Various sample volumes were 
loaded onto a Poros® Protein A 20 μm Column (Applied Biosystems, Warrington, 
UK) using a phosphate buffer (adjusted to pH 7.2) and eluted with phosphate buffer, 
pH 2. The elution peak was measured by UV detection (280 nm). The product peak 
was integrated and the monoclonal antibody concentration was determined using a 
standard curve of purified antibody. The protein A intra-assay variation (within a 
data set obtained from one experiment) has a coefficient of variation (CV) of ~ 3% 
while the inter-assay variation (from repeated experiments) was ~ 5 %. The CV for 
individual variables within an assay is calculated by the ratio of standard deviation to 
the mean while the CV of a statistical model is calculated by the ratio of the root 
mean squared error (RMSE) to the mean of the dependent variable. 
2.4.5 GyroslabTM xP workstation  
The HCP concentration was determined by GyrolabTM xP (Gyros, Uppsala, Sweden), 
a high throughput, automated adaptation of an ELISA that uses CDs with highly 
defined microstructures, to quantify HCP levels. Samples were diluted in Gyros 
Rexxip AN buffer and together with in-house reagents and buffers are added onto 
96-well microtitre plates. Biotin conjugated in-house sheep derived polyclonal 
antibodies (pAbs) against CHO HCPs are added to the CDs and spun over the 
streptavidin coated bed column. Samples are then added to the CDs and the HCPs are 
captured by the streptavidin bead-biotin pAb complex. Alexafluor647 conjugated 
pAbs against CHO HCPs are then added to the CD, which bind to the captured 
HCPs. The level of excitation of Alexafluor647 is proportional to the amount of 
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bound complexes and therefore HCPs. The quantification of HCPs levels is done by 
a comparison against a standard curve of known quantities of HCPs. The standard 
curve has a range of 6.1 – 100,000 ng mL-1. The assay’s lower limit of quantification 
is 20 ng mL-1 while the upper limit is 80,000 ng mL-1. Harvest samples which often 
provide HCP results > 1 × 106 ng mL-1 were diluted accordingly to ensure that the 
results reported were within the curve range. If the necessary dilution was 1:2, the 
sample was also analysed at 1:4 and 1:8 dilutions. Back calculated results from these 
dilutions need to be within the assay’s precision of 30 % CV. Within all ambr 
experiments performed, the assay variability was within 20 % CV.    
2.4.6 Protease assay  
The EnzChek® Protease Assay Kit (E6638, Molecular Probes, Eugene, OR) was used 
to assess protease activity within unclarified harvest samples, resulting from fed-
batch mammalian cell culture performed using the ambr system (Chapter 4). The 
assay is fluorescence-based and is capable of detecting metallo-, serine, acid and 
sulfhydryl proteases. The substrate, BODIPY FL casein, is heavily labelled with pH-
insensitive green-fluorescent BODIPY® FL dyes, resulting in almost total quenching 
of the conjugate’s fluorescence. The hydrolysis reaction initiated by the proteases 
found within the unknown samples, releases highly fluorescent BODIPY FL dye-
labelled peptides. The fluorescence increase, measured by a microplate reader, is 
proportional to the protease activity. The dye fluorescence was excited at 485 nm and 
the emission intensity at 530 nm recorded using a 495 nm cut-off filter on a 
Molecular Devices Gemini XPS microplate reader.  
2.4.6.1 Reagents preparation  
A 1.0 mg/mL stock solution of the BODIPY®-casein conjugate detection substrate 
was prepared by adding 0.2 mL of PBS to one of the vials containing the lyophilized 
substrate. This solution was then diluted 100-fold in 1X digestion buffer. The reagent 
was kept in the dark at 4oC. The 1X digestion buffer was prepared by diluting the 20 
X digestion buffer (200 mM Tris-HCl, pH 7.8) 20-folds with deionized water. Due to 
the nature of the unknown samples to be analysed (unclarified harvest samples) a 
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high dilution is required in order to accurately measure fluorescence increase. This 
would involve a higher amount of Tris-HCl digestion buffer than the one provided in 
the commercial kit, therefore the 20X Tris-HCl digestion buffer used in these 
experiments was prepared in-house using 7.4 g Tris Base and 21.9 g Tris Acid. 
Comparable results have been seen between trypsin standard curve using in-house 
digestion buffer and kit buffer (data not shown). 
2.4.6.2 Trypsin standard curve  
A solution of 50 mg mL-1 trypsin (stock 1) was diluted 100-fold in digestion buffer to 
make a 500 µg mL-1 solution (stock 2) and then diluted again 50-fold to make a 
10,000 ng mL-1 solution (stock 3). Stock 3 was then used to prepare a dilution series 
(10,000 ng mL-1 – 50 ng mL-1) with 1X digestion buffer in 1 mL total volume. An 
equal 100 µL volume of sample (trypsin) and substrate (BODIPY FL casein) were 
added to a white 96 wells microplate to generate duplicate samples. The plate was 
sealed, incubated at 40oC and then read every hour until enzyme depletion was 
achieved for the highest trypsin concentration. A buffer-only control (blank) was also 
prepared.  
2.4.6.3 Sample analysis  
Three 0.5 mL aliquots were taken at harvest from each culture of AMBR 4. The 
samples were kept at -80 oC until analysed. Once a sample was thawed and analysis 
it was subsequently discarded. Once thawed, the samples were diluted to 1.0 mL in 
1X digestion buffer in order to make up the following dilutions 1/2, 1/5, 1/10, 1/50, 
1/100, 1/500, 1/1000 and 1/2000.  An equal volume of sample and substrate (100 µL) 
was added to a white 96 wells microplate in order to generate duplicate samples for 
each dilution. Controls without the substrate (sample + digestion buffer) were also 
prepared for each dilution as well as a blank (buffer-only control). The plate was 
sealed, incubated at 40 oC and then read every hour until enzyme depletion was 
achieved. An incubation temperature of 40 oC was chosen for a faster reaction time 
as well as for consistency between plates (room temperature can fluctuate from one 
day to another). Raw intensity counts increases of the sample compared to the blank 
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of less than 20 % were considered as negative for protease activity per manufacturer 
guidelines. 
2.5 Statistical analysis  
2.5.1 Spearman’s Rank correlation test  
The strength of the correlations between variables was evaluated by Spearman’s rank 
correlation test which is a non-parametric test used to measure the strength of 
association between two variables, where the value rs = 1 means a perfect positive 
correlation and the value rs = -1 means a perfect negative correlation. Correlations 
with p-values less than 0.05 were considered significant. The formula used to 
calculate Spearman’s Rank is shown below. 
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where di is the difference in the ranks given to the two variable values and n is 
number of variables in each category.  
2.5.2 Model building  
In terms of model building, a number of different approaches exist. The aim of 
model selection is to minimize the number of predictors which account for the 
maximum variance in the dependable variable. All methods involve optimising the 
model by including all relevant variables and disregarding variables that only 
contribute a marginal increase in the predictive power of the model. These are 
forward addition, backward elimination and stepwise regression.  
2.5.2.1 Forward addition 
Forward addition starts only with the intercept and then performs “n” regressions 
with the intercept and each variable one at a time. The variable that contributed the 
most to the explanation of the response variable is added to the model. The next step 
is to perform “n-1” regressions with the intercept, the first variable added to the 
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model and the variable with the second highest significance from the remaining pool. 
The process is repeated until none of the remaining variables have a significant 
contribution to the model, given the variables that are already in the model. The main 
drawback of forward addition is the possibility of one of the included variables to 
become insignificant with the addition of newer variables.  
2.5.2.2 Backward elimination 
Backward elimination starts by constructing a model that includes all the variables. 
The least significant variable is then dropped from the model and the remaining 
variables are re-evaluated. The least significant variable is again dropped and the 
process is repeated until there are no more variables to be eliminated, all remaining 
variables are significant. Backward elimination also has its own drawbacks. 
Sometimes variables are dropped that would be significant when added to the final 
reduced model.  
2.5.2.3 Stepwise regression   
Stepwise regression is a mixture of the forward and backward selection techniques. 
Stepwise regression is a method of model building by adding or removing variables 
only based on the t-statistics of their estimated coefficients. Stepwise regression is a 
modification of the forward selection so that after each step in which a variable was 
added, all variables in the model are checked to see if they are significant. Stepwise 
regression has two levels of significance: one for adding variables and one for 
removing variables. The criterion for adding a variable to the model should be more 
rigorous than the criterion for keeping a variable in the model so the process does not 
get into an infinite loop (Howell, 2013). Stepwise selection is an algorithm for 
picking a “good” (useful) model (Kadane & Lazar, 2004).  
2.5.2.4 All possible regression 
All possible regression analysis tests all possible subsets of potential independent 
variables. If there are “n” potential independent variables then there are 2n distinct 
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subsets to be tested. All possible regression choses the best combination of predictors 
by running regression analyses for all possible predictors. One difficulty is deciding 
the optimal criteria to use in choosing the “best” model. A variety of criteria for 
choosing the best possible model exists, including the highest R2, the higher 
predicted R2, the lowest root mean square error (RMSE) or Akaike’s Information 
Criterion (AIC).  
2.5.3 Model selection  
In statistical data analysis, multiple competing models are often considered. The 
purpose of model selection is to identify a model that has a balance between the 
goodness-of-fit of the data, prediction capability and model complexity. Two of the 
main model selection criteria are the Akaike information criterion (AIC) and 
Bayesian information criterion (BIC). For both, a lower value is preferred. The 
fundamental difference between the two criteria lies in the assumptions made. A 
model with a lower AIC value indicates the model is closer to the true relationship, 
whilst a model with a lower BIC value indicates the model is more likely to be the 
true relationship (Dziak et al., 2012; Vrieze, 2012). For ecological publications from 
1993 - 2013 that implemented formal methods for multi-model inference, the 
frequency of using AIC as a model selection criteria was 84% compared to 14% for 
BIC and 2% for other approaches (Aho et al., 2014). Information-theoretic criteria 
like AIC has been widely shown as a superior tool for choosing among statistical 
models as compared to the p-value (Anderson et al., 2000; Burnham & Anderson, 
2002; Gerrodette, 2011). AIC is best suited for finding the best model for predicting 
new data (Dziak et al., 2012; Murtaugh, 2014). AIC and BIC are simply measures for 
comparison of models, allowing relative ranking of several models. As a result, AIC 
and BIC are not able to quantify the goodness of fit or the actual predictive power of 
the model. The R2 and R2 predicted as well as root mean square error (RMSE) from 
ANOVA as well as residual plots should be used to evaluate the models. In this 
analysis, the focus was towards selection of models that are able to best predict the 
responses (titre and HCP). For this reason predicted R2 was the first main criteria for 
choosing between potential models. When R2 and predicted R2 values were very 
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similar between several models, then RMSE and AIC were taken into account. For 
both a smaller value is preferred.  
2.5.4 Model assumptions  
Most statistical tests depend on specific assumptions about the variables used in the 
analysis. When these assumptions are violated, certain inferences and predictions 
from the regression analysis may be inaccurate and unreliable, resulting in over- or 
under-estimation of significance or effect size(s). Common ways to detect violations 
in regression modelling assumptions involve diagnostic plots and residual tests. The 
multiple linear regression model is based on several assumptions (e.g. residuals are 
normally distributed with zero mean, are independent, have a constant variance and 
the mean of the response, at each set of values of the predictor is a linear function of 
the predictors) (Alexopoulos, 2010; Williams et al., 2013). The assumptions which 
will be tested in this analysis are the normality and autocorrelation of the residuals 
and the linearity of the model.  
2.5.4.1 Normality of residuals  
To check the normality of residuals, a histogram plot of the residuals can be used. If 
the residuals are bell-shaped distributed, this implies that the normality assumption is 
not violated. A common test to check the normality of residuals is the Shapiro-Wilk 
test. The test is recommended for sample size of less than 50 (Razali and Wah, 
2011). The null hypothesis of this test is that the data comes from a normal 
distribution. Small p-values indicate that the hypothesis of normality of the residuals 
should be rejected. 
2.5.4.2 Autocorrelation of residuals 
Durbin-Watson test is generally used to test for the presence of autocorrelation in 
residuals. Autocorrelation means that the adjacent observations are correlated. If the 
residuals are correlated, then the regression method does not accurately estimate the 
coefficient’s error resulting in predictors being shown as significant when this might 
not be the case. The Durbin-Watson statistic will be near 2.0 is there is no 
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autocorrelation. If the statistic is near 0.0, then there is evidence of positive 
correlation whereas if the statistic is near 4, there is evidence of negative 
autocorrelation. The p-value is for the DW statistic under the null hypothesis that 
there is no autocorrelation among the residuals. If there is no prior reason to believe 
that the autocorrelation should be positive or negative, then a two-tailed rejection 
region should be used. Using a =.05, the null hypothesis of no autocorrelation should 
be rejected whenever the p-value ≤ 0.025 or p-value ≥ 0.975 (Chatfield, 2014).  
2.5.4.3 Linearity of the model  
Nonlinearity is usually most evident in a residuals vs predicted graph, which is a 
common output of the standard regression. Ideally, the residual versus predicted plot 
should show a constant band of residuals on either side of the regression line, with a 
roughly constant variance, showing no trend in the residuals (Williams et al., 2013).  
2.5.5 Model validation 
Validation methods generally involves predicting outcomes for a small subset of the 
data using the remaining observations and then repeating the process for certain 
number of other subsets.  
2.5.5.1 K-fold cross validation  
Cross validation (CV) is a method of assessing the accuracy and validity of a 
statistical model. CV is the process through which only part of the data (training set) 
is used to fit the model. The remaining data (test set) is used to test the model. The 
size of the training and test sets are determined by the number of folds defined in a k-
fold cross validation. The k-fold cross validation method randomly divides the data 
into k subsets. One subset is used as the test set while the remaining subsets are used 
as the training set. For k=10, the data is divided into ten subsets, each representing 
10% of all the data. A predictive model is trained with 90% of the data and then 
validated with the remaining 10%. The process is repeated 9 other times so that each 
subset of the data serves as the test set. The root mean square errors of the k subsets 
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are squared and summed to construct the cross validation SSE (squared sum of 
prediction errors). The resulting SSE is then used to calculate a R2 k fold value. 
2.5.6 Definitions 
The following statistical parameters have been used to evaluate the resulting cell 
culture models. Ideally, models with a high R2 and R2 predicted as well as with a low 
root mean squared error (RMSE) will be chosen.   
2.5.6.1 Pearson’s coefficient (r) 
Pearson’s coefficient (r) also named correlation coefficient, measures the linear 
relationship between two variables in a sample and is used as an estimation of the 
correlation in the whole population.   
 squares of Sumsquares of Sum
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                      (8) 
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where SSX refers to the variance of the X scores, SSY refers to the variance of the Y 
scores and SPXY refers to the variance shared between X and Y: 
 2X X-XSS                   (10) 
 2Y Y-YSS                     (11) 
     Y-YX-XSPXY                 (12) 
In simple linear regression, r2 represents the proportion of variance in the 
dependent variable that can be explained by the model. This is calculated by squaring 
the sample correlation coefficient (r) between the outcomes and their predicted 
values. If additional terms are included, R2, called the coefficient of determination, is 
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the square of the regression coefficient (R). This coefficient estimates the amount of 
variance in the dependable variable accounted for by a linear combination of the 
predictor variables. The remainder represents the proportion that is present in the 
error. The regression coefficient describes the relationship between the observed and 
predicted variables. With a perfect correlation of R = +1 or -1, then R2 = 1 and all 
variability in the dependent variable can be explained by the model. When R = 0, 
there is no relationship between the predictor(s) and the dependent variable, and 
none of the variability can be explained (Palmer & Connell, 2009; Hinton, 2014).  
2.5.6.2 R2 predicted  
R2 value is an indication of how well the model fits the experimental data, while the 
predicted R2 is an estimation of how well the model predicts a response value 
(Rouiller et al., 2012). The predicted R2 is calculated using regression analysis and 
indicates how well the model can predict responses for new combinations of 
variables within the -1 to +1 range, evaluated to develop the model (Abu-Absi et al., 
2010). R2 predicted was calculated as follows:  
  XY
 2 PRESS/SP1predR               (13) 
where PRESS represents the predicted residual sum of squares. PRESS is given by 
the following formula:  
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Regression models are generally used to predict response variables. The data 
available can be used to fit the model. Trying to assess how well the model predicts 
responses, using the same data that was used to fit the model can give over optimistic 
results. A solution to this would be to leave out an observation, fit the model with the 
remaining data and then predict the left out response. This leave-one-out-approach is 
a type of cross-validation, where a part of the data is used to fit the model while the 
rest is used to assess the model’s prediction capability.  For more complicated 
models with several predictors, the challenge of choosing the best model for 
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prediction can often arise when a large number of possible model choices exist. In 
this situation, the model with the smallest PRESS statistic should be chosen (Tarpey, 
2010; Howell, 2013). 
2.5.6.3 RMSE 
The root mean squared error (RMSE) measures the difference between the predicted 
and observed values. These differences are also called residuals and the RMSE is 
used to combine them into a single measurement. The RMSE of a model prediction 
with respect to the estimated response Ymodel is given by the square root of the mean 
squared error:  
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where Xobs is observed values and Xmodel is predicted values at time/place 
2.6 Software used  
2.6.1 JMP and Design Expert 
JMP and Design Expert have been used to analyse high-throughput data resulting 
from ambr run cultures. JMP and Design Expert are statistical software from SAS 
and Stat-Ease, respectively, capable of designing and analysing factorial design 
experiments. The software helps detect main effects and interactions as well as 
providing statistical equations and diagnostic plots for evaluation of models. Design 
Expert is an entry-level program able to perform basic statistics as well as linear 
regression while in addition JMP is capable of performing more advanced analysis 
such as multivariate analysis, statistical process control, reliability analysis, non-
parametric tests and a wider range of regression analysis as well as advanced 
graphics. Design Expert is more user-friendly and generally the results are easier to 
interpret than those from JMP. Certain features from each software have been used in 
this analysis (Chapter 5). The advanced multivariate analysis from JMP was used to 
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perform the stepwise all possible regression analysis as well as diagnostic plots and 
different methods for validating the underlying assumptions of the selected models 
while Design Expert was used for obtaining the predicted R2 statistic and the chosen 
model coefficients.  
2.6.2 C#, Microsoft Visual Studio and Microsoft Access  
The bioprocess economics and optimisation tool used was developed using the 
programming language C# (C-sharp) which runs using the .NET framework 
(Microsoft Visual Studio 2008, Microsoft Corporation, WA, USA). This was linked 
to a database (Microsoft Access, Microsoft Corporation, WA, USA). The tool, 
developed in the UCL Decisional Tools team, previously used by Simaria et al. 
(2012) and Allmendinger et al. (2014a) was updated to incorporate statistical cause-
and-effect correlations able to link mAb titre and HCP levels with key cell culture 
parameters. Cell culture factors such as culture temperature, seeding density, media 
osmolality, pH and timing of feed initiation were also integrated within the database. 
The optimisation tool was adjusted to take into account different levels of HCP.  
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Chapter 3 
3 Quality by design approach to cell culture process development  
3.1 Introduction 
As the antibody sector has matured, it has seen significant increases in upstream 
(USP) productivities, with titres reaching over 10 g L-1 in fed-batch cultures. 
However, given the complex set of interactions that can affect cell culture 
performance, it is hard to predict the consequences of titre increase on the host cell 
protein (HCP) levels at harvest and hence the robustness of downstream operations. 
Hence it is critical to have systematic methods to explore such interactions and 
improve process understanding of mammalian cell culture processes. 
The aim of this chapter was to use a QbD approach to characterise cell culture 
performance associated with different generation numbers and explore the 
consequences of titre increase on the HCP levels at harvest.  
3.2 Reproducibility of ambr system 
Within each AMBR experiment, aside from the DoE design, three additional centre 
points were added to each culture station. This was done in order to evaluate the 
ambr’s ability to provide consistency between vessels with identical conditions. The 
culture profiles of the four centre points within culture station 1 of AMBR 1 are 
presented in Fig. 3-1. Good vessel-to-vessel consistency has been observed within 
ambr vessels cultured under identical fed-batch conditions, in terms of viable cell 
density, glucose and lactate concentration (Fig. 3-1). Good comparability was also 
seen in terms of viability, antibody titre (within 10 %) and HCP levels (within 20 %) 
(data not shown). There was also a good vessel-to-vessel comparability between 
centre point conditions from AMBR 1, CS2, AMBR 2 and AMBR 3, but only 
AMBR 1, CS1 was chosen to be shown here.   
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Figure 3-1: Fed-batch culture profiles for centre points within AMBR 1 A) viable cell density, B) 
glucose concentration, C) lactate concentration. The cultures were seeded at 0.8 × 106 cells ml-1 
viable cell density, 353 mOsm kg-1 and 36.5 oC.  
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3.3  Growth profiles of CHO cells in fed-batch culture 
AMBR 1, 2 and 3 correspond to low, mid and high generation cells within DoE 
designs exploring the impact of culture temperature, starting media osmolality, 
seeding density, culture pH, timing of feed initiation and cell generation number on 
cell growth, specific antibody productivity, antibody titre and HCP concentration at 
harvest. The experimental design for AMBR 1, AMBR 2 and AMBR 3 are 
summarised in Table 3-1. The cell culture profiles for AMBR 1, AMBR 2 and 
AMBR 3 experiments using different generation number cells and their 
corresponding titre and viability profiles are summarized in Fig. 3-2, 3-3, 3-4, 
respectively. The growth profiles within all fed-batch cultures using a CHO high 
producing cell line showed a normal growth pattern. Within low generation cultures 
(AMBR 1), a maximum viable cell density (VCD) range of 13 - 27 × 106 cells mL-1, 
corresponding to a titre range of 6 – 8.3 g L-1 and a final viability of 55 - 68 % was 
seen at 36.5 oC, while a maximum VCD range of 12 - 19 × 106 cells mL-1, 
corresponding to a titre range of 6 – 8.2 g L-1 and a final viability of 70-84 % was 
seen at 33 oC. Within mid generation cultures (AMBR 2) a maximum VCD range of 
3 - 18 × 106 cells mL-1, corresponding to a titre range of 1 - 6.8 g L-1 and a final 
viability of 43 - 75 % was observed. Within high generation cultures (AMBR 3), a 
maximum VCD range of 19 - 26 × 106 cells mL-1, corresponding to a titre range of 6 
– 7.4 g L-1 and a final viability of 61 - 74 % was seen at 36.5 oC, while a maximum 
VCD range of 12 - 21 × 106 cells mL-1, corresponding to a titre range of 6.8 – 9.6 g 
L-1 and a final viability of 65 - 83 % was seen at 33 oC.  
The culture with the highest growth profile within AMBR 1 (Fig. 3-2, A)) 
was cultivated at 36.5 oC, 313 mOsm kg-1 media osmolality and 1 × 106 cells mL-1 
seeding density, while the lowest growth profile achieved was cultured at 36.5 oC 
followed by a temperature shift to 33 oC after day 4 of culture, 394 mOsm kg-1 media 
osmolality and 0.5 × 106 cells mL-1 seeding density. The culture with the highest 
growth profile within AMBR 2 (Fig. 3-3, A)) was seeded at a 0.75 × 106 cells mL-1 
seeding density and a 6.8 ± 0.1 pH was maintained while the lowest growth profile 
achieved was seeded at 0.5 × 106 cells mL-1 seeding density and a 6.6 ± 0.1 pH was 
maintained. The culture with the highest growth profile within AMBR 3 (Fig. 3-3, 
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A)) was cultivated at 36.5 oC, 320 mOsm kg-1 media osmolality and 1.25 × 106 cells 
mL-1 seeding density, while the lowest growth profile achieved was cultured at 36.5 
oC followed by a temperature shift to 33 oC after day 4 of culture, 390 mOsm kg-1 
media osmolality and 0.5 × 106 cells mL-1 seeding density. It appears that the 
different generation number cells used in the three sets of experiments, has the 
biggest influence on antibody titre at 36.5 oC. This will be discussed further in 
following sections.  
3.4 Effect of cell culture inputs and generation number on cell growth 
It has been extensively reported in literature that a decrease in temperature to 28-35 
oC from 36.5 - 37 oC (the conventional cultivation temperature for CHO cells) can 
arrest cell growth and prolong viability (Fox et al., 2004; Tait et al., 2013; Mason et 
al., 2014). This reduced growth rate has been shown to occur due to a cell cycle 
arrest in the G1 phase (Trummer et al., 2006), which also causes the cells in G1 
phase to be larger in size (Becerra et al., 2012). Moore et al. (1997) explains that low 
temperatures induce a significant suppression of cell death due to apoptosis while 
cell viability is preserved in temperature shift cultures, owing to a delay in the onset 
of apoptosis. Kaufmann et al. (1999) reported that cultures run at 37 oC show a much 
higher cell density compared to those having undergone a temperature shift. The 
increase in cell density was accompanied by lower cell viabilities at the end of the 
culture compared to cultures under hypothermic conditions. The progression of 
viable cell density and cell viability during fed-batch cultivation is presented in Fig. 
3-2, A) and B) for AMBR 1 (low generation), Fig. 3.3 A) and B) for AMBR 2 (mid 
generation), and Fig. 3-4 A) and B) for AMBR 3 (high generation). In comparison to 
the control cultures (where temperature was maintained at 36.5 oC), a temperature 
decrease to 33 oC significantly affected cell growth and viability. Reduced growth 
was observed at 33 oC while a higher viability was maintained throughout the 
culture, which agrees with literature (Abu-Absi, 2010). The CCH viable cells for 
cultures at 33 oC were on average 25 % lower than those achieved for cultures under 
optimum temperature, while the viability for the lower temperature cultures was on 
average 30 % higher at harvest point than cultures maintained at 36.5 oC. 
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Most cell culture media are designed to have an osmolality in the range of 
260 - 330 mOsm kg-1, so as to be approximately isotonic with human serum at 290 
mOsm kg-1 (Li et al., 2000). It has been widely investigated in literature the effect an 
increase in media osmolality has on cell growth, specific cell productivity and 
volumetric productivity. It was found that high osmolality media depressed cell 
growth and increased qMab (Lin et al., 1999; Ryu et al., 2000; Lee et al., 2003; Li et 
al., 2010). Lin et al (1999) explains that the increase in osmotic pressure lowers the 
water retention within the cells, resulting in shrinkage of cell size that may be the 
cause of cell growth inhibition. Within our experiments, the highest cell growth was 
achieved using base media (313 mOsm kg-1) while the lowest cell growth was 
achieved using high osmolality media (~ 394 mOsm kg-1). At 36.5 oC and low 
seeding density (0.5 × 106 cells mL-1), the maximum VCD was decreased by 
approximately 26 % and 51 % respectively when media osmolality was increased 
from 313 to 353 mOsm kg-1 and from 313 to 394 mOsm kg1 within AMBR 1 
cultures. At high seeding density (1 × 106 cell/mL), a decrease of 13 % and 19 % in 
maximum VCD was seen. In temperature shift cultures to 33 oC, the decrease in 
maximum VCD at low seeding density was 23 % and 39 %, while at high seeding 
density it was 6 % and 14 % respectively. Cultures seeded at a higher seeding density 
as well as cultures incubated under hypothermic conditions (33 oC) are less sensitive 
to increases in osmolality than cultures at 36.5 oC and low seeding density. These 
findings match those in literature; with Lee et al. (2003) reporting a decrease of 76 % 
in maximum VCD when media osmolality was increased from 300 to 450 mOsm kg-
1 and Kim et al (2002) presented an 80 % decrease in maximum VCD when 
osmolality was increased from 294 to 459 mOsm kg-1. 
Culture pH is an important environmental factor that should be accurately 
controlled to ensure the quality of the desired product. A wide range of optimum pH 
levels have been reported in literature, leading to the conclusion that the optimum pH 
for growth and recombinant protein production is cell line specific (Trummer et al., 
2006).  A decrease in culture pH from its optimum has been shown to significantly 
decrease cell growth (Tsao et al., 2005; Trummer et al., 2006). A slightly acidic 
condition was found to result in reduced glucose consumption and lactate build-up, 
leading to an increase in cell death (Tsao et al., 2005). Cultures that were maintained 
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at a pH of 6.6 showed a significant reduction in growth (by up to 3 fold) (Fig. 3-3, 
A)) as well as significantly lower specific cell productivity compared to cultures 
maintained at pH 6.8 and 7. A higher pH is accompanied by a higher cell specific 
glucose consumption rate, which gives a higher cell growth rate in the exponential 
phase (Li et al., 2010). Cultures maintained at a pH of 6.8 and 7 did not show a 
significant difference in the levels of VCD achieved, which shows that for this 
specific cell line, a pH range of 6.8 - 7 was suitable for cell growth. Link et al. (2004) 
also found a pH in the range of 6.8 - 7 to give the best growth for a recombinant 
MUC 1 fusion protein expressed by CHO-K1 cells.  
Cell generation number is seen to have an impact on cell growth.  Within cell 
cultures with a higher generation number (generation 44 and 54, compared to 
generation 33) an increase of 8.7 to 40.4 % in CCH viable cells is observed (Table 3-
2).
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Table 3-1: Experimental design setup for AMBR 1, AMBR 2 and AMBR 3 experiments 
 
 
 
 
 
 
 
 AMBR 1 AMBR 2 AMBR 3 
 CS1 CS2 CS1 CS2 CS1 CS2 
Number of 
experiments 
12 12 12 12 12 12 
Number of outliers 
removed 
1 3 0 0 1 0 
Generation number 33 44 54 
Seeding density   
(×106 cells mL-1) 
*(expected) 
0.49 
0.8 
1.14 
(0.5)* 
(0.75) 
(1) 
0.59  
0.82  
1.14 
(0.5)* 
(0.75) 
(1) 
0.42  
0.69 
1.06 
(0.5)* 
(0.75) 
(1) 
0.9  (1) 
0.58  
1.08  
1.8 
(0.5)* 
(1) 
(1.65) 
0.58  
1.19 
1.8 
(0.5)* 
(1) 
(1.65) 
Osmolality 
(mOsm kg-1) 
*(expected) 
314 
353 
394 
314 
353 
394 
313 313 
310  
331  
364 
(310)* 
(350) 
(390) 
319  
356  
389 
(310)* 
(350) 
(390) 
Temperature (oC) 36.5 33 36.5 36.5 33 
pH 6.8 
6.6 
6.8  
7 
6.6 
6.8  
7 
6.8  
Timing of feed 
initiation (day) 
2 2 2 
1 
2 
3 
2 2 
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Figure 3-2: Fed-batch culture profiles for AMBR 1 A) viable cell density, B) viability profiles, C) 
antibody titre. Two different temperatures have been used -- 36.5 oC, ··· 33 oC. Within the DoE 
design, cultures were seeded at a density of 0.49, 0.8, 1.14 × 106 cells mL-1 and the osmolality 
levels used were 314, 353, 394 mOsm kg-1 respectively. The pH was maintained at 6.8 ± 0.1 and 
feeding started on day 2 of culture. 
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Figure 3-3: Fed-batch culture profiles for AMBR 2 A) viable cell density, B) viability profiles, C) 
antibody titre. Three different pH levels have been used ··· 6.6, ─ 6.8 and 7. Within CS1 of 
AMBR 2 cultures, seeding density and pH levels were 0.42, 0.69, 1.06 × 106 cells mL-1 and 6.6, 
6.8, 7 while feeding started on day 2 of culture. Within CS2 of AMBR 2 cultures, pH and timing 
of feed initiation levels were 6.6, 6.8, 7 and day 1, 2, 3 respectively, while the starting seeding 
density was kept constant at 1 × 106 cells mL-1. A temperature of 36.5 oC and an osmolality of 
313 mOsm kg-1 were maintained for all 24 cultures. 
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Figure 3-4: Fed-batch culture profiles for AMBR 3 A) viable cell density, B) viability profiles, C) 
antibody titre. Two different temperatures have been used -- 36.5 oC, ··· 33 oC. Within the DoE 
design, cultures were seeded at a density of 0.58, 1.1, 1.8 × 106 cells mL-1 and the osmolality 
levels used were 320, 350, 390 mOsm kg-1 respectively. The pH was maintained at 6.8 ± 0.1 and 
feeding started on day 2 of culture. 
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3.5 Effect of cell culture inputs and generation number on qMab, titre 
and HCP levels 
3.5.1 qMab 
In the past decades the remarkable improvements in specific and volumetric 
productivities for mAbs have been achieved through extensive bioprocess 
engineering research (Wlaschin and Hu, 2006) and careful design/selection methods 
by the use of high-producers or strong clones (Becerra et al., 2012). Different 
approaches to try and improve the productivity of mammalian-based processes have 
focused on the increase in VCD and qMab (Tsao et al., 2005; Beccera et al., 2012). 
Temperature and media osmolality were chosen as parameters within AMBR 1 (low 
generation) and AMBR 3 (high generation) experiments due to their history of 
influencing the specific cell productivity (Kaufmann et al., 1999; Ryu et al., 2000; 
Lee at al., 2003; Becerra et al., 2012). Temperature is known as an important factor 
in process optimisation (Fox et al., 2004; Trummer et al., 2006). Lower cell culture 
temperature is often used to shift cell metabolism towards protein production and 
essentially improving productivity (Yoon et al., 2003; Tsao et al., 2005; Becerra et 
al., 2012). Initial studies into the effect of low temperature on qMab in mammalian 
cells were not encouraging, with qP either being unchanged (Chuppa et al., 1997) or 
decreased (Ryll et al., 2000). Several other studies have shown that qP can be 
significantly enhanced by culturing at temperatures in the 30 - 33 oC range 
(Kaufmann et al., 1999; Yoon et al., 2003). The effect of low temperatures on qP 
seems to be cell-line dependent, with certain CHO cell lines, achieving higher 
productivity under mild hypothermia (Fox et al., 2004). Within low generation 
cultures, a 6 – 24 % increase in qMab was seen in temperature shift cultures to 33 oC 
compared to cultures maintained at an optimum of 36.5 oC, whereas within high 
generation cultures, a 13 – 43 % increase in qMab was seen (data not shown). It seems 
that within high generation cell cultures, a shift to a lower temperature has a higher 
impact on qMab, than within low generation cultures.  
High osmolality media created by addition of sugars or salts (e.g. NaCl) has 
been known as an economical method of increasing qMab in CHO cultures (Lin et al., 
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1999; Ryu et al., 2000; Kim et al., 2002; Lee et al., 2003; Lin et al., 2010). Kim et al. 
(2002) reported increases in qMab of 390 % when media osmolality was increased 
from 294 to 459 mOsm kg-1, whereas Lee et al. (2003) saw an increase of 139 % in 
qMab when osmolality was increased from 300 to 450 mOsm kg
-1. It was observed 
that an increase in initial media osmolality from 313 to 353 mOsm kg-1 and from 313 
to 394 mOsm kg-1 through addition of NaCl increased the qMab in all cultures (data 
not shown)  
Looking at the relationship between qMab and qHCP (Fig. 3-5 D), E), F)), for 
this cell line the specific productivity for the protein of interest (monoclonal 
antibody) per cell is always positively correlated to the specific productivity of total 
HCP per cell, regardless of the generation number used (Table 3-3). As the levels of 
HCP are used in correlation plots, in this chapter HCP is expressed as ng mL-1, as 
opposed to ng mg-1 (Chapter 6). This was done in order to identify the true 
relationship between HCP levels (in absolute value) and antibody titre. 
Within AMBR 2 (generation number 44) a 10 % decrease in qMab was 
observed when compared to lower generation number cultures (AMBR 1 – 
generation number 33) whereas within AMBR 3 (generation number 54) a 22 % and 
16 % decrease in qMab, at 36.5 
oC and 33 oC, respectively, was observed, compared to 
AMBR 1 (Table 3-2). The reduction in qMab with an increase in generation number 
seen in AMBR 2 and AMBR 3, compared to AMBR 1, is an indication of cell line 
instability. For cell lines that are considered unstable, a common cause for lower 
specific productivity for the antibody with an increase in generation number is the 
loss of recombinant gene copy number (Dorai et al., 2012). The cell line instability 
problem is further discussed in the next section. 
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Table 3-2: The effect of generation number on CCH viable cells, qMab, antibody titre and HCP levels. The comparison is done between replicate conditions of AMBR 
2 and AMBR 3 in comparison to AMBR 1.  
 
Note: The values presented in this table are averages based on a minimum of two replicates across three AMBR experiments, under similar 
conditions 
 AMBR 1 AMBR 2 AMBR 1 AMBR 3 AMBR 1 AMBR 3 Stability study 
 CS1 CS1 + CS2 CS1 CS2 Mid Late 
Temperature (oC) 36.5 36.5 33 36.5 
Generation number 33 44 33 54 33 54 39 65 
CCH viable cells 
(×106 cells mL-1) 
3657 3975 (8.7 %) 4688 5414 (15.5 %) 3592 5042 (40.4 %) 3185         3509 (9 %) 
qMab  
(pg cell-1 day-1) 
42.5 38.2 (-10.1%) 41.0 31.9 (-22.2 %) 47.8 40 (-16.4 %) 11.8 9.4 (-20.8 %) 
Titre  
(g L-1) 
7.6 6.4 (-15.8 %) 8.2 7 (-14.6 %) 7.0 8.4 (19.5 %) 1.8 1.5 (-16.7 %) 
HCP levels 
(ng mL-1) 
1,713,760 2,071,358 (20.8 %) 1,820,485 2,414,488 (32.6 %) 2,333,260 3,147,810 (34.9 %) N/A 
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Figure 3-5: The plot of A), B), C) viability against HCP levels and the observed correlations between D), E), F) qMab and qHCP within AMBR 1, AMBR 2 and AMBR3 
experiments, respectively. See Materials and methods for details on AMBR 1, AMBR 2 and AMBR 3 experimental designs. 
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3.5.2 mAb titre and HCP levels  
Antibody titres can be increased through two different methods; increasing the 
integral area of viable cell days or increasing the cell specific productivity (Kim et 
al., 2002). Temperature is a key parameter that influences cell growth and 
recombinant protein production within cell culture, due to its effect on the cell cycle 
(Yoon et al., 2003). The effect of the different cell culture parameters within the DoE 
designs on titre and HCP levels is shown using 2D plots in Fig. 3-6 for AMBR 1, 2 
and 3 (low, mid and high generation, respectively). Within AMBR 1 cultures, CHO 
cells cultured at 33 oC achieved overall lower titre levels (average titre of 6.4 g L-1 
across all 12 cultures) compared to cells maintained at 36.5 oC (average titre 7.2 g L-
1). There was a 5-20 % decrease in titre for cultures at 33 oC, depending on other 
culture conditions within the DoE design. The correlation between antibody titre, 
viable cell density, antibody productivity, HCP levels and the qMab: qHCP ratio is 
shown in Fig. 3-7 for AMBR 1, 2 and 3. The increase in titre within AMBR 1 was 
correlated with an increase in viable cell density (Fig.3-7 A)), therefore the increase 
in qMab which occurred in 33 
oC cultures did not compensate for the lower cell 
growth within these cultures, resulting in lower titres compared to cultures at 36.5 
oC. These findings are in agreement with literature, where Trummer et al. (2006) 
reported a 1.5 fold decrease in titre levels in cultures run at 33 oC compared to 
cultures at 37 oC and Abu-Absi et al. (2010) also reported decreased product titre at a 
lower production bioreactor temperature. It should be noted that in both cases, the 
lower culture temperature was set and maintained from the start of the culture.  
The increase in titre within AMBR 3 cultures was correlated with an increase 
in qMab (Fig.3-7 C)) and in this scenario, higher titres are seen in 33
 oC cultures 
(average 8.6 g L-1), condition that favours higher qMab, compared to cultures 
maintained at 36.5 oC (average titre 6.9 g L-1) . There was a 15-30 % increase in titre 
for cultures at 33 oC, depending on other culture conditions within the DoE design. 
Similar results have been reported by Rameez et al. (2013) which found that a two 
fold increase in titre occurs in temperature shift cultures, performed in the ambr 
system. In comparison to our experiments in which the temperature was shifted to 33 
oC in day 4 of culture, Rameez et al. (2013) performed the temperature shift from 37 
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oC to 33 oC, in day 8 of culture, in order to allow maximal viable cell density to be 
achieved. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3-6: Impact of different cell culture parameters (seeding density, media osmolality and 
timing of feed initiation) on antibody titre and HCP levels at two different temperatures ··· 36.5 
oC, ··· 33 oC, within AMBR 1, AMBR 2 and AMBR 3 experiments. See Materials and methods 
for details on AMBR 1, AMBR 2 and AMBR 3 experimental designs. 
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The effect of temperature on HCP levels within AMBR1 and AMBR 3 
cultures is shown in Fig. 3-6. In both set of experiments, a higher level of HCPs was 
seen in 33 oC cultures compared to 36.5 oC. A 25 % and 16 % increase in HCP levels 
in 33 oC cultures was seen on average for AMBR 1 and AMBR 3 experiments, 
respectively. This is in agreement with Tait et al. (2013) which has seen the HCP 
content determined by an industry standard ELISA assay being ~ 50 % higher in the 
culture grown under mild hypothermic conditions (32 oC) compared to cultures 
grown at 37 oC. Cultures at 33 oC are also known to have higher viabilities at harvest 
compared to cultures at 36.5 oC (Fig. 3-2 B), Fig. 3.4 B)) (Trummer et al., 2006; 
Abu-Absi, 2010; Rameez et al., 2013). This explains why within all experiments 
using different cell generations, HCP levels show a positive correlation with culture 
viability at harvest (Fig. 3-5, A), B), C)). The same behaviour was seen by 
Grzeskowiak et al. (2009) which observed higher HCP levels in higher viability 
cultures using HCP ELISA. Yuk et al. (2015) also shows that high density CHO 
cultures (>107 cells mL-1) operated in fed-batch mode and having high viabilities 
(>70 %) throughout the culture duration, can accumulate a high amount of 
immunogenic HCP (1-2 g L-1) in the extracellular environment at the time of harvest 
(day 14). LDH results showed that cumulative cell lysis can be considerable in high 
density fed-batch CHO cultures, despite high viability readings. These publications 
offer a possible hypothesis for why this might be happening but for this set of 
experiments, we cannot say with confidence that this applies here. 
An increase in media osmolality was shown to enhance qMab (Lin et al., 1999; 
Kim et al., 2002; Lee et al., 2003; Lin et al., 2010), however the use of high 
osmolality media did not increase the final antibody concentration due to cell growth 
being depressed at elevated osmolality (Kim et al., 2002; Lee et al., 2003). Fig 3-2 
shows the impact of media osmolality increase on titre and HCP levels at 36.5 oC and 
33 oC. As an increase in media osmolality occurs, a significant decrease in titre levels 
is seen in all cultures seeded at low cell density. The negative effect of increased 
media osmolality starts to decline, with an increase in seeding density. Cultures 
seeded at a high cell density are not sensitive to changes in osmolality, within the 
osmolality ranges investigated.  
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To be able to take advantage of the increased qMab in high osmolality cultures 
in order to increase the final antibody concentration, several strategies have been 
proposed in literature: 1) biphasic culture, where the osmolality was maintained at a 
physiological level to promote growth and then increased to maximize qMab (Kim et 
al., 2002), 2) addition of osmoprotective compounds to the cultures (e.g. glycine 
betaine) which can improve the cell growth at elevated osmolality, sustaining the 
enhanced qMab (Ryu et al., 2000).  
Within AMBR 1 and AMBR 3 cultures, the increase in media osmolality 
does not have a significant impact on HCP levels (Fig. 3-6). I am not aware that the 
effect of osmolality on CHO HCP levels at harvest point has been previously 
reported in the literature.  
Culture pH is a parameter known to significantly influence cell growth and 
recombinant protein production (Link et al., 2004; Yoon et al., 2005; Trummer et al., 
2006; Seo et al., 2013). Significantly lower antibody titres were achieved in cultures 
at pH 6.6 as compared to cultures at pH 6.8 and 7 (Fig. 3-3 C)). This is mainly due to 
the significant decrease in viable cell numbers in cultures maintained at pH 6.6 (Fig. 
3-3 A)).  Jardon and Garnier (2003) studied the effects of pH in the ranges 6.7 – 7.7 
for the production of recombinant adenovirus vector (rAV) using HEK293 cells and 
found that significantly lower titres were seen in cultures at pH 6.7 as compared to 
pH 7.2. I am not aware that the effect of pH on CHO HCP levels at harvest point has 
been previously reported in the literature. Fig 3-2 shows the effect of culture pH on 
HCP levels within AMBR 2 cultures. It can be seen that HCP levels for all cultures at 
pH 6.6 are significantly lower compared to cultures maintained at pH 6.8 and 7 
which correlates with significant lower growth in these cultures (Fig. 3-3 A)). 
Timing of feed initiation was not found to have a significant impact on antibody titre 
and HCP levels at low pH. At pH 6.8-7, higher titres are seen in cultures for which 
feeding started on day 1 of culture, but this correlates with an equivalent increase in 
HCP levels.  
In terms of biopharmaceutical production, cell line stability can be defined as 
reproducible product concentration and quality for a given cell line over prolonged 
periods of time, starting from thawing the master cell bank to a time point 
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determined to be the longest duration allowed for production (Wurm, 2015). At 36.5 
oC, within higher generation cell cultures (AMBR 2 – Gen 44; AMBR 3 – Gen 54) 
an increase in CCH viable cells, a decrease in qMab and a decrease in antibody titre 
can be observed. The comparison is done between replicate conditions of AMBR 2 
and AMBR 3 in comparison to AMBR 1. The trends are consistent with a previous 
stability study which shows a stability issue as described in Table 3-2. Other process 
conditions within AMBR 1 and AMBR 3, at 36.5 oC were the same with the previous 
stability study. There are several studies in literature that have presented on the 
instability of protein production from recombinant cell lines. The most common 
causes were identified as a loss of recombinant gene copy number as well as the 
appearance of a secondary, less productive population of cells (Dorai et al., 2012). 
Comparing AMBR 3 with AMBR 1 at 33 oC cultures, on average, CCH viable cells 
increased, qMab decreased and antibody titre increased between replicate conditions. 
 In literature, a reduction in culture temperature from optimum (36.5 oC) to 33 
oC is known to promote an increase in qMab whereas a lower cell growth is generally 
observed, trends which are more likely to mask a cell line stability issue compared to 
cultures maintained at 36.5 oC. At higher generation numbers (AMBR 2, 3) 
compared to AMBR 1, a higher HCP level was seen in all cultures, regardless of 
culture temperature or other cell culture inputs. 
3.6 Analysis 
Overall monoclonal antibodies titres can be increased or decreased due to a 
combination effects from changes in cell densities and/or specific cell productivities 
(Li et al., 2010), each with a different impact on impurity profiles. This depends on 
factors such as the cell line characteristics, bioreactor operating parameters, media or 
feed type and the feeding strategy. These have a significant influence on cell growth, 
productivity, viability, impurity profiles and may also have an impact on product 
quality. Increases in cell densities can be achieved by media optimisation that has a 
great impact on maximizing and maintaining viable biomass, feeding strategies and 
optimal control of culture conditions such as pH, DO and glucose (Fike, 2009). It is 
normally anticipated that when high titres are achieved, an increase in HCP levels 
  
120 
 
would also be seen. It was demonstrated that by using a QbD approach to cell culture 
process development (HT ambr experimentation, HT analytics and DoE) bioreactor 
scenarios where the ratio of mAb to HCP can be varied, are identified. This can 
potentially impact the purification strategy for mAbs where HCP contamination is an 
issue. This opens the potential of designing a bioreactor process in which mAb 
harvest titre is high whilst reducing HCP levels.  
3.6.1 Analysis of low generation cell experiments (AMBR 1) 
The experimental design of AMBR 1 is shown in Table 3-1. It was demonstrated that 
within low generation cultures, conditions known to increase the specific mAb 
productivity (hypothermic conditions and high osmolality) had a negative impact on 
titre, mainly due to depressed cell growth at these conditions. Fig. 3-7 A) shows how 
within AMBR 1 cultures, the increase in antibody titre correlates to an increase in 
viable cell number (expressed by CCH viable cells) while qMab is decreased. A 
Spearman’s rank correlation test was performed to assess the strength of the 
correlations between the different variables within AMBR 1, AMBR 2 and AMBR 3 
experiments. A summary of the results is presented in Table 3-4. It can be 
hypothesized that even though qMab is decreasing, the high number of viable cells 
achieved within the culture is the main driver for the increase in antibody titre. 
Assessing the relationship between qMab and qHCP, as a function of CCH increase 
(Fig. 3-7 G)), it is observed that as the viable cell density increases, the ratio of qMab: 
qHCP is increasing, suggesting that qMab is increasing at a higher rate than qHCP, 
resulting in a purer product which eases the load on the DSP. In this scenario, titre is 
higher at conditions that correlate with a high number of viable cells within the 
culture (in these experiments, T= 36.5 oC, a high seeding density (1 × 106 cells mL-1) 
and base media (313 mOsm kg-1), as well as an optimum combination of seeding 
density and starting media osmolality (e.g. medium seed (0.75 *106 cells mL-1) and 
medium osmolality (353 mOsm kg-1); high seed (1 × 106 cells mL-1) and high 
osmolality (394 mOsm kg-1)). So overall these observations suggest that the amount 
of product increases but not at the expense of an increase in HCP levels (Fig. 3-7 
D)). Similar plots have been done in order to assess the correlation between antibody 
titre, qMab, qMab: qHCP ratio and growth rate (as opposed to CCH viable cells). The 
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same conclusion can be drawn, therefore only correlation plots using CCH viable 
cells are shown. This is consistent with a similar trend presented by Jin et al. (2010), 
although they saw significant differences in product titre; no major change was seen 
in the levels and composition of HCPs.  
3.6.2 Analysis of mid generation cell experiments (AMBR 2) 
The experimental design of AMBR 2 is shown in Table 3-1. Switching to a different 
design space than AMBR 1 and using a different cell stock, a different scenario is 
identified, where the increase in antibody titre is correlated with an increase in viable 
cell density as well as specific mAb productivity (Fig. 3-7 B)). Evaluating the impact 
of antibody titre increase on HCP levels, as a function of increases in viable cell 
density, it can be observed that titre and HCP levels increase at a similar rate (Fig. 3-
7 E)), therefore the ratio of qMab: qHCP remains constant over the whole range of CCH 
viable cells (Fig. 3-7 H)). The influence of culture pH on cell growth is the reason for 
data clustering in Fig. 3-7 B), E), H). Cultures at pH 6.6 revealed significantly lower 
growth profiles, compared to cultures at pH 6.8 and 7 (Fig. 3-3 A)).  
3.6.3 Analysis of high generation cell experiments (AMBR 3) 
The experimental design of AMBR 3 is shown in Table 3-1. Extending the design 
space used for AMBR 1 experiments and using high generation cells, a third 
distinctive scenario is identified, where the increase in antibody titre is correlated 
with an increase in qMab, while a constant level of viable cells is seen within all 
cultures (Fig. 3-7 C)). Similar to AMBR 2, in this case, titre and HCP levels are seen 
to increase at a similar rate (Fig. 3-7 F)), with the ratio of qMab: qHCP remaining 
constant (Fig. 3-7 I)).  
So overall for this cell line, low generation cell number leads to an increase in 
antibody titre and reduced HCP levels while a mid and high generation number also 
leads to an increase in antibody titre but with a concomitant increase in HCP level. 
As mentioned in section 3.5.2, in cell lines that show instability, the appearance of a 
secondary, less productive population of cells has been identified (Dorai et al., 2012). 
In the experiments presented in this thesis, this can be potentially reflected by the 
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higher number of cells (CCH viable cells) and lower specific productivity (qMab) 
present in higher generation cultures compared to low generation cultures (Table 3-
2). It can be hypothesized that the increase in HCP levels with an increase in 
antibody titre in mid (AMBR 2) and high generation number (AMBR 3) cultures is 
attributed to the higher number of cells present in higher generation cultures 
(showing lower productivity for the mAb).  
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Figure 3-7: A correlation 
plot of antibody titre 
against HCP levels within 
AMBR 1, AMBR 2 and 
AMBR 3 experiments. 
The relationship between 
A) antibody titre, CCH 
and qMab, B) antibody titre 
and HCP levels, C) CCH 
viable cells and qMab: qHCP 
ratio is shown. See 
Materials and methods for 
details on AMBR 1, 
AMBR 2 and AMBR 3 
experimental designs.  
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Table 3-3: Summary of Spearman’s rank test for the correlations between variables in Figure 3-5. 
 
 Variable correlation Spearman’s coefficient (rs) p -value Summary 
 AMBR 1 – low generation (33) 
Figure 3-5 A) HCP vs Viability 0.789 4.822 × 10-5 Strong positive correlation (significant) 
Figure 3-5 D) qMab vs qHCP 0.83 8.921 × 10
-7 Very strong positive correlation (significant) 
 AMBR 2 – mid generation (44) 
Figure 3-5 B) HCP vs Viability 0.299 0.0.2892 Weak positive correlation (insignificant) 
Figure 3-5 E) qMab vs qHCP 0.788 5.167 × 10
-5 Strong positive correlation (significant) 
 AMBR 3 – high generation (54) 
Figure 3-5 C) HCP vs Viability 0.539 0.0078 Moderate positive correlation (significant) 
Figure 3-5 F) qMab vs qHCP 0.893 3.145 × 10
-6 Very strong positive correlation (significant) 
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Table 3-4: Summary of Spearman’s rank test for the correlations between variables in Figure 3-7.  
 
 Variable correlation Spearman’s coefficient (rs) p -value Summary 
 AMBR 1 – low generation (33) 
Figure 3-7 A) Titre vs CCH 0.890 2.24 × 10-6 Very strong positive correlation (significant) 
Figure 3-7 A) Titre vs qMab -0.689 0.00079 Strong negative correlation (significant) 
Figure 3-7 B) Titre vs HCP -0.444 0.05009 Moderate negative correlation (insignificant) 
Figure 3-7 C) CCH vs qMab: qHCP 0.789 3 × 10
-5 Strong positive correlation (significant) 
 AMBR 2 – mid generation (44) 
Figure 3- 7 D) Titre vs CCH 0.773 1.52 × 10-5 Strong positive correlation (significant) 
Figure 3-7 D) Titre vs qMab 0.644 0.00069 Strong positive correlation (significant) 
Figure 3-7 E) Titre vs HCP 0.578 0.00308 Moderate positive correlation (significant) 
Figure 3-7 F) CCH vs qMab: qHCP 0.489 0.0162 Moderate positive correlation (insignificant) 
 AMBR 3 – high generation (54) 
Figure 3-7 G) Titre vs CCH -0.305 0.156 Weak negative correlation (insignificant) 
Figure 3-7 G) Titre vs qMab 0.775 1 × 10
-5 Strong positive correlation (significant) 
Figure 3-7 H) Titre vs HCP 0.571 0.0044 Moderate positive correlation (significant) 
Figure 3-7 I) CCH vs qMab: qHCP 0.230 0.289 Weak positive correlation (insignificant) 
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3.7 Conclusions 
Three AMBR experiments, using low, mid and high generation cells were performed 
in order to evaluate the impact that culture temperature, starting media osmolality, 
seeding density, culture pH, timing of feed initiation and cell generation number has 
on cell growth, specific antibody productivity, antibody titre and HCP concentration 
at harvest. A QbD approach is then presented to help establish the relationship 
between mAb titre and HCP levels within small-scale fed-batch mammalian cell 
culture. The results show that a temperature of 36.5 oC is optimum for increased 
mAb titre, cell growth and results in a lower HCP level as compared to 33 oC. High 
osmolality media increased qMab but had a negative effect on growth and antibody 
titre while a pH of 6.6 had a significant negative impact on cell growth, resulting in 
lower titres and HCP levels within these cultures. A stability issue is observed within 
higher cell generation cultures at 36.5 oC while at a lower temperature of 33 oC cell 
line instability is not apparent. Cells of a higher generation lead to an elevated ratio 
of HCP to product (AMBR 2, 3) as compared to lower generation cells (AMBR 1).  
 This chapter presents a QbD approach to cell culture process development 
(HT ambr experimentation and Gyrolab analytics linked with DoE) to show that 
there is scope for cell culture processes in which the ratio of mAb to HCP can be 
increased and the association of mAb titre to HCP reduced. It is therefore viable to 
identify conditions whereby it is possible to increase antibody titre with little impact 
on HCP levels and hence subsequent DSP operations. (36.5 oC, 313 mOsm kg-1 
media osmolality, 1 × 106 cells mL-1 seeding density, pH 6.8 and low cell generation 
number).  
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Chapter 4 
4 Analysis of problematic HCPs in cell culture processes  
4.1 Introduction 
Recent literature has emphasized the need for a better understanding of the impurity 
profile entering DSP and the cell culture factors that are likely to change this profile, 
as certain problematic HCPs have been identified in the final drug product 
(Aboulaich et al., 2014; Thompson et al., 2014). There is a limited understanding 
regarding the relationship between the protein of interest, bioprocess conditions (both 
in USP and DSP) and problematic HCPs (e.g. protease) (Bracewell and Smales, 
2013).  
 In addition to assessing the impact of cell culture inputs on the resulting mAb 
titre and HCP levels at harvest (Chapter 3), a deeper understanding was provided in 
this chapter regarding the USP factors influencing the activity of specific problematic 
HCPs (proteases). The aim of this chapter was to evaluate the impact of several cell 
culture parameters (temperature, media osmolality and seeding density) on protease 
activity at harvest as well as to examine the relationship between HCP levels, mAb 
concentration and protease activity resulting from unclarified harvest samples. A 
commercially available protease assay was optimised in order to make it suitable for 
the analysis of unclarified cell culture harvest.  
4.2 Protease assay development 
4.2.1 Trypsin standard curve  
The EnzChek® Protease Assay Kit (E6638, Molecular Probes, Eugene, OR) was used 
to measure protease activity within unclarified harvest samples, resulting from fed-
batch mammalian cell culture performed using the ambr system. The same protease 
assay kit was used by Robert et al. (2009) and Dorai et al. (2011) to measure the 
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amount of protease (aspartic acid protease and serine-threonine protease, 
respectively).  
To be able to determine if the protease assay is capable of measuring protease 
activity as well as to distinguish between low and high protease activity, a trypsin 
standard curve was performed, with trypsin concentration ranging from 50 – 10,000 
ng mL-1. An appropriate enzyme standard of known specific activity that closely 
matches the protease activity being determined was used. Trypsin is a serine protease 
that is commonly used in generating standard curves for protease activity assays. Fig 
4-1 shows the assay’s capability of distinguishing between different concentrations 
of trypsin; the trypsin concentration is proportional to the fluorescence increase.  
1000
2000
3000
4000
5000
6000
7000
8000
0 1 2 3 4 5 6
F
lu
o
re
s
c
e
n
c
e
Time (h)
 
Figure 4-1: Trypsin standard curve. The trypsin concentration varied from 50 – 10,000 ng mL-1, 
in-house Tris-HCl digestion buffer was used for making up the dilutions and the plate was 
incubated in the dark at 40o C and measured at hourly intervals. The increase in trypsin 
concentration is proportional to the increase in fluorescence 
4.2.2 Investigate the colour effect of unknown samples  
The unknown samples that were used to determine the associated fluorescence 
increase due to protease activity are unclarified harvest samples resulting from 
previously performed ambr experiments. A relatively high protease activity was 
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expected to be present in these samples due to their associated high HCP content and 
their level of clarification.  For this reason, a wide range of dilutions was used in 
order to determine the appropriate one for measuring protease activity (neat, 1/2, 1/5, 
1/10, 1/50, 1/100, 1/500, 1/1000 and 1/2000).  
The experimental protocol specifies that an equal volume of sample and 
substrate (100 µL) to be added to a 96 wells microplate in order to measure the 
fluorescence emitted from the sample, which in turn is proportional to the protease 
activity. The colour of the 1:1 mixture of unknown sample and BODIPY casein 
substrate (U+S) was quite intense, especially for samples with a low dilution. 
Coloured samples can give a fluorescence reading, regardless of the presence of 
protease within the samples. This would make it difficult to assess if the fluorescence 
increase given by the samples with substrate over time was due to protease activity 
or due to the intensity of colour within these samples. To verify if coloured samples 
exhibit a fluorescence increase, a sample of casein substrate (light pink colour), in a 
1:1 ratio to digestion buffer (colourless) (S + B) was analysed in order to identify if 
there is any fluorescence increase due to colour alone. A fluorescence increase of ~ 
3X higher than the blank (digestion buffer) was observed (data not shown). To 
identify the fluorescence increase only due to the substrate, the fluorescence 
background of the buffer was subtracted from the fluorescence background of the 
substrate and buffer 1:1 mixture: S = (B+S) – B.  
In order to determine if the colour difference between different dilutions had 
an impact on the fluorescence increase, a fixed concentration of trypsin (3000 ng mL-
1) was incubated with casein substrate for 4 h in a 1:1 dilution. Fig. 4-1 shows that 4 
h is sufficient time for most of the 3000 ng mL-1 trypsin to become depleted. The 
3000 ng mL-1 trypsin in 1:1 mixture with casein substrate was then added to the 
different dilutions of an unknown sample and the corresponding fluorescence 
increase was read at time t = 0 (Fig. 4-2 A )). Control samples (without the 
BODIPY casein substrate) were prepared for each dilution of the sample, as a 1:1 
ratio of unknown sample and digestion buffer (U+B) (Fig. 4-2 A)). The true 
fluorescence increase due to protease activity was then obtained by subtracting the 
fluorescence background of the substrate-free control (unknown (U) + buffer (B)) as 
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well as the fluorescence background of the substrate (S) from the unknown sample 
containing the substrate (unknown (U) + substrate (S)) (Fig. 4-2 B)).  
 
Protease activity = (U+S) – (U+B) – S              (16)  
 
The background fluorescence given by the casein substrate (S) was constant 
for any unknown samples analysed. The protease activity calculated as (U+S) – 
(U+B) – S showed identical trends to the protease activity calculated as (U+S) – 
(U+B), therefore the latter formula was used in subsequent calculations to determine 
the true fluorescence increase due to protease activity. The protease activity was 
expressed in fluorescence change per unit sample as opposed to being calculated 
using a trypsin standard curve. The unknown samples originate from cell culture 
unclarified harvest; thus it is very likely that the samples contain one or more 
unknown proteases. In this case a standard curve might not be relevant. Plotting the 
true fluorescence increase due to protease activity versus the log of the dilutions used 
(Fig. 4-2 B)), the dilutions under which the colour effect was eliminated, were 
identified. It can be observed that between 1/10 to 1/100 dilution, there a relatively 
flat line, meaning that under these particular dilutions the colour effect is eliminated.  
 
 
A) 
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Figure 4-2: Investigation into the colour effect of unknown samples. A) Fluorescence increase 
associated with the unknown sample containing the substrate (U+S) (  ̶ ̶  ) and substrate-free 
control (U+B) (), B) Fluorescence increase due to protease activity (U+S) – (U+B) 
4.2.3 Effect of unclarified material on assay performance  
Next, an investigation was carried out to determine whether the particles within 
unclarified harvest samples interfere in any way with the assay. A comparison was 
made between one unclarified and two clarified levels of the same unknown sample, 
at all the dilutions previously mentioned. Out of the two clarified samples, one was 
clarified only through centrifugation, whereas the other one was clarified through 
centrifugation followed by sterile filtration. The same as before, a fixed 
concentration of trypsin (3000 ng mL-1) was incubated with casein substrate for 4 h 
in a 1:1 dilution until enzyme depletion. The concentration of trypsin used in 
combination with the substrate to reach enzyme depletion was the same as 
previously, in order to maintain consistency.  This solution was then added to the 
different dilutions of the three levels of clarification and the corresponding 
fluorescence increase was read at time t = 0 (U+S) (Fig. 4-3 A)   ). For each dilution 
of each clarification level, a corresponding control sample without the casein 
substrate (U+B) was prepared as a 1:1 ratio of sample and digestion buffer (Fig. 4-3 
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A) ···). The true fluorescence increase due to protease activity was then calculated 
(U+S) – (U+B) and plotted against the log of dilutions (Fig. 4-3 B)) 
Similar trends are observed for all three samples, regardless of the levels of 
clarification. This suggests that the particles within unclarified samples do not 
interfere with the assay and the performance of the assay in determining protease 
activity is similar regardless of the level of clarification used. The fluorescence 
intensity is seen to be slightly higher for the unclarified sample. This is due to the 
higher initial colour intensity, for each dilution of this sample.   
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Figure 4-3: Comparison between unclarified and clarified levels of the same unknown sample. 
Clarification was achieved through either centrifugation ( ─ ) or centrifugation followed by 
sterile filtration ( ─ ). A) Fluorescence increase associated with the three levels of clarification of 
the unknown sample containing the substrate (U+S) ( ─ ) and substrate-free control (U+B) (---), 
B) Fluorescence increase due to protease activity (U+S) – (U+B), for each level of clarification  
4.3 Analysis of unknown samples 
4.3.1 Identification of suitable dilutions 
Previously we identified 1/10, 1/50 and 1/100 dilutions as being the only dilutions 
from the ones investigated, under which the colour effect interference was not 
apparent. Next, we compared the protease activity associated with each dilution, for 
an unknown sample. Casein substrate has been added to each of the three dilutions of 
the unknown sample (U + S) and corresponding substrate-free control samples have 
also been prepared (U + B). The samples were added to a 96 well plate, kept in the 
dark at 40oC and read every hour for 5 h. The associated fluorescence increase of the 
samples with substrate (U+S) and of the substrate-free samples (U+B) for each 
dilution is shown in Fig. 4-4 A). The protease activity is then calculated by 
subtracting the substrate-free sample’s fluorescence from the sample with substrate 
fluorescence and presented in Fig. 4-4 B). Fig. 4-4 shows that for the 1/50 and 1/100 
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dilutions, the trends are much more consistent than that for 1/10 dilution. For the 
purpose of obtaining consistent and reproducible results, 1/50 and 1/100 dilutions 
were chosen for subsequent analysis.  
 Two sets of aliquots from all AMBR 4 cultures where analysed for protease 
activity in separate days. The overall variability between the two analysis days was 
within 10% (data not shown). This did not have an impact on the trends observed, 
therefore the results of only one set of aliquots is presented in this chapter.  
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Figure 4-4: Protease activity increase over time for an unknown sample. A) The fluorescence 
increase of the sample with substrate (U+S) ( ─ ) and substrate-free sample (U+B) ( --- ) for 
dilutions 1/10 ( ─ ), 1/50 ( ─ ) and 1/100 ( ─ ). B) Fluorescence increase due to protease activity 
((U+S) – (U+B)) for each of the three dilutions   
 In order to determine the most suitable time for reading the plates, a trypsin 
standard curve was performed, with trypsin concentration varying from 50 – 10,000 
ng mL-1. The plate was read every hour up to 5 h, then at 19 h and 24 h. We can see 
from Fig. 4-5 that the same distinction between the different levels of trypsin that can 
be seen all throughout 0-5 h is also maintained at the higher time points. For the 
purpose of analysing the plates in a timely manner, a time of 5 h was chosen for 
subsequent analysis using 1/50 dilution.  
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Figure 4-5: Trypsin standard curve. The trypsin concentration varied from 50 – 10,000 ng mL-1, 
in-house Tris-HCl digestion buffer was used for making up the dilutions and the plate was 
incubated in the dark at 40o C. The increase in trypsin concentration is proportional to the 
increase in fluorescence 
4.3.2 Impact of cell culture inputs on protease activity 
Published literature regarding proteases is mainly focused on the identification of 
these enzymes using mass spectrometry as part of downstream process development. 
This class of process-related impurities is of concern in the manufacturing process of 
therapeutic proteins. They are classified as problematic HCPs due to their ability to 
either associate with the product or due to their potential impact on the therapeutic 
protein’s structural stability (Robert et al., 2009; Dorai et al., 2011; Dorai and 
Ganguly, 2014; Aboulaich et al., 2014). Only a few studies went a step further to 
actually quantify the amount of proteases present in CHO cultures (Robert et al., 
2009; Dorai et al., 2011) but none of them investigated the relationship between 
protease activity and cell culture inputs (seeding density, media osmolality) and 
outputs (mAb titre, HCP levels) at harvest.  
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4.3.2.1 Temperature  
Lowering culture temperature from its optimum temperature for growth of 36.5 oC 
has been show to improve recombinant protein productivity (Yoon et al., 2003; Tsao 
et al., 2005; Becerra et al., 2012) arrest cell growth, reduce lactate production, 
glucose consumption and ammonia production as well as to maintain higher culture 
viability for longer (Fox et al., 2004; Tait et al., 2013; Mason et al., 2014). Apart 
from having a beneficial impact on protein specific productivity, product quality has 
also been shown to be temperature dependent. Enhanced product quality 
(characterized by minimal impact on structural stability) at lower culture temperature 
has been associated with lower protease activity and the lower activity of various 
other temperature-dependent enzymes (Chuppa et al., 1997; Kaufmann et al., 1999). 
The effect of culture temperature on proteolytic activity present within bacterial and 
mammalian cell cultures has been widely studied in literature (Chuppa et al., 1997; 
Clark et al., 2004; Zhang and Chang, 2004; Dragomirescu et al., 2008). Chuppa et al. 
(1997) studied the effect of temperature (34, 35.5 and 37 oC) on proteolytic activity 
within high-density perfusion mammalian culture. They found that protease activity 
at 34 and 35.5 oC was similar, and lower than the protease activity at 37 oC. Zhang 
and Chang (2004) investigated the effect of temperature on proteolytic activity of 
human HtrA2 protease in E.coli culture over a wide range, 25 to 70 oC. The 
proteolytic activity of HtrA2 was seen to rapidly increase with temperature from 25 
to 55 oC and then decreasing towards 70 oC. Qureshi et al. (2011) looked at 
optimising culture conditions for production of protease (for industrial purposes) by 
Bacillus subtilis. They tested a temperature range of 25 to 55 oC and found protease 
activity to increase up until 45 oC when it reached maximum and then decrease. In 
both cases, protease activity was found to be lower at a lower temperature.  
 Protease activity was measured at 1/50 dilutions within AMBR 3 (Fig. 4-6 
A)) and AMBR 4 runs (Fig. 4-6 B)). The % difference in protease activity between 
replicate conditions at 33 oC compared to 36.5 oC was calculated. Within AMBR 3 
cultures, at 33 oC, a 1.5 – 25 % decrease in protease activity was observed (Fig. 4-6 
A)), while up to 26 % decrease in protease activity was seen in AMBR 4 cultures. 
This shows that regardless of the other combination of cell culture conditions present 
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within each culture, as part of the DoE design, culture temperature has a significant 
impact on proteolytic activity. A reduction in culture temperature could control the 
activity of these problematic HCPs and minimise the risk of product degradation due 
to proteolytic activity, hence maintaining product quality.  
  
 
Figure 4-6: Difference in protease activity (%) between equivalent conditions at 33 oC compared 
to 36.5 oC for (A) AMBR 3 and (B) AMBR 4 
A) 
B) 
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4.3.2.2 Seeding density   
As part of the DoE designs for both AMBR 3 and AMBR 4, the influence of other 
cell culture inputs such as seeding density and starting media osmolality on protease 
activity could also be analysed. The influence of seeding density on protease activity 
has not been previously reported in literature. It can be observed from Fig. 4-7 A) 
that there is a constant level of protease activity (expressed as fluorescence increase) 
regardless of the seeding density used within AMBR 3 cultures. This suggests that 
for these cultures, the starting cell density within the DoE designs does not influence 
the protease activity in the harvest material.  
In AMBR 4 cultures (Fig. 4-7 B)), a moderate negative correlation (R2 = 
0.41) is observed between protease activity and seeding density. For AMBR 4 
experiments, an ambr 48 (48 parallel cultures) was used as opposed to an ambr 24 
(24 parallel cultures) for AMBR 3 experiments, therefore a wider seeding density 
range was able to be investigated. It is believed that the extended seeding density 
range (1.8 – 3.5 × 106 cells/mL) may be the cause of the negative trend observed 
between protease activity and seeding density within AMBR 4. Comparing the trend 
in AMBR 4 cultures that are under the same conditions as AMBR 3 (up to 1.8 × 106 
cells/mL seeding density), a similar constant protease activity was seen for the whole 
seeding density range, comparable to the trend seen in AMBR 3 (data not shown).  
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Figure 4-7: The impact of seeding density on protease activity (measured as a fluorescence 
increase) within AMBR 3 (A) and AMBR 4 (B) cultures 
4.3.2.3 Media osmolality 
Media osmolality has generally been used in cell culture for its known ability to 
influence the specific cell productivity. Several published articles have shown that an 
elevated media osmolality can increase specific mAb productivity in CHO cultures. 
A high level of osmolality is also known to suppress cell growth (Ryu et al., 2000; 
B) 
A) 
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Kim et al., 2002; Lee et al., 2003; Li et al., 2010). The impact of media osmolality on 
protease activity was not previously investigated in literature. It seems that within the 
osmolality range explored, 310 – 390 mOsm/kg in AMBR 3 (Fig. 4-8 A)) and 310 – 
370 mOsm/kg in AMBR 4 (Fig. 4-8 B)), protease activity is not affected by starting 
media osmolality. 
 
 
Figure 4-8: The impact of starting media osmolality on protease activity (measured as a 
fluorescence increase) within AMBR 3 (A) and AMBR 4 (B) cultures 
A) 
B) 
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4.3.3 Correlation between mAb titre, HCP levels and protease activity 
4.3.3.1 mAb titre  
The relationship between mAb titre and protease activity has not been previously 
examined in literature. Within AMBR 3 cultures, a weak negative correlation (R2 = 
0.28) is seen between antibody titre and protease activity at harvest (Fig. 4-9 A)), 
while within AMBR 4 cultures, a moderate positive correlation is seen (R2 = 0.45) 
(Fig. 4-9 B)). In order to understand the difference in trends between the two AMBR 
runs, for AMBR 4, the protease activity was plotted against mAb titre for only the 
conditions that were part of the design space in AMBR 3 (pH 6.8 and up to 1.8 × 106 
cells/mL seeding density). A weak negative correlation was also seen between 
protease activity and titre in this case (Fig. 4-10 A)) which implied that the overall 
positive trend seen in AMBR 4 must be a consequence of the conditions not present 
within the AMBR 3 design space. The main difference between AMBR 3 and 
AMBR 4 design spaces is the addition of culture pH in AMBR 4. The relationship 
between protease activity and mAb titre within the additional design space of AMBR 
4 was then assessed (Fig. 4-10 B)). A moderate positive correlation (R2 = 0.54) is 
seen which seems to be driving the overall AMBR 4 trend. There is limited literature 
on the impact of culture pH on CHO derived proteases. For CHO cultures, pH has 
been seen to have a significant impact on cell growth, mAb titre and HCP levels (Fig. 
3-1 B); Fig. 3-2 AMBR 2) and due to its effect on these parameters it is likely that 
pH would also have a significant impact on protease activity at harvest. Culture pH 
has been known to have a significant impact on protease activity within bacterial 
cultures (Dragomirescu et al., 2008; Qureshi et al., 2011). Dragomirescu et al. (2008) 
investigated the pH dependence of protease activity produced in Bacillus 
licheniformis cells in the 3-12 range and seen an increase in protease activity up until 
pH 8, followed by a decrease. Qureshi et al. (2011) looked at optimising culture 
conditions for protease production by Bacillus subtilis and found that protease 
synthesis increased with an increase in initial culture pH and reached maximum at 
pH 8.5. For this cell line, within the design space investigated and at constant pH, a 
slightly negative correlation was identified between protease activity and mAb titre 
(Fig. 4-10 A)). Once culture pH was added to the experimental design, the significant 
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effect pH had on cell growth, mAb titre and HCP levels drove the positive 
relationship between protease activity and mAb titre within AMBR 4 cultures (Fig. 
4-10 B)).  
 
 
Figure 4-9: The relationship between protease activity (measured as a fluorescence increase) 
and mAb titre within AMBR 3 (A) and AMBR 4 (B) cultures 
 
A) 
B) 
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Figure 4-10: The relationship between protease activity (measured as a fluorescence increase) 
and mAb titre within AMBR 4, split by pH. A) 6.8 B) 7-7.4  
4.3.3.2 HCP levels  
The abundance and composition of HCPs present in the harvest material can be 
influenced by a variety of factors, including cell culture and harvest conditions (Jin et 
al., 2010; Gutierez et al., 2012; Tarrant et al., 2012). In Chapter 3 it was shown that 
different combinations of USP factors can have an impact on the resulting HCP 
levels. In recent years a lot of focus has been put on understanding the type of 
proteins that remain in the final drug product as well as the mechanism of how they 
A) 
B) 
  
145 
 
end up there. If we could understand the factors that influence the activity of specific 
problematic HCPs as well as identifying if their activity increases with an increase in 
overall HCP level we could potentially design processes that would ease the burden 
on the purification process. This would ensure a lower DSP process cost (DSP cost 
accounts for 45-92 % of the total cost of manufacturing a recombinant protein) 
resulting in a lower COG/g.  
The hypothesis of protease activity increasing with an increase in total HCP 
levels was investigated. The relationship between the HCP and protease activity at 
harvest has not been previously looked at in literature. For both sets of experiments 
(AMBR 3 and AMBR 4) an increase in total HCP levels at harvest did not result in a 
concomitant increase in protease activity (Fig. 4-11 A), B)). As there are few 
published studies linking the levels of total HCP with levels of specific HCPs within 
the whole population, the levels of other types of problematic HCPs can increase 
with an increase in the overall HCP level. Yuk et al. (2015) investigated the 
relationship between phospholipase B-like-2 (PLBL2) and total HCP concentration 
in the supernatant and whole cell culture fluid, for three CHO null cell lines. PLBL2 
is an HCP species present in CHO cultures, classified as problematic due to its ability 
to interact with certain recombinant humanized mAbs (Vanderlaan et al., 2015). 
They have seen an increase in PLBL2 concentration with an increase in HCP 
concentration, in all three null cell lines. It seems that different species within the 
whole HCP population are expressed differently in relation to the overall HCP trend.  
Efforts should be made to try and minimise the total level on HCP in harvest 
material, as this will reduce the risk of any immunogenic residual HCP to be found in 
the final product (Hogwood et al., 2014).  
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Figure 4-11: The relationship between protease activity (measured as a fluorescence increase) 
and HCP levels within AMBR 3 (A) and AMBR 4 (B) cultures 
4.4 Conclusions 
The impact of several cell culture parameters (temperature, seeding density, media 
osmolality) on protease activity was examined. It was shown that apart from 
temperature which has a negative impact on protease activity, the other USP 
conditions did not significantly affect protease activity. The relationship between 
protease activity and HCP levels was assessed and it was shown that an increase in 
HCP levels does not result in a similar increase in protease activity (considering the 
A) 
B) 
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proteases as a population). One of the protease assay’s limitations is the fact that it 
considers the proteases as a whole population and is not able to distinguish between 
different classes of proteases. In order to pinpoint the specific proteases, more 
advanced proteomic studies such as mass spectrometry need to be used. Due to a lack 
of resources and time limitation, a more in-depth analysis of the composition of the 
protease population was not possible. It has not been yet evaluated how the levels of 
individual proteases might increase or decrease with regards to the HCP levels at 
harvest. This could help provide a better understanding of how USP factors influence 
the levels of potential problematic individual proteases that pass on to the DSP 
process. 
The identification of cell culture inputs that have an impact on increasing 
problematic HCPs (protease) can help design processes that not only result in lower 
total HCP levels but also lower activity of specific, problematic HCPs. Determining 
the factors that have an impact on protease activity early in process development 
enables the possibility to improve the purification process to be able to reduce these 
species and potentially minimize the chance of residual protease that could cause 
product damage or eliciting an immune response in patients. Manipulating the USP 
conditions in order to reduce the activity of problematic HCPs would have a benefit 
in reducing the cost of goods by minimising the burden on DSP or through the ability 
to implement alternative, more cost effective methods.  
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Chapter 5 
5 Derivation of predictive cause-and-effect correlations for cell 
culture using multivariate data analysis 
5.1 Introduction  
The optimisation of cell culture processes in order to maximize antibody production 
as well as to reduce the time to market is an important aim within the 
biopharmaceutical industry. An important task in defining an optimisation strategy is 
to identify and predict cell culture behaviour (De Alwis et al., 2007). Cell culture 
experimentation involving trial and error optimisation of cell culture parameters, 
results in a large number of experiments, which can be time-consuming and 
expensive (Ho et al., 2006). Process modelling helps identify and evaluate product 
and process variables that might be critical to product quality and performance, 
facilitating a better planning and design of experiments. Modelling enables 
knowledge-based decision making, resulting in increased development efficiencies, 
continuous quality improvements and cost reduction (O’Kelly et al., 2012).  
 The aim of this chapter was to characterise the high throughput cell culture 
data generate using the ambr system (Chapter 3) by multivariate data analysis 
techniques (multiple linear regression, all possible stepwise regression) to derive 
statistical cause-and-effect correlations. These statistical equations are able to predict 
cell culture outputs such as mAb titre and HCP levels at harvest, based on cell 
culture inputs (temperature, media osmolality, seeding density, pH and timing of 
feed initiation) (Fig. 5-1). ANOVA analysis, using Design Expert and JMP software, 
was used to determine the significance of each parameter, either individually or in 
interaction with others on titre and HCP levels. 
5.2 Results and discussions 
For identifying the most suited predictive models for antibody titre and host cell 
proteins (HCP) from each ambr run, a stepwise all possible regression analysis (as 
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described in section 2.5.2.4) was used to narrow it down to eight hierarchical, best 
models, with increasing number of model terms. Stepwise all possible regression 
analysis tests all possible subsets of the set of potential independent variables. An 
analysis of variance is performed for each model to identify the main factors with a 
significant influence on the corresponding response (antibody titre or HCP). The titre 
and HCP results were analysed using JMP and Design Expert. The Analysis of 
Variance (ANOVA) is presented in Fig. 5-2 for titre and Fig. 5-5 for HCP, for all 
three ambr runs. The significant factors and/or interactions are presented with a * 
(Table 5-1, 5-4). The selection of an optimal model should be a balance between 
maximising predicted R2 (described in section 2.5.6.2), R2 (described in section 
2.5.6.1) as well as minimising RMSE (described in section 2.5.6.3) and AIC 
(described in section 2.5.3). Regression, like most statistical techniques, has a set of 
underlying assumptions that are expected to be in place if we want the estimated 
model to be reliable. For the selected best model for each response, the underlying 
assumptions are verified. Within all the subsequent analysis, the variables media 
osmolality, seeding density, temperature, pH and feed start time are referred to in 
coded factors as A, B, C, D and E respectively. This is for an easier interpretation of 
the results. The optimal models for antibody titre and HCP from AMBR 1 (low 
generation) are presented in more detail below, but a similar analysis was performed 
for titre and HCP from AMBR 2 and AMBR 3. 
5.2.1 Titre prediction models from AMBR runs  
5.2.1.1 Model building and selection  
The best eight models resulting from the stepwise all possible regression analysis, for 
estimating antibody titre from AMBR 1 run are presented in Table 5-1 with their 
corresponding statistics. The R-squared term (R2) defined in equation (9) (Section 
2.5.6.1)  is an indication of how well the model fits the experimental data, while the 
adjusted R2 also takes into account the number of factors evaluated. This is helpful 
when comparing amongst models that were developed from datasets with different 
number of factors. The predicted R2 is calculated using regression analysis and is 
used to indicate how well the model can predict responses for new combinations of 
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variables within the same range evaluated to develop the model. The R2 k fold 
(Section 2.5.5.1) is a measurement of internal validation of the model and is an 
indication of how accurate and valid the statistical model is at predicting new data, 
within the same design space but different than the data used to initially build the 
model. RMSE refers to the model residuals while AIC is a model selection criteria 
used to compare between potential models. The focus for the resulting models is 
towards prediction; therefore predicted R2 and R2 k fold are critical statistics that 
have to be taken into account when selecting the best model. Their value should be 
maximised for a model with the best prediction capability. 
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Figure 5-1: Integration of AMBR run experiments with predictive modelling   
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Figure 5-2: Analysis of mAb titre models for AMBR 1, 2 and 3. The analysis of variance as well as the correlation between experimental values and predictions from 
each model is presented * Significant in terms of probability (p-value < 0.05) 
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Table 5-1: Summary statistics for eight “best” models for AMBR 1 titre presented in coded factors. The coded factors A, B and C refer to the cell culture variables 
media osmolality, seeding density and temperature, respectively 
 
 
 
 
 
 
 
 
 
 
 AMBR 1 – Titre STATISTICS 
Model 
terms 
Model R2 
Predicted 
R2 
Adjusted 
R2 
R2 k fold RMSE AIC 
1 B* 0.25 0.07 0.21 0.07 0.685 47.01 
2 B*+C* 0.48 0.27 0.41 0.29 0.591 43.12 
3 A*+B*+C* 0.71 0.49 0.65 0.56 0.454 34.96 
4 A*+B*+C*+AB* 0.80 0.60 0.74 0.64 0.390 31.79 
5 A*+B*+C*+AB*+BC 0.84 0.71 0.79 0.72 0.357 31.78 
6 A*+B*+C*+AB*+BC*+B2 0.85 0.72 0.79 0.71 0.355 35.85 
7 A*+B*+C*+AB*+AC+BC+B2 0.86 0.58 0.78 0.55 0.359 41.56 
8 A*+B*+C*+AB*+AC+BC+A2+B2 0.87 0.49 0.77 0.38 0.372 49.65 
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Out of the eight models shown in Table 5-1, model 6 has the highest 
predicted R2 of 0.72, closely followed by model 5 with a predicted R2 of 0.71. The 
R2 for model 6 is also slightly higher than model 5, with 0.85 compared to 0.84. The 
addition of more and more variables to a model will always increase the R2, but 
when the increase in R2 is very small it is not worth increasing the complexity of the 
model. Model 5 is considered to be the best model as the difference between model 5 
and 6 is very small in terms of R2 and predicted R2. Model 5 also has a slightly 
higher R2 k fold of 0.72 compared to 0.71 for model 6. The selected model for 
antibody titre from AMBR 1 is analysed in more detail below. A similar analysis was 
performed for antibody titre from AMBR 2 (APPENDIX Table 5-1A) and AMBR 3 
(APPENDIX Table 5-3A). The analysis of variance of model 5, the reduced 2FI 
(two-factor interaction) model, indicates that the significant model terms are media 
osmolality (A), seeding density (B), temperature (C), the interaction between seeding 
density and media osmolality (AB) and to a lower extent the interaction between 
media osmolality and temperature (BC). The p-value of the model of <0.0001 
implies that the model is significant (Fig. 5-2). The actual vs predicted graph is 
presented in Fig. 5-2. The ANOVA analysis for the best model for titre from AMBR 
2 and AMBR 3 as well as their corresponding actual vs predicted graphs are also 
presented in Fig.5-2. The final equations for AMBR 1 titre in coded and actual 
factors are presented below:  
Titre = β0 + β1 A* + β2 B* + β3 C* + β4 AB* + β5 BC          (17)
              
Titre = 1.06 - 0.06 × Osmolality + 3.51 × 10-6 × Seeding density + 0.69 × 
Temperature + 5.11×10-8 × Osmolality × Seeding density – 5.12 × 10-7 × 
Seeding density × Temperature                (18) 
The model’s coefficients are an indication of how different cell culture 
parameters influence mAb titre. This is useful for USP scientists to easily identify 
which parameters have the biggest impact and need close monitoring for maximising 
mAb titre. Media osmolality is seen to have a significant negative impact on titre, an 
increase in starting media osmolality results in lower titres. On the other hand, 
seeding density and temperature have a positive impact on titre, an increase in both 
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parameters leads to an increase in the overall titre. The highest titre within AMBR 1 
is achieved for the lowest media osmolality and the highest seeding density and 
temperature within the design space explored. Another significant term is the 
interaction between media osmolality and seeding density. The negative effect of an 
increase in media osmolality on its own, starts to decline with an increase in seeding 
density. In terms of titre, cultures seeded at a high density are less sensitive to 
changes in osmolality than cultures seeded at a low density (Fig. 3-2).  
In order to identify if the variability within the Protein A assay (Chapter 2, 
Section 2.4.4) has an impact on the signal to noise ratio within the AMBR 1 titre 
model, the model’s coefficient of variation (% CV) was calculated and then 
compared to the CV of the assay. The difference between the assay variability (5 %) 
and the calculated % CV of the AMBR 1 titre model (4.92 %) was insignificant 
which implies that the predictive capability of the model was not influenced by the 
variability within the Protein A assay. An insignificant difference was also seen 
between the variability of titre models for AMBR 2 and AMBR 3 and the assay’s 
inherent variation.  
Abu-Absi et al. (2010) and Rouiller et al. (2012) both used QbD principles to 
characterise cell culture processes, by adopting a risk assessment exercise to identify 
potential critical and key process parameters with possible impact on process 
performance. They then used a DoE approach to evaluate the identified parameters 
and generate regression models for product titre (mAb and Fc-Fusion protein, 
respectively) as well as certain product and process related impurities. The 
comparison between the titre models generated in this work and the models they 
present are shown in Table 5-2. The comparison looks at the main parameters having 
a significant impact on product titre as well as R2 and R2 predicted. The models 
discussed here are comparable to the models presented in literature in terms of how 
well the models are able to fit the experimental data and how well they can predict 
for new combination of factors within the same design space. The models include 
process parameters not found within the literature models, such as media osmolality 
and feed start time.  
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Table 5-2: Comparison between generated titre models and titre models found in literature. The 
comparison looks at the main parameters having a significant impact on product titre as well as 
R2 and R2 predicted 
TITRE 
Literature comparison Significant factors R2 
R2 
predicted 
AMBR 1 
(Low generation) 
 
 Media osmolality 
 Seeding density 
 Temperature 
 
0.84 0.71 
AMBR 2 
(Mid generation) 
 
 Seeding density  
 pH 
 Feed start time 
 
0.98 0.97 
AMBR 3 
(High generation) 
 
 Seeding density 
 Temperature 
 
0.91 0.82 
Abu-Absi et al. (2010) 
Product: mAb 
 
 Seed bioreactor temperature 
 Production bioreactor T shift timing 
 Production bioreactor DO  
 Production bioreactor initial VCD 
 
0.88 0.61 
Rouiller et al. (2012) 
Product: Fc-Fusion protein 
 
 pH 
 DO  
 Culture duration  
 Seeding density  
 
0.96 0.94 
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Figure 5-3: Comparison between observed and predicted values of AMBR 1 titre. Runs 1-11 
correspond to CS1 within AMBR 1, maintained at a temperature of 36.5 oC and runs 11-20 
correspond to CS2 within AMBR 1, maintained at a temperature of 36.5 oC followed by a 
temperature shift to 33 oC in day 4 of culture  
Once a model has been chosen, it needs to be tested in order to ensure that the 
model is capable of predicting new data, within the same design space. This can be 
done through internal and external validation. Internal validation refers to the ability 
of the chosen model to predict data that has already been part of the experimental 
design but was not used to construct the model (k-fold cross validation). The R2 k 
fold term has been already used as a selection criterion when choosing the “best” 
model. Using the chosen model, titre values have been predicted for the experimental 
design already performed. The observed vs predicted graph (Fig. 5-3) shows that the 
model chosen gives a good prediction of experimental values. Ideally, an external 
validation of the model would also be performed. An external validation involves 
using the model to predict titre values associated with combinations of input variable 
(within the same design space) that have not been previously performed as part of the 
experimental design. New sets of experiments would be run and the final measured 
titre values would be compared to the already predicted ones in order to assess the 
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model’s ability of externally predicting titre. As further experimentation was not 
possible within the time provided, only internal validation was used to assess the 
validity of the models (for both titre and HCP). 
5.2.1.2 Verifying assumptions   
In order to test the normality of residuals the Shapiro-Wilk test (as described 
in section 2.5.4.1) was performed. The Shapiro-Wilk statistics for titre and its 
corresponding p-value are presented in Table 5-3. The p-value of 0.61 is not 
statistically significant (p-values values lower than 0.05 are generally considered 
statistically significant) therefore the hypothesis of normality of residuals should not 
be rejected. This suggests that the assumption is not violated and the residuals are 
normally distributed. 
 Table 5-3: The statistics for the Shapiro – Wilk and Durbin – Watson Tests and their 
corresponding p-value for AMBR 1 Titre and HCP 
 
* A p-value < 0.05 is generally considered statistically significant  
To verify whether or not the residuals are correlated the Durbin-Watson 
autocorrelation test (as described in section 2.5.4.2) was performed. The Durbin – 
Watson statistics for titre and its corresponding p-value are presented in Table 5.3. 
The p-value of 0.94 is not included within the two-tailed rejection region of p-value 
≤ 0.025 or p-value ≥ 0.975, therefore the null hypothesis of no autocorrelation is not 
rejected. The residuals are not correlated.  
 Shapiro- Wilk W Test Durbin – Watson Test 
 W p-value* Durbin - Watson p-value* 
Titre 0.96 0.61 2.92 0.94 
HCP 0.91 0.06 2.24 0.57 
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 To check the linearity of the model, the residual vs predicted plot is evaluated 
(Fig. 5-4). The residuals are evenly distributed on either side of the regression line 
and there is no visible trend. The assumption of linearity is satisfied. 
 
 
 
 
 
 
 
Figure 5-4: Residual versus predicted values AMBR 1 titre 
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Table 5-4: Summary statistics for eight “best” models for AMBR 1 HCP presented in coded factors. The coded factors A, B and C refer to the cell culture variables 
media osmolality, seeding density and temperature, respectively 
 
 
 
 
 
 
 
 
 
 
* Significant value in terms of probability (p-value < 0.05)  
 AMBR 1 – HCP STATISTICS 
Model 
terms 
Model R2 
Predicted 
R2 
Adjusted 
R2 
R2 k fold RMSE AIC 
1 C* 0.63 0.55 0.61 0.57 214836 553.26 
2 B+C* 0.66 0.51 0.62 0.52 213495 555.03 
3 A+C*+A2 0.70 0.54 0.65 0.57 205486 555.91 
4 A+B+C*+A2 0.72 0.50 0.65 0.51 205141 558.72 
5 A+B+C*+AB+A2 0.78 0.48 0.70 0.38 189332 559.01 
6 A+B+C*+AB+BC+A2 0.78 0.40 0.68 0.28 194900 564.44 
7 A+B+C*+AB+AC+BC+A2 0.78 0.18 0.66 -0.02 202770 571.33 
8 A+B+C*+AB+AC+BC+A2+B2 0.78 -0.19 0.62 -0.36 211784 579.78 
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Figure 5-5: Analysis of HCP models for AMBR 1, 2 and 3. The analysis of variance as well as the correlation between experimental values and predictions from 
each model is presented * Significant in terms of probability (p-value < 0.05)
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5.2.2 HCP prediction models from AMBR runs  
5.2.2.1 Model building and selection  
The best eight models for estimating HCP from AMBR 1 run, with their 
corresponding statistics are presented in Table 5-4. Out of the eight models resulting 
from the all possible stepwise regression, model 1 has the highest predicted R2 of 
0.55 closely followed by model 3 with a predicted R2 of 0.54 and models 2 and 4 
with a predicted R2 of 0.51 and 0.50, respectively. Although model 1 has the highest 
predicted R2 it also has a poor fit, shown by its low R2 value of 0.63. This is due to 
the fact that model 1 has only one predictor for HCP (temperature) not taking into 
account any other factors within the design space that might affect HCP levels. This 
suggests that model 1 might not be the most suited for HCP prediction. The second 
model in terms of prediction capability is model 3, with a predicted R2 of 0.54 and a 
R2 of 0.70. Upon testing the underlying assumptions of this model, the normality of 
residuals assumption was violated, making it an unsuited model for the prediction of 
HCP levels. Out of the two models that follow closely in terms of prediction, model 
2 and 4, model 4 fits the data better with a R2 of 0.72 compared to a R2 of 0.66 for 
model 2, as well as having a lower error, reason for which it is considered to be the 
best model.  
 The selected model for HCP from AMBR 1 is analysed in more detail below. 
A similar analysis was performed for HCP from AMBR 2 (APPENDIX Table 5-2A) 
and AMBR 3 (APPENDIX Table 5-4A). The analysis of variance of model 4 
indicates that the significant model term is temperature (C), with media osmolality 
(A), seeding density (B) and the quadratic term for media osmolality (A2) having a 
much lower contribution to the overall model. The model’s p-value of 0.0004 implies 
that the model is significant. The actual vs predicted graph is shown in Fig.5-5 for 
AMBR 1. ANOVA analysis for the best HCP model for AMBR 2 and AMBR 3 as 
well as their corresponding actual vs predicted graphs are also presented in Fig.5-5. 
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The final equations for AMBR 1 HCP in coded and actual factors are presented 
below:  
HCP = β0+β1A + β2B + β3C* + β4A2                (19) 
HCP = - 3.68 × 106 + 6.34 × 104 × Osmolality – 0.27 × Seeding density – 1.60 × 105 
× Temperature – 87.92 × Osmolality2              (20) 
The model’s coefficients are an indication of how different cell culture 
parameters influence HCP levels at harvest. The main significant factor influencing 
HCP levels is culture temperature (C), presenting the higher coefficient within the 
regression equation. Culture temperature is seen to have a significant negative impact 
on HCP levels, an increase in culture temperature leading to a lower HCP levels. 
Media osmolality and seeding density have a much lower effect on HCP levels, with 
osmolality having a small positive effect and seeding density a small negative effect. 
The lowest HCP level within AMBR 1 is achieved for high culture temperature (36.5 
oC), base osmolality (314 mOsm kg-1) and high seeding density (1.14 × 106 cell mL-
1). The same set of conditions also correspond to the highest mAb titre achieved 
within AMBR 1, which indicates that within this set of experiments, no compromise 
has to be made between high mAb titre and low HCP levels.  
 In order to identify if the variability within the Gyros HCP assay 
(Chapter 2, Section 2.4.5) has an impact on the signal to noise ratio within the 
AMBR 1 HCP model, the model’s coefficient of variation (% CV) is calculated and 
then compared to the CV of the assay. The difference between the assay variability 
(20 %) and the calculated % CV of the AMBR 1 HCP model (7 %) is significant 
which implies that the model’s ability to predict new data is affected by the high 
HCP assay variability. This is also reflected in the lower R2 predicted of the HCP 
models compared to the titre models.  
Rouiller et al. (2012) presented a HCP regression model for the production 
bioreactor of CHO cells expressing an Fc-Fusion protein. The most significant factor 
affecting HCP levels was pH and to a lesser extent DO and culture duration. The 
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comparison between this model and the HCP models generated from AMBR 1, 2 and 
3 data is presented in Table 5-5. The model presented by Rouiller et al. (2012) had an 
R2 of 0.92 and an R2 predicted of 0.88, which is higher than the statistics for the 
AMBR 1 and 3 models, but more similar to the AMBR 2 HCP model. The HCP 
models presented here include process parameters not previously used in literature to 
predict HCP, such as media osmolality, seeding density, culture temperature and feed 
start time. The analysis of variance for mAb titre and HCP levels, within AMBR 1 
experiments, indicates that the main factor with a significant influence on both titre 
and HCP is culture temperature. Culture temperature has a significant positive effect 
on mAb titre and a negative effect on HCP levels. At a high culture temperature 
(36.5 oC), a high titre and low HCP level is achieved within AMBR 1. 
The final predictive models for titre and HCP from each AMBR run are 
presented in Table 5-6 in coded factors. The HCP models presented here are not as 
good at fitting the experimental data as well as predicting new data, compared to the 
titre models. This could be explained by the fact that HCP levels, in comparison to 
product titre, are not routinely monitored and optimised through mapping the design 
space of a production bioreactor.  
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Table 5-5: Comparison between generated HCP models and HCP models found in literature. 
The comparison looks at the main parameters having a significant impact on product titre as 
well as R2 and R2 predicted 
HCP 
Literature comparison Significant factors R2 
R2  
predicted 
AMBR 1 
(Low generation) 
 Temperature 0.72 0.50 
AMBR 2 
(Mid generation) 
 
 pH 
 Feed start time 
 Media osmolality 
 
0.98 0.95 
AMBR 3 
(High generation) 
 Temperature 0.66 0.55 
Rouiller et al. (2012) 
 
 pH 
 DO  
 Culture duration  
 
0.92 0.88 
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Figure 5-6: Comparison between observed and predicted values of AMBR 1 HCP. Runs 1-11 
correspond to CS1 within AMBR 1, maintained at a temperature of 36.5 oC and runs 11-20 
correspond to CS2 within AMBR 1, maintained at a temperature of 36.5 oC followed by a 
temperature shift to 33 oC in day 4 of culture  
The observed vs predicted graph shows that the model chosen gives a good 
prediction of experimental values. 
5.2.2.2 Verifying assumptions   
In order to test the normality of residuals the Shapiro-Wilk test (as described in 
section 2.5.4.1) was performed. The Shapiro-Wilk statistics for HCP and its 
corresponding p-value are presented in Table 5-3. The p-value of 0.06 is not 
statistically significant therefore the hypothesis of normality of the residuals should 
not be rejected. This suggests that the assumption is not violated and the residuals are 
normally distributed.  
To verify if the residuals are not correlated, the Durbin-Watson 
autocorrelation test (as described in section 2.5.4.2) was performed. The Durbin – 
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Watson statistics for HCP and its corresponding p-value are presented in Table 5-3. 
The p-value of 0.57 is not included within the two-tailed rejection region of p-value 
≤ 0.025 or p-value ≥ 0.975, therefore the null hypothesis of no autocorrelation is not 
rejected. The residuals are not correlated.  
  To check the linearity of the model, the residual vs predicted plot is evaluated 
(Fig. 5-7). The residuals are evenly distributed on either side of the regression line 
and there is no visible trend. The assumption of linearity is satisfied.  
 
Figure 5-7: Residual vs predicted values AMBR 1 HCP 
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Table 5-6: Final predictive models for titre and HCP from each AMBR run presented in coded factors. The coded factors A, B, C, D and E refer to the cell culture 
variables media osmolality, seeding density, temperature, pH and feed start time, respectively 
 
 
 
 
 
 
 
 
  STATISTICS 
 Model R2 
Predicted 
R2 
Adjusted 
 R2 
R2 k fold RMSE AIC 
AMBR 1 – Titre A*+B*+C*+AB*+BC 0.84 0.71 0.79 0.72 0.357 31.78 
AMBR 1 – HCP A+B+C*+A2 0.72 0.50 0.65 0.51 205141 558.72 
AMBR 2 – Titre B+D*+E*+BD*+DE*+D2* 0.98 0.97 0.98 0.97 0.289 25.65 
AMBR 2 – HCP B+D*+E+BE+B2*+D2*+E2* 0.98 0.95 0.97 0.95 125536 652.77 
AMBR 3 – Titre  A+B*+C*+A2* 0.91 0.82 0.89 0.84 0.351 28.68 
AMBR 3 – HCP A+C* 0.66 0.55 0.62 0.57 206281 637.50 
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5.2.3 Importance of predictive models within QbD 
Following a meeting of the Process Analytical Technology Community of Practice of 
United Kingdom/Ireland, a survey aimed at finding out industrial experiences and 
opinions on the business benefits of Quality by Design was performed. The concept 
of modelling in QbD has numerous benefits and is widely used. All of the eleven 
companies surveyed (e.g. Abbott, Astra Zeneca, GSK, Merck, Pfizer, Eli Lilly, 
Bristol Myers Squibb, etc) are using Design of Experiments and empirical modelling. 
Modelling has been used for establishing an operating design space, predicting scale-
up parameters, guiding process development and improving product and process 
understanding. The implementation of statistical and mathematical modelling in QbD 
as well as other elements within the QbD framework (process analytical technology 
(PAT) tools, critical quality attributes risk assessments, real time release testing, etc) 
have brought significant benefits to the pharmaceutical industry.  Improved process, 
product knowledge and understanding, improved control strategy, improvement in 
product quality and product robustness/reproducibility, yield increase and cost 
reduction are just some of the main benefits (Kourti and Davis, 2012).  
5.3 Conclusions 
This chapter describes the application of QbD principles (HT scale-down model 
combined with statistical modelling) to the cell culture process of an IgG1 
monoclonal antibody, which resulted in the development of six predictive models 
(for low, mid and high generation cells). The experiments were performed using the 
ambr system and a DoE approach to identify the impact of cell culture inputs, both 
individually and as interactions, on critical quality attributes of the process (mAb 
titre and HCP levels). All of the parameters analysed (media osmolality, seeding 
density, culture temperature, culture pH and feed start time) were identified as main 
factors affecting mAb titre throughout all ambr runs, while culture temperature 
seemed to have the most significant impact on HCP levels, followed by culture pH, 
feed start time and media osmolality. The regression models generated were used to 
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explain the criticality of process parameters and allowed characterizing the impact of 
cell culture inputs on the performance of the cell culture process (antibody titre and 
HCP levels). The predictive models developed on the relationship between culture 
conditions, product titre and HCP levels will be used in the next chapter, within a 
whole process cost model, able to predict equipment sizes, cost of goods (COG) and 
optimal DSP process sequence associated with different cell culture strategies. This 
will enable rapid identification of the most promising and robust combinations of 
USP and DSP activities for more streamlined development in both existing and new 
facilities. 
 
 
 
 
 
  
171 
 
Chapter 6  
6 Integration of predictive cell culture correlations with bioprocess 
economics and uncertainty analysis  
6.1 Introduction 
Chapter 3 and 5 focused on using high throughput experimentation and multivariate 
data analysis to derive predictive cause-and-effect correlations for cell culture. The 
correlations provide a link between operating parameters and the cell culture 
performance in terms of cell count, antibody titre and HCP levels. The next challenge 
was to link the correlations to the impact on downstream processing, the final drug 
substance characteristics and the cost of goods. This would enable overall process 
yields, purities and costs to be determined as function of the cell culture operating 
parameters. Commercially available process economics packages tend to use simple 
short-cut mass models for cell culture that assume the yield and purity a priori with 
no capacity to substitute user-defined models. Hence this chapter explores the 
potential of integrating the correlations with cost models so as to determine the 
overall performance and robustness of whole bioprocess strategies.  
More specifically the aim of this chapter was to incorporate the predictive 
modelling equations generated in Chapter 5 with a prototype bioprocess economics 
and optimisation tool (Fig. 6-1, 6-2) in order to identify the most cost-effective 
combination of input cell culture conditions and chromatography column sizing 
strategies. The optimisation tool comprised a biomanufacturing process economics 
evaluation engine and database linked to a meta-heuristic optimisation algorithm. 
The impact of uncertainty in cell culture parameters on process performance and the 
likelihood of process metrics falling out of specification (output (kg), HCPfinal 
(ng/mg)) were assessed using Monte Carlo simulations.
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Figure 6-1: Overall integration of HT experimentation, predictive (statistical) modelling and economic modelling   
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6.2 Methodology  
6.2.1 Problem definition 
A bioprocess economics and optimisation tool using genetic algorithm developed at 
UCL (Simaria et al., 2012; Allmendinger et al., 2014) was firstly used to identify the 
impact of different titre and HCP loads from cell culture (resulting from AMBR 1, 2 
and 3) on the COG of a fixed USP and DSP process and to identify the optimal 
sizing of a DSP process (measured by the lowest COG/g). Secondly, the tool was 
used to investigate the impact of uncertainty within cell culture input parameters on 
output (kg) and HCPfinal (ng/mg). In this chapter HCP is expressed as ng/mg, as 
opposed to ng/mL (Chapter 3). FDA’s specification for HCP at the end of the 
manufacturing process is <100 ng/mg and as in this chapter, the impact of cell 
culture inputs on HCPfinal is assessed, this metric was chosen for HCP here. The 
optimisation problem considered here was subjected to an objective function, 
constraints and uncertain parameters, which are described in the following sections. 
6.2.1.1 Objective function  
The objective was to find the best combination of input parameters within each 
AMBR run that gives the minimal cost of goods per gram (COG/g) of manufactured 
product as well as understanding the impact of fluctuations in input parameters on 
the likelihood of process metrics falling out of specification. 
6.2.1.2 Constraints 
Various constraints need to be specified such that feasible results are generated by 
the optimisation tool.  
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Demand and batch constraints 
This constraint ensures that the amount of product manufactured satisfies the annual 
demand specified. The estimated total number of batches should not surpass the 
maximum number of batches that fit within the facility, during a year.  
Purity constraints  
This constraint ensures that the final level of host cell proteins (HCP) meets the 
purity target. HCPs are impurities in a mAb manufacturing process that need to be 
closely monitored and removed during the purification process in order to ensure 
patient safety. Given the initial level of HCPs (measured in ng of HCP per mg of 
product), the DSP process is required to lower the final HCP level to the final 
product specification limit of < 100 ng/mg.  
6.2.1.3 Manufacturing uncertainties  
The manufacturing process of antibodies can be subject to several uncertain factors. 
Here the focus is on potential fluctuations within input cell culture parameters. 
Uncertainties in starting media osmolality and seeding density were considered for 
AMBR 1 and 3 while uncertainties in pH and seeding density were considered for 
AMBR 2. In order to account for fluctuations in input cell culture parameters, a 
triangular distribution around each parameter was used. The framework represents 
uncertainty by associating each factor with a probability distribution, from which 
values are drawn at random during Monte Carlo (MC) trials. Uncertainty related to 
cell culture parameters, introduces uncertainty within process metrics such as product 
titre and HCP levels.  
6.3 Framework description  
The tool consists of three main components, as presented in Fig. 6-2:  
1. Meta-heuristic optimisation algorithm 
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2. Biomanufacturing process economic model 
3. Database (Simaria et al., 2012) 
The meta-heuristic optimisation algorithm searches the large decision space of 
process configurations and uses the process economic model to assess each 
alternative. The process economic model calculates several technical and financial 
outputs for a specific process configuration. The database keeps all the input data 
that needs to be used by the optimisation algorithm and process economics model, 
the output data that is generated by the framework as well as cost information with 
regards to resources such as labour and consumables.  
 
Figure 6-2: Main components of integrated bioprocess economics and optimisation tool* 
* (Adapted from Simaria et al. (2012))  
6.3.1 Bioprocess economics model  
The process economics model within the framework was based on previous UCL 
work (Lim et al., 2005; 2006 and Farid et al., 2005a; 2007b). The model was 
designed to use mass balance equations, time and detailed cost calculations in order 
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to determine cost of goods per gram (COG/g) of a specific process configuration. 
The COG contains both direct and indirect cost. The direct costs refer to the usage of 
resources such as materials (chromatography resins, buffers, membrane filters) and 
labour. The indirect costs are associated with the facility’s maintenance costs, 
depreciation and general utilities. The COG/g value is then calculated by dividing 
COG by the total amount of product manufactured in a year (Simaria et al., 2012; 
Allmendinger et al., 2014a, 2014b).  
6.4 Case study description  
An industrially-relevant case study was used to demonstrate the ability of the 
framework to calculate COG/g for different combinations of cell culture inputs and 
to determine the impact of uncertainty in the inputs on process outputs of a mAb 
manufacturing process (output (kg), HCP final (ng/mg)). The case study concentrates 
on a single-product mAb manufacturing facility that features a three chromatography 
step purification sequence to satisfy a total product demand of 500 kg/year. The 
chromatography step sequence was fixed to Protein A (Prot A) Anion Exchange 
(AEX)  Cation Exchange (CEX). The first and the third steps use packed-bed 
chromatography while the second step is a membrane chromatography step. The 
fluctuations in input parameters were modelled using triangular distribution, as 
shown in Table 6-2.  
6.5 Results and discussions  
6.5.1 Impact of cell culture parameters on COG/g 
The COG/g objective is manly affected by variations in mAb titre and process yield 
(Allmendinger, 2014b). Process yield is calculated by adding together the individual 
step yields of each unit operation in the DSP process and then dividing by the 
number of DSP steps. The impact of cell culture parameters on COG/g of a fixed 
USP and DSP manufacturing process is evaluated here; therefore process yield is 
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unchanged and does not have an effect on COG/g in this case. The main factor 
influencing the COG/g is mAb titre, as it has a direct impact on the mass of product 
manufactured which is the denominator of the COG/g. Variations in mAb titre can 
occur due to variations in input cell culture parameters.  
The model was updated to evaluate the impact of cell culture inputs used 
within the design of experiments for AMBR 1, 2 and 3 on mAb titre and HCP levels 
and consequently on COG/g. The experimental design is shown in Table 6-1. For 
each combination of cell culture inputs, the process economic model calculated the 
mAb titre and HCP levels using the predictive correlations generated in Chapter 5 
and then used these cell culture outputs to determine process and economic metrics 
as well as column sizing strategies (Fig. 6-1).  
Table 6-1: The experimental design investigated for the input cell culture parameters within 
AMBR 1, 2 and 3 
 Design space  
 Minimum Maximum Increments  Number of combinations 
AMBR 1  
Seeding density 
(× 106 cells/mL) 
0.5 1 0.25 
60 Media osmolality  
(mOsm/kg) 
310 400 10 
Temperature (oC) 33 36.5 N/A 
AMBR 2  
Seeding density 
(× 106 cells/mL) 
0.5 1 0.25 
27 pH  6.6 7 0.2 
Feed timing (h) 24 72 24 
Temperature (oC) 36.5 
AMBR 3  
Seeding density 
(× 106 cells/mL) 
0.6 1.8 0.4 
72 Media osmolality  
(mOsm/kg) 
310 390 10 
Temperature (oC) 33 36.5 N/A 
  
 
1
7
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Table 6-2: Details of case study scenario (Panel A) and probability distributions of uncertain factors (Panel B)* 
 
 
 
 
 
 
 
 
 
 
 
* In order to account for fluctuations in input cell culture parameters, a triangular distribution around each parameter was used (Tr).
Panel A: case study scenario 
Parameter Setting 
 
Chromatography steps 3 
Annual Demand 500 kg 
USP: DSP train ratio 2: 1 
Maximum final HCP level 100 ng/mg 
Bioreactor size 10,000 L 
Temperature 36.5 oC 
 AMBR 1/AMBR 3 AMBR 2 
Timing of feed initiation  48 h 24 h 
Panel B: probability distributions of uncertain factors   
Uncertain factor Probability distribution* Variation (%) 
AMBR 1   
Seeding density (×106) Tr (0.5, 0.75, 1)  33.3 
Media osmolality Tr (310, 350, 390) 11.4 
AMBR 2   
Seeding density (×106) Tr (0.5, 0.75, 1) 33.3 
pH Tr (6.6, 6.8, 7) 2.9 
AMBR 3   
Seeding density (×106) Tr (0.6, 1.2, 1.8) 50 
Media osmolality Tr (310, 350, 390) 11.4 
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For AMBR 1, the impact of titre and HCP load resulting from the 30 different 
combinations of cell culture inputs, for each temperature, on COG/g is shown in Fig. 
6-3. It can be seen that, as expected, COG/g is directly influenced by the mAb titre, 
with an increase in mAb titre resulting in a decrease in COG/g. For this set of 
experiments, in which low generation cells were used, it was previously shown that it 
is possible to increase antibody titre with little impact on HCP levels and hence 
subsequent DSP operations (Chapter 3). Here, it is shown that the combination of 
conditions that results in high mAb titre and low HCP levels also has the lowest 
COG/g. The combination of cell culture inputs, as well as the column sizing 
strategies for the lowest and highest COG/g achieved within each ambr run are 
presented in Table 6-3. The Protein A column sizing strategy for the lowest COG/g 
for each AMBR employs smaller columns (lower height) running for more cycles 
compared to the Protein A column sizing for the high COG/g cultures. This has a 
beneficial impact on the COG/g as it reduces the amount of Protein A resin used. 
Protein A is one of the most expensive unit operations within the manufacturing 
process of therapeutic proteins, particularly because of its highly expensive resin; 
therefore any savings in the amount of resin used would reduce the COG/g. 
A comparison between the COG breakdown for the lowest and highest 
COG/g achieved in AMBR 1 is presented in Fig. 6-4. The direct costs include the 
usage of resources such as materials (chromatography resins, membrane filters, 
buffers) and labour while the indirect costs are associated with the facility’s 
maintenance costs, depreciation and general utilities. A demand of 500 kg per year 
was assumed for this case study and in order for the lower titre cultures to be able to 
satisfy the annual demand; a higher number of batches is required. This will have an 
impact on the cost of labour, as a higher number of personnel would be necessary. 
The highest COG/g was achieved within cultures with the lowest mAb titre (Fig. 6-3) 
which explains the higher labour costs for these cultures. In higher titre cultures 
(lower COG/g) the resin utilisation is higher compared to lower titre cultures (72 % 
vs 63 %) which resulted in a lower cost of consumables, due to the fact that the cost 
of resins is a major contributor to the overall cost of consumables.    
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Figure 6-3: The impact of titre and HCP load resulting from AMBR 1 cell culture at A) 36.5 oC 
and B) 33 oC on the COG/g of a fixed USP and DSP process.  
 
 
A) 
B) 
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Figure 6-4: COG breakdown for the lowest and highest COG/g achieved within the design space 
of AMBR 1 
 
For AMBR 2, the impact of cell culture inputs on mAb and HCP levels is 
shown in Fig. 6-5 and on COG/g in Fig. 6-6. It can be seen that pH 6.6 has a 
significant negative impact on mAb titre and HCP levels, compared to pH 6.8 and 7 
(Fig. 6-5). This is due to its impact on suppressing cell growth (Tsao et al., 2005; 
Trummer et al., 2006). This negative impact on mAb titre, results in a significant 
increase in COG/g, regardless of other cell culture conditions within the DoE design 
(Fig. 6-6). Within a constant pH (6.8 and 7) a delay in the timing of feed initiation 
from 24 h to 72 h, resulted in a decrease in mAb titre and HCP levels for 0.5 and 
0.75 × 106 cells/mL seeding density, while for 1 × 106 cells/mL seeding density, a 
delay in timing of feed initiation resulted in a decrease in mAb titre and an increase 
in HCP levels. Generally, a delay in timing of feed initiation, led to an increase in 
COG/g, except for cultures with a pH of 6.6. 
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Table 6-3: Combination of input cell culture parameters for AMBR 1, 2 and 3 with their associated Prot A and CEX column sizing, for the lowest and highest 
COG/g achieved  in each case 
 
Combination of cell culture inputs 
COG/g 
(£) 
Column sizing 
Prot A CEX 
Media Osmolality 
(mOsm/kg) 
Seeding Density 
(×106 cells/mL) 
Temperature 
(oC) 
pH 
Time of feed 
initiation 
(h) 
height – diameter – cycles 
(cm – cm – no) 
AMBR 1 
310 1 36.5 6.8 48 96.3 20-120-7 24-90-9 
400 0.5 33 6.8 48 117.5 24-100-3 19-120-3 
AMBR 2 
310 0.5 36.5 7 24 99.4 23-100-9 24-120-5 
310 0.5 36.5 6.6 24 194.3 23-120-1 17-90-2 
AMBR 3 
370 1.8 33 6.8 48 96.4 23-120-8 15-120-10 
390 0.6 36.5 6.8 48 103.4 24-100-7 19-90-9 
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Figure 6-5: The impact of cell culture inputs on mAb titre and HCP levels within AMBR 2 cultures 
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Figure 6-6: The impact of cell culture inputs on COG/g within AMBR 2 cultures
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Figure 6-7: The impact of titre and HCP load resulting from AMBR 3 cell culture at A) 36.5 oC 
and B) 33 oC on the COG/g of a fixed USP and DSP process. 
 
 
 
A) 
B) 
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For AMBR 3, the impact of titre and HCP load resulting from the 36 different 
combinations of cell culture inputs on COG/g is shown in Fig. 6-7. Here, the COG/g 
is again directly influenced by the mAb titre, an increase in mAb titre resulting in a 
decrease in COG/g. This observation is more apparent in 36.5 oC cultures.  
 
Figure 6-8: Boxplots showing the distribution of COG/g for different AMBR runs. The box 
represents the 25th and 75th percentile with the median indicated by the middle horizontal line. 
The whiskers represent the observations with the lowest and highest COG/g for each AMBR 
run.  
The distribution of COG/g for all the combinations in cell culture inputs in each 
AMBR run is presented using box plots in Fig. 6-8. AMBR 2 (using mid generation 
cells) displayed the widest variation in COG/g. This is due to pH 6.6 which resulted 
in significantly lower titres than pH 6.8 and 7, resulting in high COG/g.  
6.5.1.1 Monte Carlo simulations   
In order to determine the number of simulation runs required to reach convergence, 
running averages of the simulation results were monitored until they levelled off 
(Fig. 6-9). This translated into running 150 Monte Carlo simulation runs in order to 
reach convergence in the output metrics and to characterise the variability in 
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performance measures (output and HCP final) due to uncertainty in seeding density 
and media osmolality for AMBR 1 and 3, and seeding density and pH for AMBR 2.  
6.5.1.2 Analysis 
The tool was used to predict the likelihood of product loss or failure to meet demand 
in AMBR 1 and 3, while in AMBR 2 the likelihood of the final HCP level (HCPfinal) 
being higher than 70 ng/ mg was assessed. MC simulations were employed to 
generate possible random outcomes by using the probability distribution of the input 
parameters, leading to a frequency distribution of outcomes for each output (output 
(kg), HCP final (ng/mg)). From these distributions the likelihood of particular 
thresholds being achieved can be determined (Stonier et al., 2013).  
 The expected fluctuations in cell culture input parameters can result in 
fluctuations in product titre and final HCP. Uncertainty within product titre can have 
a considerable impact on output. Fluctuations in product titre can lead to a) failure to 
meet demand (if fluctuation in cell culture parameters result in a lower titre than 
expected) or b) product waste (if resulting titre is higher than expected and the DSP 
cannot handle the excess) (Allmendinger, 2014a). Uncertainty with regards to 
processing time and step yields can also exist within a manufacturing process but are 
not examined in this thesis.  
  
188 
 
 
 
 
Figure 6-9: Running average in product yield for A) AMBR 1, C) AMBR 3 and in HCP final for 
B) AMBR 2 during Monte Carlo simulation trials.  
A) 
B) 
C) 
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For AMBR 1 and 3 a product output in the range of 500-550 kg/year was 
considered acceptable, with anything below or over this range, being considered out 
of specification. For AMBR 2, HCPfinal <70 ng/mg was considered in specification 
and anything above it out of specification. The general guidelines for HCP levels in 
the final product are set to less than 100 ppm (ng/mg). There are currently no 
guidelines referring to levels of specific HCPs within the whole population that can 
be found in the final product and have the potential to impact on the product 
structural stability. Bracewell et al. (2015) questions if the final HCP limit of 100 
ng/mg is acceptable and emphasizes that there should be more detailed criteria, based 
on a better understanding of the HCP population present. In all three sets of 
experiments performed, all of the cell culture input combinations satisfied the 100 
ng/mg limit of HCPs in the final product. Considering that the 100 ng/mg limit might 
not be acceptable in the future, within AMBR 2 the probability of HCPfinal > 70 
ng/mg was considered as being out of specification. 
The probability distributions (based on triangular distribution) used for cell 
culture input factors within each AMBR, with their corresponding % variation are 
shown in Table 6-2. These distributions are the initial distributions tested. Density 
plots showing the probability of falling out of specification with respect to output are 
shown in Fig. 6-11 A), B), C) for AMBR 1 and in Fig. 6-11 D), E), F) for AMBR 3. 
Different changes made to the initial distributions were also assessed. This allowed 
the identification of how tight cell culture inputs need to be controlled for the product 
output and HCPfinal not to fall out of specification.  
In AMBR 1 experiments, using the initial probability distributions, a 50 % 
probability of failing to meet demand and a 1 % probability of product waste were 
identified (Fig. 6-11 A)). In Chapter 3 it was shown that at 36.5 oC, mAb titre within 
AMBR 1, was influenced more by media osmolality than seeding density (Fig. 3-2). 
Considering this, the probability distribution for seeding density was kept constant 
while the distribution for media osmolality was first tightened to 340 ± 30 (310 – 370 
mOsm/kg). In this case, the probability of failing to meet demand was lowered to 25 
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% while the probability for product loss increased to 19 % (Fig. 6-10 B)). Product 
loss can occur in situations when titres are higher than expected and the 
chromatography columns do not have sufficient excess capacity to cope with higher 
product loads. Subsequently, the media osmolality distribution was tightened even 
further to 330 ± 20 (310 – 350 mOsm/kg) and the probability for both failure to meet 
demand and product lost were within acceptable limits (Fig. 6-11 C)). A 10% 
probability of failure was considered as being acceptable. A tighter control in the 
starting media osmolality needs to be performed in order to maintain process 
robustness. 
In AMBR 2 experiments, probability distribution within input parameters was 
used to assess the probability of HCPfinal (ng/mg) falling out of spec (HCPfinal > 70 
ng/mg). Using the initial probability distributions (Table 6-2), there is a 67 % 
probability of HCP final being higher than 70 ng/mg (Fig. 6.12 A)). It has been shown 
that pH has a significant impact on growth, mAb titre and HCP levels therefore a 
tighter pH control (6.8 ± 0.1) was assessed. This resulted in a decrease in the 
probability to 14 % (Fig. 6-12 B)). Cultures at pH 6.8, within AMBR 2, showed 
lower levels of HCP at harvest compared to cultures at pH 7 (Fig. 3-2). It was 
anticipated that a tighter pH control (6.8 ± 0.1) would result in lower levels of HCP 
final, for a fixed USP and DSP process, compared to a pH control of 6.8 ± 0.2. A 
further change was made in the probability distribution for seeding density (0.75 ± 
0.2 × 106 cells/mL) resulting in 0% chance of HCPfinal being higher than 70 ng/mg 
(Fig. 6-12 C)). Culture pH needs to be controlled within a tight range to ensure that 
the final HCP levels do not exceed a certain limit. 
For AMBR 3, using the initial probability distributions, a 33 % probability of 
failing to meet demand and a 4 % probability of product waste were identified (Fig. 
6-11 D)). Lowering the osmolality distribution range from 350 ± 40 (310 – 390 
mOsm/kg) to 340 ± 30 (310 – 370 mOsm/kg) resulted in an improvement in the 
probability for both ends of the spectrum (Fig. 6-11 E)). After exploring several 
changes within the seeding and osmolality distribution ranges, it was found that for a 
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seeding density of 1.2 ± 0.2 × 106 cells/mL and an osmolality of 340 ± 30 mOsm/kg, 
the probability of falling out of specification is relatively close to the acceptable 
limits (Fig. 6-11 F)). As for AMBR 1, a tighter control in starting media osmolality is 
required to ensure process robustness.  Performing uncertainty studies using MC 
simulations, combined with predictive correlations can be used to determine process 
validation acceptance criteria (PVAC) for key process parameters (media osmolality, 
seeding density, pH) (Fig. 6-10). Similar studies have been performed by Looby et 
al. (2011) and Gommers et al. (2014).  
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6-10: Steps used for establishing PVAC using HT experimentation, ANOVA and Monte 
Carlo simulation methods 
Process Characterisation Studies  
(DoE driven HT small-scale experiments using the ambr system) 
Develop ANOVA Prediction Models  
(Cause-and-effect predictive correlations link the variation in 
operating parameters to process performance e.g. mAb titre and HCP 
levels as a function of key process parameters e.g. seeding density, 
media osmolality, pH, temperature, timing of feed initiation) 
Simulate Potential Manufacturing Variability Using  
Monte Carlo Simulation  
(Using ANOVA prediction models, run uncertainty analysis using 
Monte Carlo simulations for each performance parameter (product 
output and HCP 
final
) assuming a triangular distribution for the 
operating parameters) 
Establish Process Validation Acceptance Criteria for key process 
parameters 
(Define acceptable limits for each key process parameter (e.g. media 
osmolality, seeding density, culture pH) 
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Figure 6-11: Density plots showing the impact of tighter osmolality and seeding density control on the probability (P(x)) of the product output falling out of specification in 
AMBR 1 and AMBR 3, using MC = 150 for Seeding density 0.75 ± 0.25 × 106 cells/mL A) Osmolality 350 ± 40 mOsm/kg; B) Osmolality 340 ± 30 mOsm/kg; C) Osmolality 
330 ± 20 mOsm/kg in AMBR 1 and for Seeding density 1.2 ± 0.6 × 106 cells/mL D) Osmolality 350 ± 40 mOsm/kg; E) Osmolality 340 ± 30 mOsm/kg; F) Seeding density 1.2 ± 
0.2 × 106 cells/mL, Osmolality 340 ± 30 mOsm/kg in AMBR 3 
A) A) B) C) 
D) E) F) 
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Figure 6-12: Density plots showing the impact of tighter pH and seeding density control on the probability (P(x)) of the HCPfinal (ng/mg) falling out of specification in 
AMBR 2, using MC = 150 for Seeding density 0.75 ± 0.25 × 106 cells/mL A) pH 6.8 ± 0.2; B) pH 6.8 ± 0.1; C) Seeding density 0.75 ± 0.2 × 106 cells/mL, pH 6.8 ± 0.1 
 
 
A) B) C) 
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6.6 Conclusions  
The application of a meta-heuristic optimisation tool using genetic algorithms to an 
industrially relevant case study allowed the identification of the most cost-effective 
combinations of input cell culture conditions and column sizing strategies for AMBR 
1, 2 and 3 (low, medium and high generation number cultures). The stochastic aspect 
of the tool was used to perform an uncertainty analysis, using Monte Carlo 
simulations, to help understand the impact of uncertainty in cell culture inputs on 
process performance. Antibody titre was identified as the main factor having an 
impact on COG/g, an increase in titre resulting in a decrease in COG/g. Cell culture 
inputs that resulted in higher titres, also resulted in lower COG/g. Under the current 
model assumptions, at high mAb titres, the sizing strategy for Protein A 
chromatography employs smaller columns with a higher number of cycles, saving on 
the quantities of resin used and in this case leading to a lower COG/g. This is 
dependent on the resin/membrane reuse strategy. Within the low generation cell 
culture (AMBR 1), a tighter control of the media osmolality range ensured that the 
resulting product output did not fail to meet demand or allowed for product waste, 
within the acceptable limits. In the higher generation cell culture (AMBR 3), a tighter 
control in both seeding density and media osmolality ranges was necessary to remain 
in specification. These uncertainty studies using MC simulations linked to ANOVA 
derived cause-and-effect predictive correlations can be used to establish acceptable 
operating ranges for key process parameters (media osmolality, seeding density, pH). 
The results can be used by the cell culture process development team within a 
biopharmaceutical company to understand which cell culture parameters need a 
tighter control in order to avoid process outputs falling out of specification. Using the 
integrated QbD framework (process characterization studies based on DoE 
experiments using the ambr system, statistical analysis for deriving predictive 
correlations and uncertainty analysis using MC simulations), proven acceptable 
ranges (PARs)/process validation acceptance criteria (PVAC) for key process 
parameters can be determined (Fig. 6-10). Systematic approaches similar to the one 
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showed in this thesis are likely to be the core of “QbD-based” future regulatory 
submissions (Looby et al., 2011). 
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Chapter 7  
7 Conclusions and Future work 
7.1 Conclusions  
The overall output of this research is a systematic framework combining state-of-the-
art high throughput cell culture experiments (ambr system) with statistical 
correlations (derived through multivariate analysis techniques) and process economic 
models. This integrated framework enabled the identification of cell culture 
strategies that balance the needs of upstream and downstream manufacturability, 
robustness to process variations and cost-effectiveness, early in the development 
cycle.  
  DoE designed experiments were performed using the ambr system in order to 
evaluate the impact, different increases in antibody titres has on the resulting host 
cell protein levels at harvest. It has been shown that increases in mAb titre can be a 
result of different combinations of increases in cell densities and specific cell 
productivities (Fig. 3-3), each with a different impact on HCP levels and subsequent 
DSP steps. A Quality by design approach to cell culture process development was 
used to demonstrate that there is scope for cell culture processes in which the ratio of 
mAb to HCP can be increased and the association of mAb titre to HCP reduced. A 
combination of cell culture parameters that resulted in an increase of antibody titre, 
without a subsequent increase in HCP levels was identified within AMBR 1 
experiments (36.5 oC, 313 mOsm kg-1 media osmolality, 1 × 106 cells mL-1 seeding 
density, pH 6.8 and low cell generation number). Within these experiments, three 
different cell generation cells were used and a stability issue was observed within 
higher cell generation cultures at 36.5 oC while at a lower temperature of 33 oC cell 
line instability was not apparent. Cells of a higher generation lead to an elevated ratio 
of HCP to product (AMBR 2, 3) as compared to lower generation cells (AMBR 1).
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Recent literature has emphasized the need for a better understanding of the 
impurity profile entering DSP and the cell culture factors that are likely to change 
this profile, as certain problematic HCPs have been identified in the final drug 
product (Aboulaich et al., 2014; Thompson et al., 2014). There is a limited 
understanding regarding the relationship between the protein of interest, bioprocess 
conditions (both in USP and DSP) and problematic HCPs (Bracewell and Smales, 
2013). In addition to assessing the impact of cell culture inputs on the resulting mAb 
titre and HCP levels at harvest, a deeper understanding was provided on the impact 
of cell culture parameters on the activity of specific problematic HCPs (proteases). 
Proteases are a sub-class of host cell proteins, identified as problematic by a variety 
of publications, due to their ability of associating with the product throughout the 
DSP process or having an impact on the product’s structural stability (Dorai and 
Ganguly, 2014; Aboulaich et al., 2014; Wang et al., 2014). Culture temperature was 
identified as having the most significant impact on protease activity at harvest, a 
decrease in temperature resulting in a decrease in protease activity. Apart from 
temperature, other cell culture conditions investigated (seeding density and media 
osmolality) did not seem to have a considerable impact on protease activity. The 
relationship between protease and HCP levels was also assessed and it was shown 
that an increase in HCP levels does not result in a similar increase in protease 
activity. 
 The high throughput cell culture data generate using the ambr system was 
characterised by multivariate data analysis techniques (multiple linear regression, all 
possible stepwise regression) to derive statistical cause-and-effect correlations. These 
statistical equations are able to predict cell culture outputs such as mAb titre and 
HCP levels at harvest, based on cell culture inputs (temperature, media osmolality, 
seeding density, pH and timing of feed initiation). A set of equations for product titre 
and HCP levels were derived from AMBR 1, 2 and 3 (each set of experiments 
presenting a different cell generation number).  
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 The resulting cell culture predictive correlations were linked to a meta-
heuristic optimisation framework (optimisation algorithm, a biomanufacturing 
process economic model and a database). This allowed the selection of the most cost-
effective combination of input cell culture conditions and chromatography column 
sizing strategies (Table 6-3). The impact of uncertainty in cell culture parameters on 
process performance and the likelihood of process metrics falling out of specification 
were assessed using Monte Carlo simulations. The COG/g objective function was 
significantly influence by mAb titre, an increase in titre resulting in lower COG/g. 
Within AMBR 1 and AMBR 3 the variability in product yield (kg) due to uncertainty 
in seeding density and media osmolality was examined, while for AMBR 2, the 
variability in final HCP (ng/mg) due to uncertainty in seeding density and pH was 
assessed. Media osmolality and culture pH were identified as critical culture 
parameters, that need to be closely monitor in order to ensure that the resulting 
process metrics do not fall out of specification. Fluctuations in input parameters that 
can cause fluctuations in product titre can lead to situation in which the demand is 
not met or expensive product is wasted due to the insufficient capacity of purification 
steps to handle the increased product load.  
7.2 Future work  
There are a few areas within this work that might benefit from additional 
investigation or alternative approaches. Model validation is necessary in order to 
assess the ability of a statistical model to accurately predict outputs. This can be 
tested through internal and external validation. As previously presented in Section 
5.2.1.1, internal validation (using k-fold cross validation) has been used as one of the 
criteria to help identify the model with the best prediction capability. To further 
investigate how good the chosen models are at predicting outputs with new 
combinations of input variables (within the same design space), external validation 
should be performed. Future work should involve setting up an experimental design 
with new combinations of input variables. Once the experiments are completed, the 
measured output values (e.g. titre and HCP) should be compared with the previously 
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predicted valuates in order to evaluate how efficient the model is at externally 
predicting outputs.  
The systematic framework combining microscale experimentation with 
statistical correlations and process economic models has been shown to be an 
effective way of identifying robust and cost-effective cell culture strategies. This 
framework provides a foundation to build upon, where predictive correlations can be 
created for downstream processing steps such as primary recovery and 
chromatography. High throughput scale-down experimentation can be adopted to 
generate data in order to characterise the impact of cell culture conditions on 
clarification and purification potential. This data can then be used to develop models 
that link cell culture properties (e.g. cell density, viability, mAb titres) and recovery 
operating conditions (e.g. flow rate) to the performance of centrifugation and depth 
filtration (e.g. clarification, yield, purity, filter capacity) and purification potential.  
The impact of different ways of increasing antibody titre on HCP levels at 
harvest has been assessed within a high-producing CHO cell line. Three sets of 
experiments, each using a different generation of cells, resulted in three different 
bioreactor scenarios. The cell line used was seen to exhibit instability, with lower 
specificity for the mAb (qMab) in higher generation cultures. It is uncertain if the three 
scenarios identified are caused by the significant influence of the generation number 
on the cultures or by the different combinations of conditions within the three DoE 
designs examined. The application of the QbD approach (ambr system and Gyrolab 
workstation high throughput platform, linked with DoE) to a high producing stable 
CHO cell line could help identify the underlying cause of the different scenarios 
seen. If a cell line is seen to display a scenario in which the increase in antibody titres 
would not result in a subsequent increase in HCP levels, the optimisation strategies 
should be focused around the cell culture parameters that resulted in such a trend.  
 Cell culture processes are very complex unit operations and they generally 
require a large number of factors to be characterised in order to be able to try and 
accurately describe such processes. In the experiments performed, cell culture factors 
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such as temperature, seeding density, media osmolality, pH and timing of feed 
initiation were used to characterise cell culture processes. Further work can be 
focused on assessing the impact of additional cell culture parameters such as levels 
of dissolved oxygen, agitation speed as well as additional culture temperatures over a 
wider range, on antibody titres and HCP levels at harvest. Different outputs such as 
aggregate levels and DNA could also be investigated.  
 The antibody sector has seen significant increases in upstream productivities 
in recent years, with titres reaching over 10 g L-1 in fed-batch cultures. This increase 
in USP titres has resulted in increased focus to be placed on how these USP changes 
impact on the HCP profile and levels following onto the downstream process. It has 
been reported that certain HCP species can be found in the final drug product 
(Aboulaich et al., 2014; Thompson et al., 2014). Recent studies have confirmed the 
need for a better understanding of the presence and potential risk of certain 
problematic HCPs. In this work the impact of cell culture inputs on protease activity 
(identified as problematic HCPs) was assessed as well as the relationship between 
protease activity and total HCP levels. It was shown that the protease activity does 
not increase with an increase in HCP levels. Other published work, looked at the 
relationship between other problematic HCPs and total HCP levels (e.g. PLBL2, Yuk 
et al., 2015) and showed that an increase in PLBL2 concentration was seen with an 
increase in HCP concentration. This suggests that different species within the whole 
HCP population are expressed differently in relation to the overall HCP trend. Future 
work could be focused on investigating the impact of cell culture conditions on the 
levels of other problematic HCPs and evaluate how their levels change with the 
overall HCP levels. Identifying cell culture inputs that have an effect on the levels of 
different problematic HCPs could help design processes that not only result in lower 
total HCP levels but also lower levels of specific, problematic HCPs and in this way 
lowering the burden on to DSP.  
 As previously mentioned, one of the limitations of the chosen protease assay 
is its inability to distinguish between different protease species within the whole 
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protease population. The activity of different type of proteases (e.g. acidic, serine, 
metallo-) could either increase or decrease under different cell culture conditions. In 
order to identify the individual classes of proteases and how their activity changes 
with changes upstream, more advanced proteomic studies should be investigated. 
Future work could investigate the use of alternative proteomic methods such as mass 
spectrometry alone, or in combination with 2D-PAGE gels or liquid chromatography 
(LC-MS/MS). These methods have the ability to detect and monitor multiple 
proteins, in the same sample. So far it has been shown that it can be evaluated how 
the total levels of HCPs at harvest as well as the total protease activity within these 
HCP populations can change when the process parameters are changing. This future 
work would help provide a more in-depth understanding of how the activity of 
individual proteases might vary between different samples and over time.  
 It was previously shown that increases in antibody titres can be driven by two 
main mechanisms: increases in cell densities or specific cell productivities, each with 
a different impact on resulting HCP levels (Fig. 3-3). It would be valuable to 
investigate if the HCP profiles as well as the levels of certain problematic HCPs 
differ between processes in which an increase in antibody concentration is achieved 
through different mechanisms. For this cell line, the relationship between the specific 
productivity for the antibody (qMab) and the specific productivity for HCPs (qHCP) 
was evaluated. It was found that qMab and qHCP are positively correlated, despite the 
different combinations of conditions within the DoE design (Fig. 3-4). This might 
suggest that an increase in qMab could lead to a difference in expression for certain 
problematic HCPs.  
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Table 5-1A: Summary statistics for eight “best” models for AMBR 2 titre presented in coded factors. The coded factors B, D and E refer to the cell culture variables 
seeding density, pH and feed start time, respectively 
 
 
 
 
 
 
 
 
 AMBR 2 – Titre STATISTICS 
Model 
terms 
Model R2 
Predicted 
R2 
Adjusted 
R2 
R2 k 
fold 
RMSE AIC 
1 D* 0.58 0.50 0.56 0.49 1.307 86.09 
2 D*+D2* 0.96 0.94 0.95 0.94 0.430 34.55 
3 D*+E+D2* 0.96 0.94 0.96 0.94 0.401 34.23 
4 D*+E*+DE*+D2* 0.97 0.95 0.97 0.95 0.346 28.50 
5 B+D*+E+DE*+D2* 0.98 0.95 0.97 0.95 0.345 31.12 
6 B+D*+E*+BD*+DE*+D2* 0.98 0.97 0.98 0.97 0.289 25.65 
7 B+D*+E*+BD*+BE+DE*+D2* 0.99 0.94 0.98 0.94 0.268 26.12 
8 B+D*+E*+BD*+BE+DE*+B2+D2* 0.99 0.94 0.98 0.94 0.272 31.23 
9 B+D*+E*+BD*+BE+DE*+B2+D2*+E2* 0.99 0.92 0.98 0.93 0.281 38.24 
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Table 5-2A: Summary statistics for eight “best” models for AMBR 2 HCP presented in coded factors. The coded factors B, D and E refer to the cell culture 
variables seeding density, pH and feed start time, respectively.  
 
 
 
 
 
 
 
 
 
 
 AMBR 2 – HCP STATISTICS 
Model  
terms 
Model R2 
Predicted 
R2 
Adjusted 
 R2 
R2 k fold RMSE AIC 
1 D* 0.77 0.73 0.76 0.74 369805 688.62 
2 D*+D2* 0.95 0.94 0.94 0.94 177531 655.18 
3 D*+E+D2* 0.96 0.94 0.95 0.94 161510 652.70 
4 B*+D*+B2*+D2* 0.97 0.94 0.96 0.94 153935 652.77 
5 B+D*+E+B2*+D2* 0.97 0.94 0.96 0.94 142699 651.90 
6 B*+D*+E+DE+B2*+D2* 0.98 0.94 0.97 0.94 136509 652.99 
7 B+D*+E+BE+B2*+D2*+E2* 0.98 0.95 0.97 0.95 125536 652.77 
8 B+D*+E+BD+BE*+B2*+D2*+E2* 0.98 0.94 0.97 0.93 127115 657.89 
9 B+D*+E+BD+BE*+DE+B2*+D2*+E2* 0.98 0.94 0.97 0.92 130201 664.46 
  
 
2
2
8 
Table 5-3A: Summary statistics for eight “best” models for AMBR 3 titre presented in coded factors. The coded factors A, B and C refer to the cell culture variables 
media osmolality, seeding density and temperature, respectively. 
 
 
 
 
 
 
 AMBR 3 – Titre STATISTICS 
Model  
terms 
Model R2 
Predicted 
R2 
Adjusted 
 R2 
R2 k fold RMSE AIC 
1 C* 0.70 0.64 0.68 0.65 0.605 47.30 
2 B*+C* 0.82 0.74 0.80 0.73 0.481 38.60 
3 B*+C*+BC* 0.86 0.77 0.83 0.76 0.436 36.21 
4 A+B*+C*+A2* 0.91 0.82 0.89 0.82 0.351 28.68 
5 A+B*+C*+AB+A2* 0.92 0.83 0.90 0.84 0.335 29.47 
6 A+B*+C*+AB+BC+A2* 0.93 0.82 0.90 0.82 0.337 33.18 
7 A+B*+C*+AB+BC+A2*+B2 0.93 0.81 0.90 0.78 0.337 37.22 
8 A+B*+C*+AB+AC+BC+A2+B2 0.93 0.78 0.89 0.72 0.349 43.69 
  
 
2
2
9 
Table 5-4A: Summary statistics for eight “best” models for AMBR 3 HCP presented in coded factors. The coded factors A, B and C refer to the cell culture 
variables media osmolality, seeding density and temperature, respectively.  
 
 AMBR 3 – HCP STATISTICS 
Model  
terms 
Model R2 
Predicted 
R2 
Adjusted 
 R2 
R2 k fold RMSE AIC 
1 C* 0.59 0.51 0.57 0.51 218900 636.08 
2 A+C* 0.66 0.55 0.62 0.57 206281 635.18 
3 A+C*+AC 0.68 0.53 0.62 0.57 205586 637.15 
4 A+C*+AC+A2 0.68 0.48 0.61 0.53 210049 640.62 
5 A+B+C*+BC+A2 0.71 0.49 0.62 0.52 205719 642.56 
6 A+B+C*+AB+BC+A2 0.72 0.46 0.62 0.47 206660 646.20 
7 A+B+C*+AB+AC+BC+A2 0.73 0.42 0.61 0.47 209678 650.94 
8 A+B+C*+AB+AC+BC+A2+B2 0.74 0.27 0.59 0.34 215761 657.16 
